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Abstract
The effects the anthracycline Doxorubicin exerts on variants o f  the human lung carcinoma cell 
line DLKP was investigated in this thesis, in an attempt to understand the means by which the 
chemotherapeutic agent exerts its cytotoxic and cytostatic effects on human lung tumours. 
Sensitive DLKP-SQ and resistant variants DLKP-SQ/A250 10p#7, DLKP-A2B and DLKP- 
A5F were exposed to equitoxic doses o f  Doxorubicin, which resulted in approximately 50%  
cell kill after 72 hours. The subsequent effects on the cell cycle and apoptosis induction were 
studied in an attempt to identify any differences between sensitive and resistant cells, that m ay  
contribute to the resistant state.
Doxorubicin treatment induced a permanent G2/M  arrest in sensitive cells by 24 hours, and a 
temporary arrest m resistant variants at an earlier time o f  12-16 hours with a subsequent 
bypass o f  the G2/M  arrest to re-emerge in and accumulate in G l. The transient G2/M  arrest 
and subsequent progression into G l indicated insufficient checkpoint monitoring o f  D N A  
damage induced by doxorubicin treatment in the resistant variants. The G 2/M  checkpoint 
controller complex cyclin B-cdkl , was investigated in an attempt to explain the G2/M  over-ride 
seen in  drug resistant cells. Doxorubicin treatment did not alter cyclin B or cdkl protein levels, 
or the complex-forming ability o f  cdkl. The G2/M arrest seen in sensitive cells may be due to 
an increase in inhibitory phosphorylation on cdkl. In contrast T yrl5 phosphorylation did not 
change in resistant variants and cdkl kinase activity seems to increase following drug 
treatment, unlike the sensitive cells which displayed little alterations in kinase activity upon 
drug treatment. Further investigation o f  the mechanism o f  G2/M  override in the resistant 
variants involved examination o f  the cdkl regulators w ee l kinase and cdc25 phosphatase. 
Initial studies on these regulators raised some mechanistic possibilities o f  G2/M  override. 
Apoptosis occurs in each o f  the four cell lines after Doxorubicin treatment, with kinetics o f  cell 
death dependent on the concentration o f  Doxorubicin and exposure tune used. The mechanism  
o f  apoptosis induction in the cell lines was investigated. Analysis o f  procaspase expression 
revealed that caspase-3 is greatly downregulated in resistant cell lines, and caspase-8 is reduced 
to a lesser extent. Levels o f  procaspases did not decrease during apoptosis, indicating lack o f  
caspase activation in general, and very low  caspase-3 activation occurs during doxorubicin- 
induced apoptosis, raising doubts about caspase-3 involvement in the apoptotic pathway. The 
caspase-3 substrate PARP was not cleaved in any o f  the cell lines during apoptosis, although 
the cytoskeletal protein fodrin was cleaved in all four cell lines. Furthermore the caspase 
inhibitors zYAD-ftnk, YVAD-fm k and DEVD-fmk which readily cross cell membranes, failed 
to protect the cells from doxorubicin-induced apoptosis, raising the possibility o f  caspase
redundancy or a caspase-independent mechanism in these cells. Involvement o f  the Fas- 
mediated pathway was also investigated, and resistant variants do not express altered levels o f  
CD95 receptor compared to  sensitive cells. W hen the cells were treated with inhibitors o f  the 
Fas signalling pathway, or with a combination o f  caspase inhibitors and CD95 inhibitors, they 
continued to die by apoptosis. The fact that cell permeable inhibitors o f  both caspases and 
CD95 signalling do not prevent doxorubicin-induced death lends further weight to the possible 
existence o f  a caspase-independent pathway.
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1.0 Introduction
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1.0 Introduction
1.1 Chemotherapy in the treatment of cancer
C ancer is on e o f  the m ajor causes o f  death in  the w orld  tod ay , w ith  m ore than 100  
cancer typ es occurring and 6 m illion n ew  cases d iagnosed  every  year. A pproxim ately  
h a lf  o f  th ese  cases resu lts in  death, and the rem ainder can  b e su ccessfu lly  treated by  
surgery, radiotherapy or chem otherapy.
T he m ain aim o f  chem otherapy is to  elim inate all cancer cells  w h ilst inflicting as little  
dam age as p ossib le  o n  the surrounding norm al cells; m axim um  tum our ce ll kill 
accom panied  w ith  m inim um  norm al cell kill. S ince the com m en cem en t o f  
chem otherapy in  1962 , advances and breakthroughs in  cancer research and drug 
d esign  have led  to  the d iscovery o f  structurally and functionally d iverse  
chem otherapeutic drugs such  as anthracyclines, v in ca alkaloids, ep ip od oph yllotoxins, 
antim etabolites and covalent D N A  binding drugs. T h ese drugs can  specifically  target 
som e o f  the alterations on ly seen  in tum our cells, and can  interfere w ith  D N A , R N A  
and protein synthesis. H ow ever , the failure o f  tum ours to  respond to  chem otherapy is 
a significant problem  in  the clinic; a cancer m ay respond w e ll to  initial treatm ent but 
after a tim e b ecom e resistant to  further therapy.
1.1.1 Anthracyclines
A nthracyclines are popularly used  in cancer chem otherapy especia lly  doxorubicin  
(A driam ycin) and daunorubicin (D aunom ycin). Their principal m od e o f  action  is 
through  binding to  D N A  and intercalating b etw een  the paired b ases in  D N A . In doing  
this, they form  a tight drug-binding com p lex  w h ich  results in  cytotox icity . T he  
anthracyclines bind to  double stranded D N A , causing the D N A  to  u n co il at the site o f  
binding and inhibit the action  o f  top oisom erase II, an en zym e in volved  in  the control 
o f  D N A  supercoiling. A nthracyclines are also involved  in  the form ation o f  reactive  
o x y g en  sp ecies w h ich  induce D N A  strand breaks. D o xoru b icin  is cy to tox ic  to  both  
exponentially grow ing and lag  phase cells, although cells is the exponentia l phase are
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m ore sensitive to  adriamycin, probably due to  increased D N A  synthesis. B a rlog ie  et 
al (1 9 7 6 ) revealed that cells in the S phase o f  the cell cyc le  are m ost sen sitive to  
doxorubicin  treatm ent perhaps due to  the fact that the D N A  is  u n coiled  at th is phase  
for D N A  replication.
D oxoru bicin  is u sed  in chem otherapy o f  a broad range or cancers including breast, 
bladder, ovaries, lung, thyroid and stom ach  carcinom a, as w e ll as b on e and so ft tissu e  
sarcom as. D auonrubicin is principally u sed  in  the treatm ent o f  acute m yelog en o u s  
leukaem ia. A nthracyclines are adm inistered intravenously, and exhibit tw o -p h a se  
pharm acokinetics, D oxoru b icin  has an initial half-life ( a  t%) o f  10 m inutes fo llo w ed  
by a s lo w  decline over 3 0  hours (P t^ ). D aunorubicin  has half-lives o f  4 0  m inutes ( a  
t^ )  and 50  hours ((3 th)- H o w ev er  anthracycline treatm ent is associated  w ith  serious  
side effects, the principle being cardiotoxic effects (G audin et al, 1993; H utch ins et 
al, 19 93 ) and is believed  to  be due to  the generation  o f  reactive ox yg en  sp ecies  
(Pratt et al, 1994). A nthracyclines are also m utagenic, carcinogenic and cau se  
im m unosuppression.
1.1.2 Epipodophyllotoxins
P od op h y llo tox in  is  produced  by the plant podophyllum  peltatum  (A m erican  
m andrake) and is a m itotic  inhibitor that acts by b inding to  tubulin, b lock in g  
polym erisation  o f  tubulin thereby preventing the form ation  o f  m icrotubules (L on g
1992). Sem isynthetic derivatives o f  p od op h yllo tox in  including e top osid e  (V P -1 6 )  and 
ten ip osid e (V M -2 6 ) h ave been  used  in the treatm ent o f  hum an cancers su ch  as 
testicular, lym phom a, leukaem ia, and K ap osi’s sarcom a (V an  M aanen et al., 1988a, 
1988b).
T op o isom erase II is the major cellular target o f  th ese  drugs in hum an cancers (R o ss  
et al, 1984). The drug acts by stabilising th e com p lex  b etw een  top o isom erase  II and 
D N A , w h ich  causes an interference in  the activity o f  top o isom erase  II resulting in  
D N A  double strand breaks and cytotoxicity . T he m ain side e ffects  o f  
ep ip od oph yllotoxins is b on e m arrow  depression, w h ich  lim its their d osage. V P - 16
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and V M -2 6  are usually adm inistered intravenously and have a term inal half-life o f  
approxim ately 4 -8  hours, w ith  30-50%  o f  V P -1 6  recovered  as unchanged  drug in  
urine (Pratt el al., 1994).
1.1.3 Vinca Alkaloids
V in ca alkaloids are iso lated  from  the periw inkle plant catharanthus rosea, and 
include vincristine and vinblastine. T h ese drugs are com m on ly  u sed  in the treatm ent 
o f  acute leukaem ia, H od gk in ’s and n on -H od gk in ’s lym phom a, sm all-cell lung cancer, 
w ilm ’s tum our, neuroblastom a, rhabdom yosarcom a and E w in gs sarcom a (Pratt,
1994). C om plete rem ission  has b een  reported in  80-90%» o f  acute leukaem ias treated  
w ith  v in ca alkaloids (Pratt, 1994). V in ca  alkaloids exhibit a relatively lo w  tox ic ity  to  
b on e m arrow  cells, and are often  u sed  in com bination w ith  other chem otherapeutics.
T h e cy to tox ic  m echanism  o f  action  is through binding to  m icrotubules, and disruption  
o f  the balance b etw een  polym erisation  and depolym erisation  o f  m icrotubules. T hese  
drugs are usually adm inistered as bolus intravenous injection, and vinblastine has a 
term inal h a lf life o f  approxim ately 24  hours, w hereas vinblastine has a term inal half- 
life o f  about 85 hours. The m o st com m on side effect o f  v in ca  alkaloid treatm ent is 
peripheral neuropathy, although vinblastine has le ss  n eu rotox ic  side effects than  
vincristine. A nother relatively new , sem i-synthetic v in ca alkaloid is  vinorelb ine, w h ich  
is  com m only u sed  as a single agent in  the initial treatm ent o f  n on  sm all cell lung  
cancer (N S C L C ). T he incidence o f  neurotoxicity  associa ted  w ith  vinorelb ine is  
significantly lo w er  than that observed  w ith  other v in ca  alkaloids (H ohneker, 1994).
1.1.4 Taxanes
T axo l w a s  originally derived from  the bark o f  the pacific y e w  tree (Taxus brevifolia), 
but sem isynthetic derivatives had n o w  b een  developed . This class o f  drugs is very  
effective  in  the treatm ent o f  m etastatic breast cancer, refractory ovarian cancer, 
ovarian cancer, N S C L C  and squam ous cell carcinom a (Pratt, 1994). N eu trop en ia  is  
the m ost com m on side effect o f  taxo l treatment. T axanes act by stabilising
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microtubules, and induce formation of microtubule bundles, with minimal effects on 
the synthesis of DNA, RNA and protein.
1.1.5 Pyrimidine Analogues
Pyrimidine analogues are part of the antimetabolite family of drugs, which are 
structurally similar to existing compounds involved in cellular metabolic pathways. 
They induce cytotoxicity by interfering with production of nucleic acids by 
substituting themselves for purines or pyrimidines in the anabolic nucleotide 
pathways. For example 5-fluorouracil is a pyrimidine antagonist that is widely used in 
chemotherapy of the most commonly occurring types of solid tumours including 
colorectal, breast, head and neck, gastric and pancreatic cancers (Pratt, 1994). 5- 
fluorouracil is usually administered as a continuous infusion, and the most common 
side effects are gastrointestinal toxicity and bone marrow depression.
1.2 Chemotherapy Resistance
A recurrent problem in the treatment of cancer with antitumour drugs is the 
development of drug resistance. It is a major obstacle to successful chemotherapy . 
Over the past 25 years, extensive research has led to an understanding of some of the 
mechanisms responsible for drug resistance. Distinct biochemical and genetic 
alterations have been identified as key elements in the developments of drug 
resistance, and these resistance mechanisms can interplay with each other, further 
complicating the ability to overcome drug resistance. A cell may be intrinsically 
resistant (before drug treatment) or acquire resistance mechanisms after drug 
treatment. Many mechanisms of resistance have been identified such as development 
of drug efflux pumps (Pgp; MRP), alterations in expression of enzymes such as 
topoisomerases, and the drug detoxifying enzymes, glutathione-S-transferases 
(Bellamy, 1996).
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1.2.1 P-gly coprotein
By far the best characterised mechanism of resistance is that involving p- 
glycoprotein. Pgp was originally identified as a 170 kDa protein overexpressed in 
drug resistant cells (Juliano and Ling, 1976). Pgp is a membrane-associated, energy- 
dependent efflux pump encoded by the MDR1 gene, which is present on 
chromosome 7q21 (Bosch and Croop, 1998). It is a member of the ATP-binding 
cassette (ABC) transporter family. ABC transporters widely occur in many organisms 
such as bacteria, yeast, plants, insects, animals and humans (Ames et al. 1992) and 
serve as transporters across membranes in diverse functions such as nutrient uptake, 
ion transport, cell signaling and extrusion of toxins. Pgp is normally found in adrenal 
glands, kidney, liver, colon and rectum tissue in humans indicating that it has roles 
other than drug efflux. There are two classes of Pgps, class 1 includes the drug- 
transporting p-glycoproteins and class II are those not involved in drug resistance.
The treatment of human cell lines with chemotherapeutic drug results in the 
upregulation of Pgp mRNA and protein (Mickley el al. 1989; Mazzanti et al. 1996), 
and Pgp is expressed in a wide variety of tumours that exhibit multiple drug 
resistance (MDR). An MDR cell has the ability to develop cross-resistance to a broad 
range of structurally and functionally-unrelated drugs. Overexpression of Pgp in 
tumour cells can confer cross resistance to such drugs as anthracyclines, 
epipodophyllotoxins, vinca alkaloids, Taxol and actinomycin D (Germann and 
Chambers, 1998). High levels of Pgp expression have also been detected in many 
intrinsically resistant tumours. Overexpression of Pgp is associated with decreased 
cellular uptake of a drug, and allow cells to survive in the presence of higher drug 
concentrations.
1.2.2 MRP
Multidrug resistance-associated protein (MRP) is another member of the ABC 
transporter superfamily and like Pgp is involved in conferring an MDR phenotype to 
tumour cells (Cole et al. 1998). Quite often non-Pgp mediated resistance is due to
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the expression of MRP, and it has been identified in non-Pgp MDR from a variety of 
human cell types such as leukaemia, breast, non-small cell lung, small cell lung, 
cervix, prostate and bladder carcinomas. Cells can also co-express both Pgp and 
MRP, but the individual contributions from each protein is unknown. Several 
homologues of MRP exist in humans including cMOAT (multispecific organic anion 
transporter)/MRP2, hMRP3, hMRP4 and hMRP5 (Kool et al. 1997; Kool et al. 
1999a, 1999b). These proteins are thought to play a role in the detoxification 
process, and MRP is thought to be a clinically relevant marker of drug resistance.
MDR can also develop as a result of an alternative resistance mechanism that 
prevents cytotoxic drugs from reaching their cellular targets, and one such 
mechanism involves lung resistance-related protein (LRP). LRP is a human major 
vault protein (Scheper et a l , 1993) and may play a role in MDR. Overexpression of 
LRP has been found in many drug resistant cells, and could serve as a clinically 
relevant marker of drug resistance in vivo (Izquierdo et a l , 1998).
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1.3 Cellular effects of chemotherapy
1.3.1 Cell cycle effects
DNA damage is a consequence of chemotherapy in tumour cells, and this results in 
the cell shutting down its normal activities until DNA repair is completed. Many 
chemotherapy drugs affect the cell cycle by causing it to arrest either in Gl/S or 
G2/M phases. Certain drugs target a specific phase in the cell cycle, for example 
etoposide induces a G2/M arrest by reducing the activity of cdkl kinase, the main 
controller of mitotic entry (Lock and Ross, 1990a). Doxorubicin also induces a G2/M 
arrest, and at very high doses it can induce a Gl arrest (Barlogie et al., 1976).
Understanding the mechanisms regulating cell cycle progression and checkpoint 
activation in response to drug treatment is important for elucidating pathways that 
regulate normal growth, and also to understand how genetic defects identified in 
tumour cells can deregulate the cell cycle. Furthermore, differences in the response of 
normal and cancer cells to DNA damaging agents could lead to improvements in 
chemotherapy or design of novel drugs specific for defects in cell cycle control 
mechanisms of tumour cells.
1.3.2 Apoptosis induction
The majority of chemotherapy drugs eliminate cells by interfering with normal cellular 
metabolism and triggering apoptosis (Reed, 1997; Toft and Arends, 1997). 
Depending on the intensity of insult to the cell, either apoptosis or necrosis can take 
place. Apoptosis usually occurs in response to low or moderate damage, but necrosis, 
an unregulated catastrophic mode of cell death, occurs when the cell is intensely 
damaged or stressed. The fact that apoptosis occurs in response to chemotherapeutic 
drug treatment indicates the presence of a genetically controlled cell death pathway in 
cells, that can be triggered, and allows an organism to eliminate damaged cells in an 
orderly fashion.
8
Resistance to undergo chemotherapy-induced apoptosis represents another problem 
for successful chemotherapy. Elucidation of the apoptotic pathway and signalling 
cascades induced by drugs will hopefully allow the resistance to be overcome, and 
result in design of drugs that can specifically target and activate the apoptotic 
pathway in tumour cells.
1.3.3 Role of p53 in cellular response to chemotherapy
p53 tumour suppressor is a potent inhibitor of cellular proliferation (Lane, 1992; 
1993). The primary role of p53 is in maintaining genetic stability through elimination 
of cells with DNA damage from the viable cell population by cell cycle arrest or 
apoptosis. p53 is a critical mediator of a number of cellular responses to DNA 
damage including cell cycle arrest in G1 phase and induction of apoptosis.
In some cells, DNA damage can lead to an arrest in the G1 phase of the cell cycle 
(Pellegata et al. 1996). This phenomenon is largely co-ordinated through p53 
accumulation and activation, which induces p21 transcription (El-Deiry et al. 1993; 
Dulic et al. 1994; Agarwal et al. 1995). p53 acts as a sensor of DNA damage, and 
can induce cell cycle arrest before entry to S phase where replication of damaged 
DNA would be lethal for the cell. p21 actively inhibits entry to S phase of the cell 
cycle, and is further discussed in section 1.4.6. The G2 checkpoint, however seems to 
be independent of p53; cells containing mutated or null p53 do not arrest in Gl, but 
still arrest in G2 suggesting a separate checkpoint in G2 (Kastan et al. 1992; Kuerbitz 
et al. 1992; Han et al. 1995). p53 also plays a role in apoptosis induction in the 
presence of DNA damage induced by irradiation and anticancer drugs (Lowe et al. 
1993; Allday et al. 1995). It acts as an activator of apoptosis when DNA is damaged, 
however cells lacking p53 can still undergo apoptosis following irradiation and 
chemotherapy (Han et al. 1995), so the G2 checkpoint is thought to control 
apoptosis induction. However, the Bcl-2 family also play a critical role in induction of 
apoptosis, and this is further discussed in section 1.5.9.
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1.4 The Eukaryotic Cell cycle
1.4.1 Introduction
The animal cell cycle is a regulated process consisting of a round of DNA replication 
called S phase, followed by cell division or mitosis (M) in which the replicated 
chromosomes are segregated to form two identical daughter nuclei. Both these 
events are closely monitored to ensure that the S and M phases will occur in the 
correct sequence, so that M will not occur before S has completed and vice versa. 
Several control mechanisms have evolved to maintain the ordered sequence and 
prevent these events from occurring at inappropriate stages of the cell cycle. The cell 
cycle is outlined in figure 1.1. Gap phases termed G1 and G2 are present between M 
and S, and between S and M, respectively. These phases act as preparatory periods 
during which the cell can prepare for entry to S or M phases. There is also a resting 
phase termed Go, in which cells can remain for an indefinite period of time, during 
which cells become quiescent, but can re-enter the cell cycle at any time when 
conditions become favourable for growth and division (Pardee, 1989).
The cell integrates signals from the environment into the cell cycle, and depending on 
whether conditions are sub-optimal or favourable for growth, the cell can either grow 
and divide or remain quiescent. Therefore the cell requires a stringent regulatory 
mechanism to control entry to the cell cycle and progression though the various 
phases. Today’s understanding of the cell cycle comes from extensive studies in the 
budding yeast S. cerevisiae, fission yeast S. pombe, Xenopus eggs and more recently, 
mammalian cell systems.
The main controllers of the cell cycle are protein kinase complexes each consisting of 
a cyclin and a cyclin-dependent kinase (cdk). Nine cyclins have been identified to 
date, named in order of their discovery, cyclin-A, -B, -C, -D, -E, -F, -G, -H and I 
(Lew etal., 1991; Xiong et al., 1991; Koff etal., 1991; Bai etal., 1994; Bates et a l , 
1996; Nakamura et a l , 1995) and these are the regulatory and activating subunits of 
the complex. Cyclins were first identified in Xenopus eggs as proteins whose levels 
oscillated through the cell cycle and dropped after every mitosis (Evans et a l , 1983),
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suggesting that they might be proteins that control progress through the cell cycle 
and whose activity is regulated by the relative amount present. Cyclins share a 150 
amino acid region of structural homology called the cyclin box (Hunt et a l , 1995), 
and this is required for binding to cdks.
Cyclins have been classified as Gl or G2 cyclins depending on which phase they are 
involved in. The Gl cyclins including cyclin-C, -D and -E, are short-lived proteins 
that are degraded soon after their activity has peaked. This degradation is facilitated 
by the presence of a PEST region in the C-terminus of these cyclins (Deshaies et a l , 
1995). PEST is a sequence of four amino acids which confers instability to proteins 
by targeting it to the ubiquitination system of proteolysis. The G2 cyclins including 
cyclin-A and -B, are stable throughout interphase and are specifically degraded at 
mitosis. Degradation occurs due to the presence of a destruction box in the N- 
terminus of the protein; again, proteolysis occurs via ubiquitination (Glotzer et a l ,
1991). Cyclin F is the largest of the cyclins; lOOkDa and is also thought to be 
involved in cell cycle coordination throughout the cell cycle (Bai et a l , 1994). 
Cyclin-Gl and -G2 are unique in that they do not have a destruction box, or a 
destabilising PEST region, and expression increases after DNA damage, suggesting a 
role in negative regulation of the cell cycle (Bates et a l, 1996; Home et a l ,  1997). It 
has also been suggested that cyclin I may play a role in negatively regulating the cell 
cycle (Horne et al, 1997) although no definitive evidence exists to date.
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Cdks are the catalytic subunit of the cyclin-cdk complex and require association with 
a cyclin to attain peak kinase activity. Cdks were originally identified in budding yeast 
and called cdc (cell division cycle) proteins (Hartwell, 1970; Hartwell, 1991) on the 
basis that when these proteins were mutated, yeast cell division was inhibited. Eight 
cdks have been identified in mammalian cells and all share structural similarities 
including a PSTAIR motif which is thought to bind to the cyclin box. Each cdk 
interacts with a specific subset of cyclins, and these interactions are listed in table 1.1.
CDK CYCLIN PARTNER ACTIVITY PHASE
cdkl (cdc2) cyclin A, -B G2, G2/M
cdk2 cyclin A, -E Gl, S
cdk4 cyclin D entry to Gl
cdk5 cyclin D entry to Gl
cdk6 cyclin D entry to Gl
cdk7 cyclin H activating cdks in all phases
cdk8 cyclin C possible role in regulation of 
RNApolymerase
Table 1.1 cdks and their cyclin binding partners
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1.4.2 Activation of cyclin-cdk complexes
Cyclin levels vary throughout the cell cycle, and the fluctuations in levels control the 
activation of inactive cdks which are present in constant levels in the cell. Once the 
cyclin-cdk complex has formed, it becomes a substrate for a number of kinases which 
either positively or negatively regulate its activity, as outlined in figure 1.2. Cdks are 
regulated by a series of complicated mechanisms (reviewed by Morgan, 1995, Lees, 
1995). Activation of a cdk occurs when cyclin-cdk complex is phosphorylated on a 
conserved threonine residue, Thrl61 on cdkl, Thrl60 on cdk2 (De Bondt, 1993, 
Morgan and De Bondt, 1994, Russo et al., 1996). This activating phosphorylation is 
carried out by cyclin activating kinase (CAK) which is composed of cyclin H and 
cdk7 (Fesquet et al., 1993; Fisher and Morgan, 1994). Cyclin H and cdk7 also bind 
to a third protein to form a ternary complex, and this protein was identified as MAT1 
(menage-a-trois 1) and is thought to act as an assembly factor for the cyclin and cdk 
(Devault et a l , 1995). The assembly factor in some way promotes binding of the 
cyclin and cdk and activates the cdk.
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Figure 1.2 Regulation of cyclin-cdk complexes
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1.4.3 Inhibition of cyclin-cdk complexes
Inhibitory phosphorylations occur on the cdk near the ATP binding site (see figure 
1.2). Thrl4 and Tyrl5 are conserved phosphorylation sites in cdkl and cdk2, and the 
presence of phosphates on these residues inhibits kinase activity, perhaps through 
interference with ATP binding. Weel HU (originally identified in S. pombe) is 
responsible for phosphorylation on Tyrl5 (Parker et al., 1992, McGowan and 
Russell,1995, Watanabe et al, 1995, Blasina et al.,1997) and the human Mytl can 
phosphorylate both Thr 14 and Tyr 15 (Mueller et al., 1995, Liu et al., 1997, Booher 
et al., 1997), although Booher et al. (1997) revealed that Mytl only phosphorylates 
cdkl-containing complexes. The weel kinase plays an important role in mitotic 
control which will be discussed in section 1.4.7. The inhibitory phosphates are 
removed by a dual specificity phosphatase cdc25 (Lee et al., 1992) resulting in 
dephosphorylation and activation of the cyclin-cdk complex (see figure 1.2).
Three cdc25 homologues exist in humans, cdc25A, cdc25B and cdc25C. cdc25A is 
involved in activation of cyclin E-cdk2 (Hoffmann and Karsenti, 1994), cdc25C 
dephosphorylates and activates cyclin B-cdkl (Hoffmann et al, 1993), and cdc25B is 
thought to play a role in activating cyclinB-cdkl also. All cdc25 phosphatases must 
be phosphorylated themselves in order to become active and a positive feedback 
mechanism had been identified, through which active cyclinB-cdkl can activate 
further cdc25C. Cdks are also inhibited by the actions of a family of proteins called 
cell cycle inhibitors and will be discussed in section 1.4.6.
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1.4.4 Entry to cell cycle and G1 progression
Cells in culture entering G1 require serum mitogens continuously for a period of 
time, after which they become serum independent. The point at which they switch 
from being serum-dependent to serum-independent is called the Restriction point 
(Pardee et al., 1974), and at this point the cell commits itself to continue through the 
cell cycle.
The main cyclin-cdk complex involved in entry to G1 is cyclin D-cdk4. Cyclin D 
proteins are the rate limiting controllers of G1 phase progression, are induced by 
mitogens in G1 and synthesis throughout the cell cycle depends on persistent growth 
factor stimulation (Matsushime et al., 1991a, 1991b, 1992). If growth factors are 
removed before S phase entry D-type cyclins are rapidly degraded and the cell fails to 
enter S phase. However, if growth factors are removed after the Gl/S transition, cell 
division can still proceed. So cyclin D is most important in mid to late G1 when cells 
need mitogens to pass the restriction point. Cyclin D proteins therefore are mitogen- 
induced genes which act as growth factor sensors, linking the external environment to 
the cell cycle machinery. Cyclin D binds mainly to cdk4/cdk6 and kinase activity 
increases during mid G1 phase, peaking as the cells approach Gl/S boundary 
(Matsushime et al, 1994, Meyerson and Harlow, 1994). The retinoblastoma protein 
is one of the principle substrates of cyclin D-cdk4 (Kato et al., 1993; Dowdy et al., 
1993).
The main role of the retinoblastoma protein (pRb) is to act as a signal transducer 
linking the cell cycle to the transcriptional controls in the cell. It is a key protein in 
the transition between cellular proliferation and growth inhibition, a molecular switch 
that can suppress expression of genes needed for the progression of the cell cycle 
(For review, see Weinberg, 1995). The phosphorylation state is the primary control 
mechanism of pRb, and phosphorylation levels vary during the cell cycle (De Caprio 
et al, 1989,1992). When hypophosphorylated (mainly in Gl), pRb acts as a growth 
suppressor and binds to and negatively regulates the activity of transcription factors 
such as E2F, pi07, and pl30. These transcription factors play a critical role in 
progression into S phase and have consensus binding sites in the promoter regions of
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many genes required for S phase. When bound to E2F, pRb inhibits its function as a 
transactivator, thereby preventing induction of genes whose expression is required for 
cell cycle progression. However upon phosphorylation on specific sites, a 
conformational change occurs in pRb, and its growth suppressive effect on E2F is 
removed, releasing the transcription factor to activate genes required for Gl/S 
transition and S phase, such as c-myc, dihyrofolate reductase, cyclin E, cyclin A and 
cdkl. The process of cyclin D-cdk4 mediated release of E2F is outlined in figure 1.3.
Figure 1.3 Effect of cyclin D-cdk4 on pRb
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1.4.5 Entry to S phase
After induction of cyclin D, expression of cyclin E increases in iate G1 and binds to 
cdk2, thereby resulting in an accumulation of cyclin E-cdk2 complex levels (Dulic et 
a l , 1992), and cyclin E-cdk2 activity peaks at the Gl/S transition (Koff et al., 1992,
1993). Cells that fail to form active cyclin E-cdk2 complexes cannot pass the Gl/S 
transition confirming its role in control of entry to S phase (Koflf et al., 1993, 
Resnitzky and Reed, 1995). Once cells enter S phase, cyclin E is rapidly degraded 
resulting in the destruction of the cyclin E-cdk2 complex. However cdk2 can now 
form a complex with cyclin A, therefore cdk2 has two periods of oscillating activity, 
and it acts on different substrates depending on which cyclin it binds to.
Cyclin A-cdk2 activity is essential for initiation of S phase. Cyclin A levels begin to 
rise at the end of G1 phase, and cyclin A-cdk2 activity peaks at the onset of S phase. 
In early S-phase cyclin A-cdk2 binds directly to, and phosphorylates E2F, and in 
doing do inhibits its DNA binding ability, thereby inactivating E2F and turning off the 
Gl/S phase genes that are no longer required once the DNA replication has begun. 
(Krek et al., 1995, Xu et a l , 1994). Cyclin A also binds to cdkl during G2 phase 
(Pagano et a l , 1992), and is required during the G2/M transition, so cyclin A can 
play a role in two cell cycle phases depending on which cdk it binds to.
Cardoso et al. (1993) demonstrated that cyclin A co-localises with sites of DNA 
replication during S phase, suggesting that it may directly participate in the assembly, 
activation or regulation of replication structures. In fact, accumulating evidence 
implicates cyclin A-cdk2 as a negative regulator of DNA replication. Before initiation 
of replication, a number of proteins such as origin recognition complex (ORC) 
proteins, cdc6 and mini-chromosome maintenance (MCM) proteins form preinitiation 
complexes at replication origins. Piatti et al. (1996) revealed that an absence of cdk2 
kinase activity in G1 allows assembly of these proteins required for DNA replication. 
Low levels of cyclin A-cdk2 kinase activity during Gl/S allows initiation of DNA 
replication, and once replication begins at the onset of S phase, the cdk2 kinase 
activity increases. High levels of cyclin A-cdk2 activity during S phase then 
negatively regulates DNA replication, by preventing association of MCM proteins
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with chromatin (Hua et al., 1997). This inhibitory activity serves to limit DNA 
replication to a single round per cell cycle. Hua and Newport (1998) also discovered 
that the cdc6 protein in the preinitiation complex is targeted by cdk2 to be degraded, 
and this is a key step in the initiation of DNA replication, because failure to remove 
cdc6 results in inhibition of DNA replication.
Recently the replication activity of DNA polymerase was investigated during the cell 
cycle in the presence of cyclin E-cdk2 and cyclin A-cdk2 (Voitleitner et al., 1999). At 
peak activity in late Gl, cyclin E-cdk2 phosphorylates DNA polymerase and 
stimulates its activity, thus initiating DNA replication and onset of S phase. However 
cyclin A-cdk2 phosphorylates DNA polymerase during S phase and reduces its ability 
to initiate DNA replication in vitro. This study confirms the roles of both cyclin E and 
cyclin A in the initiation and progression of S phase, showing that cyclin E-cdk2 is 
necessary for initiation of S phase, and once DNA replication has begun, cyclin A- 
cdk2 ensures that it cannot be initiated again thus preventing re-replication.
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1.4.6 Cell Cycle inhibitors
In addition to inhibition by phosphorylation, cyclin-cdk complexes are inhibited and 
regulated by a group of proteins called cdk inhibitors (CKI). In animal cells two 
families of CKIs namely the Cip family and the INK4 family, have been identified 
based on protein sequence similarity, mechanism of inhibition and specificity,. The 
Cip family (cdk interacting proteins) is comprised of p21/CIPl/WAFl (Xiong et a l ,
1993), p27/KlPl (Toyoshima et al., 1994) and p57/KIP2 (Matsuoka et al., 1995), 
and they preferentially inhibit cdks of the Gl/S phase (Harper et a l , 1995, Sherr,
1995). p21 is the most extensively studied of this family (Gartel et a l , 1996, review). 
It can bind cdk2 and cdk4 in complex with cyclins and inhibit the phosphorylation of 
pRb and prevent cell cycle progression (Harper et a l , 1993). It is under the control 
of p53, and after DNA damage, p53 can induce p21 transcription, resulting in a cell 
cycle arrest. p21 exists in a quaternary complex with a cyclin, cdk and proliferating 
cell nuclear antigen (PCNA), a DNA replication factor (Flores-Rozas et a l ,  1994). 
By binding to PCNA p21 can inhibit DNA replication (Waga et a l , 1994). The 
stoichiometry ofp21 molecules in a cyclin-cdk complex governs its ability to inhibit 
the cyclin-cdk activity, and multiple molecules are required for cdk inhibition. In fact, 
complexes containing one molecule of p21 are still active (Zhang et a l , 1994, Harper 
etal., 1995).
p27 levels are elevated in terminally differentiated cells, and play a role in G1 
checkpoint. It is responsible for blocking cells in G1 phase in response to TGF(3 
treatment by potently inhibiting cyclin E-cdk2 (Polyak et a l , 1994). Even though p27 
levels are high in quiescent cells, they decrease rapidly when the cells enter the cell 
cycle in the presence of mitogens. If mitogens are removed, p27 levels rise again to 
inhibit cell cycle progression in conditions that are unfavourable for growth. In cells 
lacking p27, serum deprivation does not prevent cells from entering G1 (Kato et al.,
1994).
The INK4 (inhibitor of cdk4) family consists of pl5, pl6, pl8 and pl9. As the name 
suggests these are selective for cdk4 inhibition, and can inhibit monomeric cdk4 as 
well as cdk4 complexed with a cyclin (Hannon and Beach, 1994, Guan et al., 1994,
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Hirai et a l ,  1995). p 15, pl6, pl8, pl9, p21 and p27 have been shown to block 
phosphorylation of pRb by inhibiting cyclin D-cdk4 activity thus reducing E2F release 
and S phase entry (Xiong et a l , 1993, Hannon and Beach, 1994, Toyoshima et a l , 
1994, Hirai et a l , 1995, Lukas et a l , 1995). Therefore the activity of these inhibitors 
is critical in the timing and progression of S phase and proliferation, and any defects 
may lead to deregulated cell cycle control and unrestrained proliferation. Some of 
these defects will be discussed later.
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1.4.7 Entry to Mitosis
An understanding of the G2-M transition derived from genetic studies in a number of 
organisms such as fission yeast (S. pombe) and Xenopus eggs (Nurse, 1990, Norbury 
et al., 1991). The key component of the mitotic pathway in cells is a mitotic regulator 
comprised of cyclin B (Pines and Hunter, 1989) and the kinase catalytic subunit 
cdc2/cdkl (Draetta and Beach, 1988) which form mitosis-promoting factor (MPF) 
(Matthews and Huebner, 1985, Lee and Nurse, 1988).
MPF, once active can exert its effect on many cellular substrates to effectively and 
rapidly induce cytoskeletal rearrangement and cytokinesis. Indeed, the active kinase is 
intimately involved with reorganisation of the structural features of the cell during 
mitosis. Cyclin B-cdkl causes dramatic changes in the microtubule network, the actin 
microfilaments and the nuclear lamina. The nuclear lamina is a structure that underlies 
the nuclear membrane during interphase, and is composed of lamin subunits. Lamins 
are hyperphosphorylated at mitosis, promoting their disassembly (Nigg et a l ,  1992). 
Proteins in the intermediate filament network such as vimentin and desmin are also 
phosphorylated by cdkl, promoting their dismantling at mitosis (Chou et al., 1990). 
Another significant substrate is caldesmon, which is a component of cytoplasmic 
filaments and binds actin and calmodulin (Yamashiro et a l ,  1991). Histone HI when 
phosphorylated by cyclin B-cdkl, possibly plays a role in chromosome condensation 
during mitosis (Langan et al., 1989).
MPF is associated with a kinase activity that varies through the cell cycle, peaking at 
M phase and rapidly declining at the end of mitosis. Cyclin B levels accumulate 
gradually from Gl, and upon reaching a threshold level it binds to cdkl (Pines and 
Hunter, 1989). However the cyclin B-cdkl complex is not active until modified by 
phosphorylations resulting in an abrupt increase in cdkl kinase activity, promoting 
onset of mitosis. The switch that controls the transition between inactive cyclin B- 
cdkl and active cyclin B-cdkl is controlled by a number of phosphorylations as 
earlier described. Cdkl must be phosphorylated on Thrl61 by CAK for activity, and 
inhibitory phosphates occur on Thrl4 by Mytl and on Tyrl5 through the action of 
the mitotic inhibitor wee! (Parker and Piwnica-Worms, 1992). Weel was identified
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as a protein kinase that is required for delay in entry to mitosis (Russell and Nurse, 
1987, Featherstone and Russell, 1991). Weel is itself negatively regulated through 
phosphorylation by niml kinase. Cdk activity occurs through dephosphorylation of 
Thrl4 and Tyrl5 by the cdc25C phosphatase (Strausfeld et a l ,  1991). These 
inhibitory phosphates play a critical role in timing of entry to mitosis, and cells that 
have mutated cdkl which cannot be phosphorylated on Thrl4 and Tyrl5 fail to pause 
before entry to mitosis (Krek and Nigg, 1991, Norbury et al., 1991).
1.4.8 Regulation of Mitotic cdk controllers
Regulation of weel kinase and cdc25 phosphatase activities is one of the key 
determining factors in the timing of mitotic progression. Cdc25 is regulated through 
several complex pathways. Both cdc25B and cdc25C are involved in entry to mitosis, 
and show different patterns of activation during the cell cycle indicating that they 
have different roles to play in the activation of cyclin B-cdkl. Cdc25B activity 
appears in late S phase and peaks in G2 (Lammer et al., 1998). A rise in cdc25C 
activity was demonstrated by Izumi et a l (1992) as cells entered mitosis, and 
decreased upon exit from mitosis. The rise in cdc25C activity during mitosis is due to 
phosphorylation (Doree et a l , 1989, Hunt, 1989, Solomon et al., 1990) and active 
cyclin B-cdkl is capable of phosphorylating and directly activating cdc25C 
(Hoffmann et a l , 1993). This suggests that there is a positive feedback mechanism in 
which a small amount of already active cyclin B-cdkl can activate cdc25C, and this in 
turn dephosphorylates cdkl resulting in a rapid activation of cyclin B-cdkl. If 
phosphorylation sites in cdc25C are mutated, its mitosis promoting activity is reduced 
(Izumi and Mailer, 1993) thus supporting the idea of a role for cdc25C activation in 
progression through mitosis. However, the question remains as to what the initial 
activator of cyclin B-cdkl is, in order for the feedback loop to commence. Cdc25B is 
a good candidate for this, during G2 it is translocated into the cytoplasm, and 
cytoplasmic cyclin B-cdkl is an excellent substrate for cdc25B during late G2. 
Cdc25B could then dephosphorylate cyclin B-cdkl in the cytoplasm, promoting 
translocation of the active cyclin-cdk complex to the nucleus where it could 
phosphorylate and activate cdc25C thus initiating the feedback loop. However
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déphosphorylation of cdkl by cdc25B does not result in maximal cdk activity, but 
perhaps sufficient to phosphorylate cdc25C. Lammer et al. (1998) found that 
depletion of cdc25B prevented entry to mitosis in HeLa cells thus confirming a role 
for cdc25B in mitotic progression.
Cdc25 proteins can also be controlled by another family of proteins called polo-like 
kinases (Kumagi and Dunphy, 1996). In Xenopus, the polo-like kinase Plx can 
phosphorylate and activate cdc25C, and depletion of Plx suppresses cdc25C 
phosphorylation and cyclinB-cdkl activation (Abrieu etal., 1998).
1.4.9 Localisation control in mitosis
Many of the controller and effector proteins involved in mitosis are further regulated 
by their subcellular compartmentalisation during interphase and mitosis. Cyclin B has 
perhaps the most extensive restrictions. Three forms of cyclin B exist in different 
areas of the cell during the cell cycle. Cyclin B1-cdkl is located in the cytoplasm with 
microtubules during interphase, due to the presence of a cytoplasmic retention signal 
(CRS) in cyclin B1 (Pines and Hunter,1991, Heald et a l, 1993, Jackman et a l , 1995) 
but is rapidly translocated to the nucleus at the onset of mitosis. Cyclin B2-cdkl 
complex is found in the Golgi apparatus, apparently serving to phosphorylate and 
induce golgi fragmentation during mitosis (Lowe et al., 1998). Cyclin B3-cdkl is 
predominantly found in the nucleus throughout the cell cycle, and studies in 
Drosophila suggest that it may not be required for mitosis (Jacobs et a l , 1998).
Weel protein kinase has nuclear location until the onset of mitosis at which time it is 
transported to the cytoplasm, thus removing it from the nucleus where it has an 
inhibitory role, allowing cdkl activity to initiate mitosis (Baldin and Ducommun, 
1995, Heald et a l , 1993). Cdc25C is also regulated by subcellular localisation. 
Cdc25C is found in the nucleus during interphase and early mitosis (Miller et al.,
1991). Cyclin B-cdkl is localised to the cytoplasm during interphase (Pines and 
Hunter, 1991, Gallant and Nigg, 1991) and only enters the nucleus at the onset of 
mitosis, so by spatial separation cdc25C cannot be activated and consequently cyclin
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B-cdkl remains inactive until the required time. Thus the spatial organisation and 
temporal activation or inhibition of the MPF regulators is very important for the G2- 
M transition, onset of mitosis and cytokinesis.
1.4.10 Chemotherapy Drugs and G2/M Arrest
Treatment of cells with agents that cause DNA damage often leads to a delay or 
arrest in G2 of the cell cycle. G2/M arrest has been reported in cells after treatment 
with different drugs such as doxorubicin (Barlogie et a l , 1976, Krishan et a l , 1976, 
Kimler et a l , 1978), rubidazone, etoposide and melphalan (Barlogie et a l , 1978), 
also mitomycin C, bleomycin, hydroxyurea and lucanthone (Kimler el al., 1978). 
This delay is enforced by altered regulation of the G2/M controllers, mainly cyclin B- 
cdkl kinase activity. Alterations in the controllers of this kinase results in diminished 
activity and prevention of entry to mitosis, for example failure to dephosphorylate the 
inhibitory phosphates from cdkl results in an inactive cdkl which enforce a G2 delay. 
A summary of the possible alterations occurring after drug treatment is outlined in 
figure 1.4.
During a G2/M arrest there is altered regulation of cyclin B and cdkl (Tsao et a l ,
1992). Cyclin B protein levels were also found to be decreased after an ionising 
irradiation-induced G2/M arrest (Muschel et a l , 1991, Datta et al, 1992), however 
no changes in cdkl or cdc25 protein levels were reported, so the regulation of the 
proteins must be other than at a translational level (Datta et a l , 1992). Preliminary 
studies by Lock and Ross (1990, 1991) demonstrated a decrease and inhibition of 
cdkl kinase activity during a G2 arrest after etoposide treatment. They consequently 
demonstrated that the inhibition of kinase activity after etoposide treatment was due 
to a failure to dephosphorylate the activating tyrosine residue (Lock, 1992), even 
though cyclin B-cdkl complex forming ability is not affected (Lock and Keeling,
1993). More recently Ling et al. (1996) studied the effect of Doxorubicin on P388 
cells and found inhibition of cdkl activity due to absence of dephosphorylation on 
Tyrl5. Other chemotherapy drugs such as cisplatinum (Nishio et a l , 1993), 
camptothecin (Tsao et al, 1992), nitrogen mustard (O’Connor et a l , 1992), 5-
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fluorouracil (Okamoto et al., 1996) and nucleoside analogues (Halloran et a l ,  1998) 
have been shown to induce a G2/M arrest, induced by a failure to dephosphorylate 
Tyrl5 of cdkl resulting in a reduced cdkl kinase activity. In addition, Weel activity 
is reportedly disrupted during a G2 arrest (Leach et al., 1998). Cdc25C activation 
has been shown to decrease after irradiation, and reduction of cdc25C phosphatase 
activity results in increased inhibitory phosphorylation of cdkl in cells after treatment 
with DNA damaging agents. These findings are summarised in figure 1.4.
Drug treatment '
e.g. Doxorubicin
Cyclin B Cdkl expression Cdc25C expression Weel expression
expression altered not affected not affected altered?
I
Cyclin B-cdkl 
complexes form
i
Inhibitory P on 
Y15 not removed
I
I
Cdc25C activity 
maybe decreased
Cyclin B-cdkl 
kinase activity 
decreased
I
G2/M arrest
Figure 1.4 Summary of cellular effects of drug treatment resulting in G2/M 
arrest
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1.4.11 DNA Damage Checkpoints
The fact that cells have the ability to arrest after experiencing damage to their DNA 
led to the discovery of cell cycle checkpoints. Checkpoints exist in the cell cycle to 
act as regulatory surveillance mechanisms to control the order and timing of the 
critical events of DNA replication in S phase and chromosome segregation at mitosis. 
Therefore the checkpoint response plays a significant part in maintaining genomic 
stability throughout the cell cycle, by monitoring the state of the DNA and arresting 
cell cycle progression in response to DNA damage or inhibition of DNA replication 
(Elledge, 1996).
1.4.12 G2/M Checkpoint pathway in response to DNA damage
A family of DNA damage sensor proteins, called Rad proteins, exist in fission yeast 
(S. pom be) which are required for checkpoints to occur (Carr, 1997). Human 
homologues of these DNA damage sensor proteins have been identified 
demonstrating an evolutionary conserved checkpoint pathway (Review, Weinert, 
1998). When DNA damage occurs, checkpoint proteins such as Rad24 bind to 
damaged DNA (Garvik et al., 1995) which results in phosphorylation of Rad9 (Emili 
et al., 1998, Sun et al., 1998). Rad9 is essential for a checkpoint to occur, and is 
thought to phosphorylate another Rad family member, Rad53, also essential for cell 
cycle arrest in response to DNA damage (Walworth, 1998, Sun et al., 1998). This 
process is illustrated in figure 1.5. Until recently the exact mechanism of interaction 
between checkpoint proteins and the cell cycle was unknown, but it has been 
suggested that in some way they could arrest the cell cycle through indirect inhibition 
of cdkl kinase.
DNA damage
*  cell cycle arrest in
Activation of C hkl 
protein leading to
G2/M
Phosphorylation
of Rad 9
Figure 1.5 DNA damage-induced G2/M Checkpoint
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The link between the DNA damage sensor proteins and the cell cycle emerged from 
the discovery that human cdc25C is phosphorylated on a specific residue in response 
to DNA damage (Peng et al., 1997). Phosphorylation is carried out by Chkl protein 
kinase, a homologue of the S. pombe Chkl which is required for the DNA damage 
checkpoint. In response to DNA damage Chkl is activated, presumably by the Rad 3 
and other Rad proteins (Walworth et al., 1996). When Chkl is active, it 
phosphorylates Cdc25C on ser216, and induces a conformational change which 
creates a binding site for 14-3-3 proteins (Furnari et al., 1997, Sanchez et al., 1997) 
resulting in the inhibition of cdc25C’s ability to dephosphorylate and activate cdkl. 
Therefore the key event in the pathway leading to G2/M arrest is the phosphorylation 
of cdc25C by Chkl (see figure 1.6).
However the phosphorylation of cdc25C by Chkl, and binding of 14-3-3 protein to 
cdc25C does not reduce the enzymatic activity of cdc25C, so another regulatory 
mechanism must exist, perhaps involving limiting substrate availability. Cdc25C is 
cytoplasmic during interphase, and enters the nucleus at G2 to initiate M. Chkl is 
nuclear, and when cdc25C is phosphorylated by Chkl in the nucleus in response to 
DNA damage, a nuclear 14-3-3 protein binds (Lopez-Girona et a l , 1999). Rad24 is a 
14-3-3 protein important in the DNA damage checkpoint pathway in fission yeast (S. 
pom be), and it is a sufficiently small protein that can passively diffuse in and out of 
the nucleus. It contains a hydrophobic region called a nuclear export signal (NES) 
which exports it from the nucleus. Lopez-Girona el al. (1999) recently demonstrated 
that Rad24 binds to phosphorylated cdc25C after DNA damage and escorts it from 
the nucleus, thus separating cdc25 from its substrate cyclinB-cdkl.
28
DNA Damage
i
Rad 3, Rad 24
1
!' Clikl f  chk-1 f P Ì Levels increase
active c dc25 -S216 cdc25-s2i6- 14-3-3 
Inactive cdc25
(c d c 2 lYI5-P
inactive
Figure 1.6 G2/M Checkpoint in response to DNA damage
Another mechanism regulating G2 arrest following DNA damage involves the cellular 
localisation of cyclin B. Smeets et al. (1994) demonstrated that cyclin B was 
cytoplasmic in cells arrested after DNA damage and the restriction of cyclin B to the 
cytoplasm contributed to the G2/M arrest (Jin et al., 1996). Jin et al. (1998) reported 
that expression of cells with a mutant cyclin B which remains in the nucleus 
throughout the cell cycle results in cells that can override a G2/M arrest after DNA 
damage, thus confirming that cyclin B localisation assists the G2/M arrest after DNA 
damage. Consistent with these findings, Toyoshima et al. (1998) reported that cells 
expressing mutant nuclear cyclin B fail to exhibit a G2 delay following DNA damage. 
Recently Innocente et al. (1999) established that p53 arrests the cell cycle in G2 by
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lowering intracellular levels of cyclin B and attenuating the activity of the cyclin B 1 
promoter. Taken together, these results suggest that maintenance of Thrl4 and 
Tyrl5 phosphorylation of cdkl and nuclear export of cdkl-cyclin B are the two 
primary mechanisms through which eukaryotic cells achieve a G2 arrest following 
DNA damage.
1.4.13 Cell Cycle and Cancer
To maintain the stability of their genome, proliferating cells normally arrest in either 
Gl/S or G2/M in response to cellular damage, and the presence of these checkpoints 
provides the cell with additional time for repair processes to remove any potentially 
lethal damage before DNA is replicated or segregated. A wealth of evidence supports 
the idea that loss of checkpoint control can lead to genomic instability, inappropriate 
survival of genetically damaged cells and the evolution of cells to a malignant state 
(Kaufmann et al., 1995; Paules et a l , 1995).
Dysregulation of cell proliferation is a frequent event in tumorigenesis, and this 
unconstrained proliferation can be a result of gain or loss of function of the proteins 
that control the cell cycle. Many of the cell cycle proteins associated with Gl- S 
transition in the cell cycle are altered in some way leading to a destabilisation of the 
normal growth control pathway and unrestrained proliferation. Moreover the 
majority of tumours have mutations in one or another of the genes involved in 
controlling progression throughout the Gl phase of the cell cycle. Malignant cells 
acquire independence from the mitogenic signals that are normally required for cell 
cycle progression. Cells lacking p53 fail to arrest in Gl or G2 after DNA damage, 
demonstrating that lack of p53 can result in defective checkpoint control and enhance 
the genomic instability and genomic rearrangements (Kastan et a l , 1991, Hartwell,
1992).
Cyclin D1 acts as a positive regulator of Gl by removing the growth suppressive 
function of Rb. Any defect in the action of cyclin D such as overexpression will lead 
to Rb being constantly hyperphosphorylated thus allowing free E2F to induce
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transcription of S phase genes. Cyclin D1 has been mapped to the llql3 locus close 
to the BCL1 region, which is frequently amplified in many tumours (see review, 
Motokura and Arnold, 1994). Overexpression of cyclin D1 is associated with poor 
prognosis of patients with breast cancer (Borg et al. 1991; Schuuring et al, 1992; 
Michalides et al., 1996, van Diest et al., 1997) and human pancreatic carcinoma 
(Gansauge et al., 1997). Antisense cyclin D1 can decrease cyclin D1 levels and 
prevent tumorigenicity in human colon carcinoma cell lines (Arber et al., 1997).
pl6 is frequently mutated, deleted or inactivated through methylation in many 
different types of human cancers, suggesting its role as a tumour suppressor. 
Deletions and mutations of chromosome 9p21, the location of pi6, occurs very 
frequently in pancreatic, head and neck, non-small cell lung, bladder and ovarian 
carcinomas (Hall and Peters, 1996), and perhaps is the most common genetic 
alteration in human lymphoblastic leukemia (Kamb et al., 1994, Hussussian et 
a l, 1994, Quesnel et a l , 1994). Furthermore, pi 6-null mice spontaneously develop 
aggressive tumours within 6 months (Serrano et al., 1996). Cdk4 overexpression or 
mutation can be detected in various tumour types including glioblastoma and 
melanoma (He et al., 1994, Bartkova et al., 1996). There is also a possibility that 
cells may acquire resistance through altered expression of cell cycle regulatory genes 
(Hocchauser, 1997)
The G2 checkpoint is also implicated in tumorigenesis. Attenuation or inactivation of 
the G2 checkpoint can result in cells with increased genomic instability, and also 
promotes immortalisation in normal human fibroblasts (Kaufmann et a l , 1995). 
Paules et al. (1995) investigated the G2 checkpoint control in familial cancer 
syndromes and concluded that these cells have a defective G2 checkpoint which may 
have contributed to development of tumorigenesis.
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1.5 Apoptosis
1.5.1 Introduction
Apoptosis is a genetically regulated biological process that is fundamental to the 
development of organisms and to homeostasis of tissues (Kerr el a l , 1972). Various 
stimuli can trigger diverse regulatory pathways which activate a conserved execution 
machinery. This results in dramatic structural changes such as cytoplasmic shrinkage 
and distortion, membrane blebbing and formation of membrane-bound cell fragments 
called apoptotic bodies. These changes are accompanied by chromatin condensation, 
a cytosolic increase in Ca2+, decrease in cellular pH and DNA cleavage and 
fragmentation (Cobb et al., 1996, Umansky (review), 1996).
All nucleated animal cells constitutively express the entire complement of proteins 
required to undergo programmed cell death (Tamaoki and Nakano, 1990). Apoptosis 
serves many functions in animal development such as sculpting structures; eliminating 
cells between developing digits, controlling cell numbers and deleting unwanted 
structures, such as female reproductive organs in males. Any abnormal, misplaced or 
harmful cells are also eliminated by apoptosis (Jacobson et a l ,  1997).
The best characterised cell death pathway to date is in Caenorhabditis elegans. This 
roundworm is 1mm in length and during the course of its development, 131 out of 
1090 cells are genetically programmed to die. Using genetics and loss-of-function/ 
gain-of-function experiments, 13 genes involved in programmed cell death have been 
discovered which have helped to elucidate the apoptotic pathway in humans. These 
are summarised in table 1.2.
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GENE FUNCTION HUMAN HOMOLOGUE
ces-1 prevents neuronal cell death not known
ces-2 negatively regulates ces-1 HLF (hepatic leukemic factor)
egl-1 induces apoptosis BH-3 domain proteins
ced-3 promotes apoptosis Caspases
ced-4 in combination with ced-3, promotes 
apoptosis
Apaf-1
ced-9 prevents apoptosis Bcl-2
ced-1
ced-6
ced-7
engulfment of cell corpses
ABC transporter (ced-7)
ced-2
ced-5
ced-10
engulfment of cell corpses and migration 
of distal-tip cells DOCKI8O (ced-5)
nuc-1 degradation of DNA caspase-activated nuclease (CAD) (putative)
Table 1.2 Genes involved in the apoptotic pathway in C. elegans
Although this overall pathway is poorly understood, it is now accepted that caspases 
play a key role in the regulation of this biochemical process. Caspases comprise a 
family of cysteine proteases which have similar cleavage specificity in that they cleave 
their substrates after an aspartate residue. They are synthesised as a inactive 
precursor, which must be proteolytically cleaved at specific aspartate residues to 
become active. They can be cleaved themselves (autoprocessing) or by other 
enzymes.
1.5.2 Discovery of ICE
Initial studies on Caenorhabditis elegans revealed a ced-3 gene, which is essential for 
cell death to occur in the worm (along with ced-4). This ced-3 gene encoded a
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protein, which has significant homology to the human interleukin-ip-converting 
enzyme (ICE). ICE is a cysteine protease that cleaves pro-interleukin-ip to generate 
the active form. ICE, synthesised as a 45 kDa proenzyme, is then cleaved into two 
subunits of 20kDa and lOkDa, the active enzyme consisting of two 20kDa and two 
lOkDa subunits.
Overexpression of genes encoding ICE induces apoptosis in mammalian fibroblasts 
(Miura et al. 1993) suggesting a role for ICE in the apoptotic pathway. However 
ICE- knockout mice seem to develop normally and appear healthy, thus questioning 
the role of ICE in apoptosis. In addition Kuida et al. (1995) found ICE-null mice to 
be resistant to killing by Fas-mediated apoptosis, while retaining their sensitivity to 
most other forms of apoptotic induction. Currently the only known substrate of ICE 
is pro-lL-ip, this raised the possibility that additional proteases were involved in the 
apoptotic process.
Subsequent research led to the discovery of ICE-like proteases based on their 
structural homology to ICE and CED-3. Identification and studies of ICE-like 
proteases were carried out in a number of ways; gene-knockout studies to look at the 
effect of absence of a protease gene on apoptosis, transfection studies to look at the 
effect of overexpression of a protease gene on apoptosis and finally protease inhibitor 
studies to look at the effect of inhibiting a protease.
Since the discovery of the similarity between CED-3 and caspase-1 (ICE), a large 
family of proteases have been identified comprising of 14 (to date) caspases, and are 
listed in table 1.3. All identified caspases are structurally related, share amino acid 
homology and have an essential cysteine residue in their pentapeptide active site; 
QACxG
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CASPASE OTHER NAMES PROPOSED FUNCTION
caspase-1 ICE n/a
caspase-2 Nedd-2 / Ich-1L effector caspase
caspase-3 CPP32 / YAMA / apopain effector caspase
caspase-4 ICErein / Tx / Ich-2 development
caspase-5 ICEreim inflammation
caspase-6 Mch2 effector caspase
caspase-7 Mch3 / ICE-LAP-3 effector caspase
caspase-8 MACH/FLICE/Mch5 initiator caspase
caspase-9 ICE-LAP6/Mch6 initiator caspase
caspase-10 Mch4 initiator caspase
caspase-11 Ich-3 inflammation
caspase-12 —
caspase-13 ERICE
caspase-14 MICE
Table 1.3 Caspases involved in the apoptotic pathway
Caspases are expressed as inactive proenzymes and range in size from 20 to 50 kDa. 
The proenzyme is cleaved after a specific Asp residue to form two active subunits of 
20 kDa and 10 kDa, although this can vary in size depending on the caspase in 
question. Caspases are composed of three domains, the prodomain at the NH2- 
terminal, the large p20 subunit and the small plO subunit. See Figure 1.7.
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Figure 1.7 Activation of caspases
Activation of caspases involves proteolytic processing of the procaspase resulting in 
cleavage of the prodomain and two subunits. These subunits then heterodimerise and 
bind to another heterodimer of the same caspase to form a tetramer (see figure 1.7). 
A tetrameric formation is essential for catalytic activity of the complex and substrate 
binding (Walker et al., 1994; Wilson el al., 1994).
A linker domain sometimes separates these subunits. The function of the linker 
domain is as yet unknown but may play a role in caspase regulation. The prodomain 
is highly variable in length and sequence. Caspases with short prodomain include 
caspase-3, -6, and -7, whereas caspases with long prodomains include caspase-1, -2, 
-4, -5, -8, -9, and -10. It is thought that the main function of prodomains is in the 
regulation of the activation of procaspases. Van Creikinge et al. (1996) demonstrated
36
that the prodomain of caspase-1 (ICE) is absolutely required for dimérisation and 
autoactivation to occur, and that dimérisation occurs before activation.
1.5.3 Caspase Specificity
Caspases have a unique specificity in that they cleave directly after an aspartate 
residue. Caspases are among the most specific of proteases, with an absolute 
requirement for an aspartate residue in the PI position of their substrate cleavage 
site. Therefore the sequence of amino acids at the N-terminal side of the cleavage site 
in the substrate is important, and four amino acids at the positions PI, P2, P3 and P4 
directly influence the ability of a particular caspase to cleave a substrate. Sleath et al. 
(1990) originally established that ICE had a requirement for Asp in the PI position, 
and all identified caspases share this phenomenon. The cleavage site in procaspases is 
located directly after the Asp residue, and from this evidence it was shown that 
caspases are involved in the cleavage of other caspases, and led to the emergence of 
the hierarchical theory. Based on the substrate specificity caspases can be grouped 
into three categories (Thornberry et a l, 1997; Talanian et al., 1997). All caspases 
have stringent requirement for Asp in PI, the next most important residue is P4, and 
this is the determining factor for substrate specificity.
GROUP SEQUENCE-P4P3 P2 Pi MEMBERS
I WEHD Caspase-1, -4, -5
II DExD Caspase-2, -3, -7
III L/VExD Caspase-6, -8, -9
Table 1.4 Sequence Specificity of caspases
Caspases have overlapping substrate specificities, and this may indicate a certain 
degree of redundancy. Group I caspases (caspase-1, -4, -5) can tolerate large aromatic
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or hydrophobic amino acids in P4. Group II caspases (caspase-2, -3, -7) require an Asp 
residue in P4. Group m caspases (caspase-6, -8, -9) prefer amino acids with large 
aliphatic side chains but can tolerate many different amino acids in P4. P3 residue can be 
substituted generally without any major effects on enzymatic activity, except for caspase- 
9, which has an absolute requirement for His in this position. Glu is the preferred P2 
residue for all caspases.
In addition to the above findings, Talanian et al. (1997) showed that caspase-2 requires an 
additional P5 residue in its substrates for maximum activity, but this can be one of a 
specific set of amino acids. The substrate specificity of caspase-6 is interesting because 
these preferred sequences are found in the activation site of caspase-3, indicating that 
caspase-6 may act upstream of caspase-3.
One other important finding by Thomberry et al. (1997) was that caspase-1, -2, -4, -5, -8 
and -9 have long prodomains, and their substrate specificity sequences are very similar to 
their activating sequences, suggesting autocatalysis.
This finding of caspase substrate specificities led to an understanding of their biological 
functions. When the substrate specificity sequences of group III (-6, -8, -9) were 
compared to caspase amino acid sequences, it was noted that these specific sequences 
were found in the activation sites of both caspase-3, and -7, indicating that group m  
caspases were upstream components which could amplify an apoptotic signal in the 
caspase cascade. Caspase-3 and -7 must therefore be downstream effectors.
1.5.4 Caspase Inhibitors
The cowpox virus protein CrmA is a potent inhibitor of ICE. CrmA is a serpin (serine 
protease inhibitor) which contains a tetrapeptide sequence that ICE recognises as a 
cleavage site. It can therefore bind to ICE and prevent the active protease from its 
normal activity. CrmA expression can protect cells against apoptosis induced by 
many different agents (Gagliardini et al., 1994, Tewari et al. 1995). Baculovirus p35
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also inhibits ICE activity but has a much broader spectrum of activity (Bump et al.,
1995).
The fact that these proteins could suppress apoptosis by inhibiting ICE provided 
researchers with a very powerful tool with which they could further investigate the 
role of ICE-like proteases in apoptosis. This led to the development of synthetic 
inhibitors with specific target sequences to which the ICE-like proteases could bind 
and cleave.
As previously mentioned, there are three groups of caspases based on their substrate 
specificity. An important point to note is that the different families act on different 
substrates. Based on a specific substrate sequence, synthetic inhibitors can be 
designed to specifically inhibit, a particular protease. All inhibitor peptides contain the 
aspartate residue, which is essential for cleavage. Caspases similar to ICE 
preferentially bind to YVAD, Y being hydrophobic, consequently ICE-specific 
inhibitor peptides contain a YVAD tetrapeptide. CPP3 2-like proteases must bind to a 
sequence with an anionic residue, usually another aspartate, DEVD, so CPP32- 
specific inhibitors utilise this sequence. This sequence is also seen in substrates such 
as PARP, Ul-70kDa and DNA-dependent protein kinase. Depending on the group 
conjugated to the peptide, the inhibitor can be reversible or irreversible. Reversible 
inhibitors have nitriles, ketones or aldehydes conjugated to the peptide (e.g. Ac- 
VAD-CHO, Ac-YVAD-CHO), while irreversible inhibitors have thiomethylketones 
conjugated. Cell permeability can be achieved by addition of groups such as 
fluoromethylketones (e.g. DEVD.fink).
Studies using such inhibitors have confirmed the involvement of various caspases in 
apoptosis. DEVD-CHO, the CPP32-specific inhibitor has been shown to inhibit 
apoptosis induced by Fas (Gamen et al., 1996; Hasegawa et al., 1996; Anel et al., 
1997) and by granzyme B (Anel et al., 1997), therefore effectively inhibiting CPP32 
activity and showing that caspase-3 has a dominant role in Fas- and granzyme B- 
mediated apoptosis. Similar studies have been carried out using the YVAD, the ICE- 
specific inhibitor (Shimizu et al. 1995, 1996) to investigate the possibility of the 
existence of an ICE cascade using ICE inhibitors YVAD and DEVD. When ICE is
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specifically inhibited they found CPP32 to be also inactive, but when CPP32 was 
specifically inhibited, there was no effect on the activity of ICE. This suggests that 
ICE is active upstream of CPP32, and may participate in a protease cascade.
1.5.5 Proteolysis and caspase substrates
When apoptosis occurs in a cell it is accompanied by many ultrastructural changes, that 
are manifested as the prominent hallmarks of apoptosis - cell shrinkage, membrane 
blebbing, chromatin condensation and DNA fragmentation. The contribution of caspases 
to this process is not completely clear but there is a co-ordinated regulated hierarchical 
sequence of protein cleavage that leads to the eventual dismantling of the cell. Over 40 
proteins have been identified which are cleaved during apoptosis, but so far only a small 
number of these have been shown to play a definite role in apoptosis. These proteins are 
modified in such a way as to alter their normal role and contribute to the induction of 
apoptosis. Caspases promote disassembly in a number of ways such as nuclear structural 
protein cleavage, cytoskeletal protein cleavage, cleavage of membrane transport proteins, 
and inactivation of protective proteins.
Lamin cleavage
Lamins are intermediate filament proteins responsible for the structural rigidity of the 
nuclear membrane. During apoptosis nuclear lamina collapse when lamins are cleaved 
allowing chromatin condensation to take place. Zhivotovsky et al. (1997) reported 
caspase involvement in the cleavage of lamins during apoptosis, but the caspase involved 
was not responsible for PARP cleavage. Caspase-6 and not caspase-3 is responsible for 
cleavage of lamin A and is the main laminase in the cell (Takahashi el al., 1996; Orth et 
al., 1996).
PARP cleavage
PARP is a 116kDa nuclear DNA repair enzyme, that is cleaved during apoptosis into a 
98kDa and 25 kDa fragment, and is a widely used marker for onset of apoptosis. This 
cleavage may interfere with its role as a DNA repair enzyme. Tewari et al. (1995) and 
Nicholson el al. (1995) confirmed that PARP is specifically cleaved in vitro by
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caspase-3, and this along with caspase-7 are the main caspases responsible for PARP 
cleavage (He et al., 1998). The biological relevance of PARP cleavage is questionable 
however because PARP-deficient mice appear to develop normally (Wang et al., 1995). 
PARP is now a readily accepted indicator of apoptosis, by monitoring the appearance 
of one or both of the cleavage products (for example see He et al., 1998).
Fodrin Cleavage
Fodrin is an abundant membrane-associated cytoskeletal protein that is cleaved early 
during apoptosis, possibly allowing membrane blebbing and cell shrinkage to take place. 
Janicke et al. (1998) reported an absolute requirement for caspase-3 in fodrin cleavage 
during apoptosis in MCF-7 cells.
Gelsolin cleavage
Gelsolin is another important cytoskeletal protein cleaved during the onset of apoptosis. It 
is involved in Ca2+-dependent cleavage of actin filaments to form monomeric actin. 
However when gelsolin is cleaved during apoptosis, it cleaves the filamentous actin in a 
Ca2+-independent manner, and is thought to mediate morphological changes in apoptosis 
(Kothakota el al, 1997).
Kinectin cleavage
An example of caspase-mediated inhibition of membrane transport during apoptosis is the 
cleavage of kinectin, which is a kinesin-binding integral membrane protein anchored in the 
endoplasmic reticulum. Kinesin is an ATP-driven motor protein involved in membrane 
trafficking pathways. During apoptosis kinectin is cleaved which in turn inhibits the 
kinesin activity (Machleidt et al., 1998). Caspase-7 specifically cleaves kinectin, which is 
interesting given that the specificity profile for caspase-3 and -7 are almost 
indistinguishable.
Cleavage of ICAD
DNA fragmentation is a critical event in the apoptotic process and is brought about 
through the activation of Dnases and nucleases which can cleave the DNA into fragments. 
The activation of Dnases has been found to be regulated by caspase activity. Caspases can 
cleave an inhibitor of Dnase, which then allows activation of Dnase. ICAD (inhibitor of
41
CAD), also known as DNA fragmentation factor (DFF) is a subunit of CAD (Caspase 
Activating Dnase) and is cleaved during apoptosis in living cells. Intact 1°® remains 
bound to CAD and inhibits Dnase activity. However, during apoptosis ICAD is cleaved to 
form a 1 lkDa fragment, and cleavage results in the inhibitory actions being removed from 
CAD. Then CAD is free to activate Dnase and nucleases which bring about DNA 
fragmentation. Active caspase-3 is required for lCAD cleavage and activation of the 
enzyme (Tang and Kidd, 1998). Liu et al. (1997) demonstrated that once caspase-3 
cleaves ICAD its activity is no longer required for DNA fragmentation to occur. This raises 
the possibility that caspase-3 mediated cleavage of ICAD is the triggering factor for DNA 
fragmentation. CP AN (Caspase activated nuclease) is a homologue of 1°® (Halenbeck et 
al., 1998).
Altogether cleavage of these proteins results in the shutdown of many cellular activities 
like membrane trafficking, DNA repair, mRNA splicing and disruption of the cytoskeleton 
and nuclear membrane thus leading to the disassembly of the cell.
42
1.5.6 Apoptotic Execution pathway
Since all caspases cleave after an Asp residue, the notion that caspases could sequentially 
activate others arose, and was confirmed with evidence of the existence of a caspase 
cascade. Enari et al. (1996) demonstrated that Fas sequentially activates ICE-like and 
caspase-like proteases, and cpp3 2-like proteases act downstream together with a 
cytosolic component to induce apoptosis. Greidinger etal. (1996) also provided evidence 
of a sequence of caspase activation, which was accompanied by a sequence of substrate 
cleavage.
Initiator and Effector Caspases
When a pro-apoptotic stimulus "damages" the cell, the signal is transduced through the 
membrane-associated receptors and promotes activation of the initiator pro-caspases 
(such as caspase-8, -10, -9). These in turn activate the effector pro-caspases downstream, 
and the effector caspases in conjunction with certain cofactors implement the execution 
phase of apoptosis - namely the morphological and biochemical features of apoptosis. 
Caspase-8 has been shown to activate many of the other caspases indicating that it must 
be at the apex of the cascade. Recently procaspase-3 was confirmed as the major cellular 
target of caspase-8 activity (Stennicke et al. 1998). Different stimuli activate different sets 
of initiator caspases, but these distinct signals are thought to converge into one common 
pathway involving the effector caspases. An outline of this proposed system can be seen 
in figure 1.8 and will be discussed in the following sections.
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Figure 1.8 Outline of apoptotic pathways in the cell
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1.5.7 CD95 Pathway
A growing number of cell surface receptors have been identified that play an important 
role in signal transduction in the apoptotic pathway. The best characterised receptors are 
CD95 (Fas/APO-1) and tumor necrosis factor receptor TNFR1 (p55/CD120a) 
(Nagata,1997) which belong to the TNF superfamily of type I transmembrane receptors. 
Other receptors recently identified by their homology to the CD95 and TNF receptors are 
DR3 (Chinnaiyan et al., 1996; Marsters et al., 1996), DR4 (Pan et al., 1997), DR5 (Wu 
et al., 1997) and DR6 ( Pan et al., 1998).
These receptors share a homologous region in their intracellular domain called a death 
domain (DD) (Tartaglia et al., 1993; Itoh et al, 1993) that is capable of transmitting a 
cytotoxic signal to induce apoptosis. A family of ligands has also been identified that 
activate their corresponding receptor of the TNF superfamily, including CD95-L (Fas-L), 
TNF and TRAIL/Apo-2L (Pitti et al., 1996). CD95-L binds to CD95 and TNF binds to 
TNFR1 (Beutler et al., 1994). TRAIL can induce apoptosis by binding to DR4 and DR5 
(Wiley et al., 1995; Pitti et al, 1996). DR6 ligand interactions remain elusive and the 
physiological function has not yet been identified. Yet another group of TNFR 
homologues exist which act as decoy receptors, and inhibit signal transduction, of which 
three have been so far identified; DcRl, DcR2 and DcR3, the first two being cell surface 
molecules and the latter a soluble secreted protein. The inhibitors DcRl and DcR2 act by 
competing with the functional receptors DR4 and DR5 for TRAIL binding, thus acting as 
decoys that prevent TRAIL from inducing apoptosis (Ashkenazi and Dixit, 1998).
CD95 and its ligand play a critical role in various pathological and physiological forms of 
cell death (Nagata et al., 1997) such as autoimmune disease due to dysregulation of the 
CD95 system. Overexpression of CD95 and hypersensitivity to apoptosis has been 
reported in HIV-1 infected T-lymphocytes (Debatin et al, 1994). A role for CD95- 
induced apoptosis has been found in autoimmune diabetes (Chervonsky et al., 1997) and 
in alcohol-induced hepatitis (Galle et al., 1995). Many diverse stimuli can induce 
apoptosis via activation of the CD95 pathway, for example overexpression of c-myc can 
induce apoptosis dependent on the CD95/CD95L interaction (Hueber et a l, 1997). 
Chemotherapy drugs can also induce apoptosis mediated by the CD95 system (Friesen et
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al., 1996; Muller et al., 1997). However these findings are somewhat controversial given 
that other reports exist which demonstrate that chemotherapy-induced apoptosis can 
occur in a CD95-independent fashion (Eischen et al, 1997; Gamen et al., 1997; Villunger 
etal., 1997).
The CD95 and CD95L interaction transduce an apoptotic signal by the binding of CD95 
to adaptor molecules via a homologous region celled a death domain (DD). The first of 
these adaptor molecules to be identified was FADD (Fas-associated death domain) by 
Chinnaiyan and co-workers (1995). Overexpression of FADD could induce apoptosis, 
thus confirming its role in apoptotic signaling. In particular the N-terminal alone of FADD 
was sufficient to induce apoptosis, and this domain was termed the death effector domain 
(DED). If just the c-terminal of FADD was overexpressed apoptosis did not occur, 
suggesting that DED is linked to the downstream signaling involved in apoptosis. FADD 
preferentially binds to CD95 through the homologous DD, whereas TRADD binds to 
TNFR. TRADD lacks a DED so must first bind to FADD in order to transduce signals 
downstream (see figure 1.9).
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Caspase-8
Activation
Figure 1.9 CD95/CD95L activation of procaspase-8
The initiator caspases, -8 and -10 differ from other caspases in one respect, that they 
possess two distinct sequences in their prodomains with homology to a region in FADD 
called the DED domain. The remainder of the proteins are similar to the other caspases. 
FADD plays a critical role as an double-adaptor protein in the CD95 pathway of 
apoptosis. When CD95-L binds to its transmembrane receptor CD95, the signal is 
transduced and FADD binds to Fas through homologous DD domains. Procaspase-8 can 
then bind to FADD through its DED domain, and consequently procaspase-8 is activated 
by autoprocessing. This is outlined in figure 1.9. It is thought that when caspase-8 binds 
to FADD some structural change may occur to facilitate its activation. Because caspase-8 
is thought to be at the apex of the apoptotic pathway, its mode of activation remained 
elusive for some time, but recently the mechanism has been explained by an induced
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proximity model. Muzio et al. (1998) confirmed that procaspase-8 contains an intrinsic 
caspase activity at a low level, however when procaspase-8 molecules come together and 
bind to FADD through homologous DEDs, the concentration of caspase activity 
increases to a sufficient level to allow proteolytic autoactivation (i.e. procaspase-8 
molecules induce self-proteolysis to yield active caspase-8). Therefore FADD acts as a 
cofactor that brings molecules of procaspase-8 together for activation.
Once active, caspase-8 can process other downstream caspases such as caspase-3 in 
response to CD95-mediated apoptosis (Armstrong et al., 1996; Schlegel et al., 1996). 
Stennicke et al. (1998) confirmed that caspase-3 can be directly activated by caspase-8 
and caspase-10, indicating that activation of caspase-3 is the central event in the further 
transmission of the apoptotic signal. Furthermore, Rohklin et al. (1998) demonstrated that 
caspase-3 and caspase-7 are activated during CD95-mediated apoptosis, presumably 
through the action of caspase-8.
Recently Juo et al. (1998) provided evidence for an absolute requirement for caspase-8 in 
the initiation of CD95-induced apoptotic cascade. Caspase-8-deficient cells were unable 
to activate downstream caspases such as caspase-2, -3, -7 and proteolytic cleavage was 
also blocked. Chemotherapeutic drugs however can induce apoptosis independently of 
caspase-8. In caspase-8 mutant cells, apoptosis still occurred when induced by 
adriamycin, etoposide, staurosporine or UV irradiation, although there was a 30-40% 
reduction in apoptosis (Juo et al., 1998). This indicates that there must be another parallel 
pathway present in which another initiator caspase can transduce pro-apoptotic signals to 
the downstream caspases.
1.5.8 Activation of caspase-9
Liu et al. (1996) investigated the apoptotic pathway in a cell-free system and 
concluded that dATP and three cytosolic apoptotic protease factors (Apafs) are 
required for apoptosis to occur. They identified apaf-2 as cytochrome c, this protein 
was released to the cytosol upon apoptotic stimulation, and in combination with 
Apafs was responsible for the cleavage of procaspase-3 to its active form.
#
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Cytochrome c is an essential component of the mitochondrial respiratory chain, and is 
normally located in the inner mitochondrial membrane and in the intermembrane 
space (Gonzales and Neupert, 1990). Numerous groups including Kluck et al. (1997) 
demonstrated cytochrome c release into the cytosol during the early stages of 
apoptosis thus supporting a central role for cytochrome c in the induction of 
apoptosis. Another essential protein for apoptosis to take place was identified as 
apaf-3 (Zou et a l, 1997), and Li et al. (1997) revealed this to be human caspase-9.
Further studies revealed apaf-1 to be a 130 kDa cytosolic protein with a region in its 
NH2-terminus homologous to the prodomain of caspase-9. This region is called a 
caspase recruitment domain or CARD (Hofmann et al., 1997). The presence of a 
CARD in apaf-1 implicates it as a recruitment protein for caspases. CARD regions 
have been found in other caspases with long prodomains, such as caspase-1, -2, and 
-4, but not in caspase-3 or -6, implying that caspases with a CARD may have roles as 
upstream initiators. Li et al. (1997) reinforced this by demonstrating that apaf-1 can 
interact with caspase-4, -8 and -9.
Apaf-1 also contains a WD40 repeat region, that is thought to be involved in the 
regulation of apaf-1 activity. Apaf-1 is capable of self-association, and this self­
association can directly induce pro-caspase-9 binding and results in caspase-9 
cleavage and activation (Srinivasula et a l, 1998; Hu et a l , 1998). However, deletion 
of the WD40 repeat region makes apaf-1 constitutively active and capable of 
processing procaspase-9 independent of cytochrome c and dATP, therefore the 
WD40 repeat region acts as a negative regulator of apaf-1 activity (Hu et al. 1998). 
Overexpression of apaf-1 in HL-60 cells increased apoptosis levels five-fold (Perkins 
et al., 1998). Yoshida et al. (1998) demonstrated that apaf-1 is essential for apoptosis 
to occur in brain development.
Apaf-1 is thought to bring about caspase-9 proteolytic processing by first binding to 
cytochrome c to become active, then self-associating to form apaf-1 oligomers in the 
presence of dATP, thus a large multimeric apaf-1-cytochrome c complex is formed 
(Zou et a l , 1999). Caspase-9 precursor molecules are then induced to bind through
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the homologous CARD domains (Li et al., 1997; Pan et al., 1998), which results in 
autocatalysis to form active caspase-9 (Srivinasula et al., 1998). Upon activation, 
caspase-9 can then process procaspase-3, thus triggering the substrate cleavage 
events of apoptosis. An important finding by Li et al. (1997) was the requirement of 
caspase-9 for activation of caspase-3, and can also activation of caspase-7 
(Srinivasula et a l, 1998). Caspase-9 can therefore be described as a central regulator 
of downstream caspases, and is positioned at the apex of the signaling cascade 
involving cytochrome c and apaf-1. A caspase-9 mutant which lacks the catalytic site 
yet retains the prodomain for binding to apaf-1, is a potent inhibitor of apoptosis, 
presumably by blocking the interaction between apaf-1 and normal caspase-9 (Seol 
and Billiar, 1999). Furthermore, an alternatively spliced endogenous form of caspase- 
9 can interact with apaf-1 through the CARD domain, and block caspase-9 
activation, and subsequent caspase-3 activation (Srivinasula et al., 1999). Taken 
together, these reports confirm that caspase-9 interaction with apaf-1 and 
cytochrome c is a critical pathway involved in apoptosis.
1.5.9 Regulation of apoptosis by BcI-2 family
Bcl-2 plays an important role in apoptosis regulation, and overexpression of bcl-2 
provides cells with a survival advantage. Bcl-2 is the mammalian homologue of ced- 
9, which was shown in C. elegans to prevent pro-apoptotic actions of ced-3 and ced- 
4. Bcl-2 blocks apoptosis after a wide variety of stimuli and in doing so, allows the 
cells that experience DNA damage to avoid death and enables the acquisition of 
genetic aberrations and the emergence of neoplasia. Bcl-2 is located in the outer 
mitochondrial membrane, endoplasmic reticulum and nuclear envelope, however 
some Bcl-2 family members are largely cytosolic, such as Bax. Numerous Bcl-2 
family members have been identified in mammalian cells (see table 1.5), and have 
been divided into pro-apoptotic members (e.g. Bcl-xs, Bax, Bad) and pro-survival 
members (e.g. Bcl-2, Bcl-XL).
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MEMBER ROLE DOMAINS
Bcl-2 anti-apoptotic BH-1, -2 and -3
Bc1-Xl anti-apoptotic BH-1, -2 and -3
Bcl-w anti-apoptotic BH-1, -2 and -3
Mcl-1 anti-apoptotic BH-1,-2 and-3
NR-13 anti-apoptotic BH-1, -2 and -3
CED-9 anti-apoptotic BH-1 and -2
Bax pro-apoptotic BH-1, -2 and -3
Bad pro-apoptotic BH-1, -2 and -3
Bok pro-apoptotic BH-1, -2 and -3
Bcl-Xs pro-apoptotic BH-1, -2 and -3
Bid pro-apoptotic BH-3
Bad pro-apoptotic BH-3
Bik pro-apoptotic BH-3
Hrk pro-apoptotic BH-3
Bim pro-apoptotic BH-3
Blk pro-apoptotic BH-3
Table 1.5 Anti-apoptotic and Pro-apoptotic Bcl-2 members
All Bcl-2 family members contain at least one of four conserved motifs called Bcl-2 
homology domains (BH domains). These domains participate in the formation of 
various dimerisations and in pore formation, the BH3 domain in particular being 
essential for pro-apoptotic function. Pro- and anti-apoptotic proteins can hetero or 
homodimerise, and depending on the ratio of pro- to anti-apoptotic proteins, the 
susceptibility of a cell to apoptosis can be determined. For example, overexpression 
of Bax enhances apoptosis, but if Bcl-2 is overexpressed it can heterodimerise with 
Bax and apoptosis is prevented. Overexpression of anti-apoptotic proteins such as 
Bcl-2 (Kamesaki et ah, 1993) or B c1-Xl (Ibrado et ah, 1996; Schmitt et ah, 1998)
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can inhibit caspase-3 activation (Ibrado et al., 1996), indicating that the Bcl-2 family 
interfere with one of the central events in apoptosis, namely caspase activation.
1.5.10 Functions of Bcl-2 family - Regulation of Apoptosis
Bcl-2 proteins can regulate apoptosis in two ways, the first involving cytochrome c 
release from mitochondria and the second involving interaction with apaf-1. Pro- 
apoptotic proteins like Bax and Bid can directly induce cytochrome c release from 
mitochondria (Jurgensmeisier et al., 1998; Luo et al., 1998) perhaps via a pore 
forming ability. It has previously been shown that both anti-apoptotic and pro- 
apoptotic Bcl-2 family members can form ion channels in vitro (Minn et al., 1997; 
Schendel et al., 1998; Schlesinger et al., 1997). Bcl-Xi. and Bcl-2 can prevent 
cytochrome c release from mitochondria (Kharabanda et al., 1997; Kluck et al., 
1997; Yang et al., 1997).
However the Bcl-2 family proteins can regulate apoptosis independently of 
dimerisation. Bax can antagonise Bcl-XL without heterodimerising with Bcl-XL 
(Simonian et al., 1997). Luo et a l (1998) and Li et al. (1998) recently reported Bid 
to be a direct link between activated caspase-8 and the downstream caspases. 
Possessing only a BH3 domain, full length Bid usually exists as an inactive form in 
the cytosol of cells, but when caspase-8 becomes activated during the apoptotic 
signaling pathway, Bid is cleaved and activated by caspase-8. The truncated part 
translocates to the mitochondria, thus unleashing its pro-apoptotic activity and 
inducing cytochrome c release into the cytosol, which in turn initiates the 
downstream caspase activation and subsequent cell shrinkage and nuclear 
condensation. The countereffect of the anti-apoptotic protein Bcl-XL inhibits all the 
apoptotic changes induced by the active Bid.
The second method of regulation is through binding to apaf-1, and consequently 
governing activation of procaspase-9. It is thought that Bcl-XL can bind to apaf-1 and 
prevent caspase-9 from binding to it. If a pro-apoptotic member such as Bik is
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present, heterodimers can form, allowing free apaf-1 to bind to procaspase-9. (see 
figure 1.10). Procaspase-9 is then activated through autocatalysis.
Figure 1.10 Apaf-1 regulation by bcl-2 family
Bcl-2 family members act downstream of caspase-8 activation. Srinivasan et al. 
(1998) demonstrated that Bc1-Xl can block apoptosis in cells with a catalytically 
active caspase-8. This may occur through the ability of Bc1-Xl to interact with apaf-1 
and inhibit its association with caspase-9 (Hu et al., 7998). Bcl-XL shares a CED-4 
domain with apaf-1. So through binding at this region Bcl-XLmay prevent caspase-9 
from binding to the CARD region in the N-terminal of apaf-1. This finding indicates 
that Bc1-Xl can regulate apoptosis independently of its association with intracellular 
membranes.
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Evidence that Bcl-XL lies upstream of caspases was provided by Schmitt et al. (1998) 
who reported that Bcl-XL delayed activation of effector caspases but it could not 
block caspase-3 activity once caspase-3 has been activated.
1.5.11 Regulation of Bcl-2 family
Playing such a critical role in apoptosis regulation suggests that Bcl-2 family 
members must be tightly regulated to maintain an environment which can switch on 
or prevent cell death at the introduction of a stimulus. Regulation occurs at different 
levels, both transcriptionally and post-translationally. In particular, the BH-3 domain- 
containing proteins seem to be regulated by being restricted to the cytosol of living 
cells, but in response to a death signal they can be activated as a result of increased 
transcription or translation or post-translational modification such as phosphorylation 
or cleavage, and then transported to the mitochondria. Bax is upregulated in response 
to DNA damage (Kozopas et al., 1993; Akashi et al., 1999) and translocates to the 
mitochondria (Wolter et a l, 1997). When survival signals exist in the cell, Bad is 
phosphorylated in response to the survival factor IL-3, binds to a 14-3-3 protein and 
becomes sequestered in the cytosol. The phosphorylation of Bad prevents it from 
heterodimerising with Bc1-Xl, thus allowing Bcl-XL to promote cell survival. 
However, on removal of IL-3 Bad is dephosphorylated, and then can move to the 
mitochondria to induce apoptosis (Zha et al., 1996). Bid is also activated in response 
to apoptotic stimuli, is cleaved and translocated to the mitochondria (Luo et al., 
1998; Li et al., 1998).
Pro-survival members can also be modified through phosphorylation or cleavage. 
Depending on the phosphorylation sites occupied on Bcl-2 or Bc1-Xl, the anti- 
apoptotic activity can be increased or prevented (Haidar et al., 1994; 1995; 1996; 
Maundrell et al., 1997, Chang et al., 1997, lto et al., 1997). Cheng et al. (1997) also 
demonstrated that Bcl-2 could be cleaved by caspases resulting in its conversion to a 
pro-apoptotic member, perhaps by activating the pro-apoptotic activity of its BH3 
domain. Bcl-Xi. can undergo a similar cleavage.
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1.5.12 Apoptosis and DNA damaging drugs
Since there are a number of possible apoptotic signaling pathways present, each 
converging on the activation of effector caspases, the pathway resulting from 
chemotherapeutic drug treatment has very important implications for effective tumor 
cell kill and any resistance to undergo chemotherapeutic drug-induced apoptosis. Any 
defects in this pathway would result in defective apoptosis and ensuing resistance.
Numerous groups have verified the role of caspases in apoptosis induced by various 
DNA damaging agents with diverse chemical structures and mechanisms of action. 
DNA damaging agents such as Ara-C, cisplatinum, etoposide, camptothecin (Datta et 
al., 1996), CPT-II (Suzuki et al., 1996) and MC540 (Pervaiz et ah, 1998) have been 
shown to activate caspase-3 activity. Faleiro et al. (1997) have reported that the 
major active caspases in cells induced to undergo apoptosis by etoposide are caspase- 
3 and caspase-6, and these caspases are present as multiple species which can vary in 
activity between cell type. Etoposide treatment of HL-60 cells also induces multiple 
species of caspase-3 and caspase-6, but procaspase-2 was not activated (Martins et 
ah, 1997b) indicating that the stimulus activated specific caspases. Simizu et al. 
(1998) recently demonstrated the requirement of caspase-3 for apoptosis (mediated 
by hydrogen peroxide production) induced by camptothecin, vinblastine, inostamycin 
and adriamycin. Keane et al. (1997) have also shown that caspase-3 activity is 
essential for apoptosis to occur after staurosporine treatment.
All of the reports confirm the role of caspase-3 in apoptosis induced by 
chemotherapeutic drugs, but caspase-3 is an effector caspase. So the question 
remains as to what are the initiator complexes involved in the chemotherapeutic drug 
signaling pathway? The main contenders are obviously CD95 or a caspase containing 
a CARD domain, namely caspase-9. A body of evidence exists for each of these 
initiators at present. Originally CD95 was thought to be the main signaling protein 
involved, but with the recent discovery of caspase-9, some very convincing reports 
prove the involvement of caspase-9 in cytotoxic induced apoptosis.
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Fas-involvement
Fulda et al. (1997) showed that CD95 and CD95-L levels were upregulated on 
neuroblastoma cells after treatment with doxorubicin, VP-16 and cisplatinum, and 
they proposed that this upregulation of CD95/Fas was responsible for apoptotic 
induction in the cells. Furthermore when CD95 and CD95-L production was inhibited 
by cyclosporin A, there was a significant (up to 50%) reduction in drug-induced 
apoptosis. They also demonstrated that CD95-resistant cells were resistant to 
doxorubicin and cisplatinum suggesting a common signaling pathway. These findings 
indicate that the activation of caspases was most probably through the activation of 
the CD95/CD95-L pathway. These results are reinforced by a recent publication by 
Fulda et al. (1998) in which they report cleavage of the apical caspase-8, the 
downstream caspase-3 and PARP cleavage in doxorubicin treated neuroblastoma 
cells.
In contrast to these findings, a number of groups report that CD95-independent drug- 
induced apoptosis can also occur. Eischen et al. (1997) concluded that even though 
CD95-and chemotherapy-induced pathways converge on downstream apoptotic 
pathways, the mechanism of drug-induced apoptosis can occur in a CD95-induced 
manner. Using leukaemia cells which were resistant to CD95-induced apoptosis they 
demonstrated that these resistant cells were sensitive to apoptosis induced by a wide 
variety of chemotherapeutic agents such as etoposide, doxorubicin, cisplatin, 
staurosporine and methotrexate. Cells then treated with the ZB4 Fas-blocking 
antibody were still susceptible to apoptosis when cells were treated with etoposide or 
doxorubicin, suggesting a CD95-independent apoptotic pathway for these drugs.
Villunger et al. (1997) carried out similar experiments and found that drug treatment 
increased CD95-L expression, consistent with the findings of Fulda et al. (1997). In 
contrast to Fulda’s notion that upregulation of CD95-L expression might render cells 
more sensitive to drug-induced apoptosis, Villunger et al. (1997) showed that 
apoptosis occurred independently of the CD95/CD95-L signaling pathway. In 
addition, Ferrari et al. (1998) reported that the two apoptotic pathways could be 
dissected by ATP depletion, and depletion of ATP resulted in inhibition of 
chemotherapy-induced apoptosis, but did not affect the CD95 system. Thus apoptosis
56
involving apaf-1 and caspase-9 was the pathway involved in chemotherapeutic- 
triggered apoptosis.
Caspase-9 Involvement
The finding that drug-induced apoptosis could occur independently of the 
CD95/CD95-L pathway led researchers to search for another upstream component of 
the apoptosis pathway which could act in an independent and parallel fashion, and yet 
converge on the similar pathway in which caspase-3 is activated and apoptotic events 
commence. The pathway involving caspase-9, apaf-1 and cytochrome c soon became 
apparent. When cytochrome c is released from mitochondria, apoptosis is induced. 
Apaf-1 is the human homologue of the C. elegans CED4 protein (Zou el a l, 1997), 
and this along with the cytochrome c (apaf-2) and caspase-9 have been shown to 
activate caspase-3 (Zou et al. 1997). Kuida et al. (1998) recently showed that 
caspase-9 deficient mice had reduced apoptosis, a result of inhibition of procaspase-3 
activation. Caspase-9 is necessary in vivo for cytochrome c-mediated caspase-3 
activation and apoptosis to occur. These findings indicate that caspase-9 is a key 
activator of the apoptotic cascade.
Hakem et al. (1998) investigated the physiological role of caspase-9, using caspase-9 
deficient mice and their various cell types to look at the propensity of cells to 
undergo apoptosis when treated with various DNA damaging agents. Three different 
apoptotic pathways were proposed from results; 1) Solely dependent on caspase-9: 
caspase-9 deficient thymocytes are resistant to apoptosis induced by dexamethasome 
or y-irradiation, but caspase-3 deficient thymocytes were sensitive to apoptosis 
induced by these stimuli. 2) caspase-3 dependent: caspase-9-deficient activated T- 
cells died after a-CD95 treatment, but caspase-3-deficient cells were resistant to 
apoptosis suggesting that caspase-8 (DED) or caspase-4 (CARD) may act upstream 
in this situation. 3) Pathway independent of both caspase-3 and caspase-9: 
thymocytes deficient to either caspase-3 or -9  were sensitive to apoptosis induced by 
UV-irradiation, indicating that thymocytes can die independently of either caspase. 
Taken together these results indicate that the requirement for caspase-9 is cell type- 
specific and stimulus specific.
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Caspase-Independent Apoptosis
Chol-Ha et al. (1998) provided evidence of a caspase-independent apoptotic pathway 
in Bcl-2-overexpressing cells. Using polyamine analogues which resulted in a G2/M 
arrest and apoptosis, they found activation of caspase-3, DNA fragmentation, PARP 
cleavage and cytochrome c release. Yet when Bcl-2 was overexpressed all the 
apoptosis features were inhibited but the cells still underwent apoptosis suggesting 
the existence of a caspase-independent pathway.
Considering the numerous reports supporting both the CD95 and caspase-9- 
cytochrome c pathways, clearly the activation of either pathway is cell type- 
dependent and stimulus specific.
1.5.13 Drug Resistance and Apoptosis
The primary mechanism of action of chemotherapeutic drugs with different cellular 
effects is through induction of apoptosis in tumour cells. This pathway is highly 
regulated and influenced by many factors, and a defect in any of the steps in the 
pathway can alter or halt the pathway in such a way as to inhibit or interfere with 
apoptosis. Such defects may have important implications in drug resistance, and 
effective chemotherapy.
1.5.13.1 Contribution of Caspase Activation to drug resistance
A number of reports by Frankfurt et al. (1994a, 1994b) highlighted the fact that drug 
resistant cells were resistant to apoptosis following exposure to a variety of cytotoxic 
agents. It is now accepted that deregulation of the apoptotic pathway may be 
important in the development of drug resistance in tumours (Haq and Zanke, 1998). 
Geyp et al. (1996) investigated this phenomenon and found that drug resistant T-cells 
were inherently resistant to apoptosis, using serum withdrawal as a stimulus in order 
to overcome any potential interference from P-glycoprotein. Cells with increased 
metastatic potential were also resistant to apoptosis induction (McConkey et al.,
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1996). Antoku et al. (1997) demonstrated that down-modulation of caspases in 
Jurkat leukaemia cells by the naturally occurring caspase inhibitor Crm A, enhanced 
the resistance of the cells to chemotherapeutic drugs such as Ara-C, doxorubicin, 
etoposide and cisplatinum. This suggests that decreased caspase activity may have a 
role in certain forms of drug resistance. Nagane et al. (1998) also reported 
suppression of caspase-3 activity in drug resistant human glioblastoma cells. Cisplatin 
resistant squamous carcinoma cells fail to activate caspase-3 when compared to 
parental cells (Kojima et al. 1998).
Droin et al. (1997) recently carried out a study of caspase gene levels in a panel of 
resistant leukaemia cells. In untreated cells, caspase gene expression is very 
heterogeneous, their expression seems to be independent of each other, and there is 
no clear correlation between the ability of cells to undergo apoptosis and the normal 
basal expression of caspase in mRNA. This may be due to the functional redundancy 
that exists between caspases or the fact that the caspases investigated (caspase-2,-3,- 
6) are very much downstream caspases and would be regulated at an earlier stage in 
the pathway. However, when the cells were etoposide-treated, an upregulation of 
caspase-2 and caspase-3 mRNA was noted in cells that were sensitive to apoptosis, 
with unaltered regulation in more resistant cells. These results suggest that the extent 
of up regulation of caspase genes after drug treatment in leukaemia cells could be 
predictive of their sensitivity to drug treatment and apoptosis induction.
1.5.13.2 Contribution of Bcl-2 to apoptosis resistance
Bcl-2 is a key regulator of caspase activation and therefore can influence greatly the 
caspase activation pathway. Depending on the presence of either pro- or anti- 
apoptotic Bcl-2 family members, caspase activation can be influenced accordingly. In 
the study by Kojima et al. (1998) of decreased caspase-3 activity and its links to 
multi-drug resistance, they found that overexpression of Bc1-Xl was responsible for 
the failure of cells to activate caspase-3. Bcl-XL overexpression was induced as cells 
developed resistance to the selecting drugs vincristine and doxorubicin, and this 
overexpression had a direct effect on the processing of caspase-3.
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Mitochondrial cytochrome c release was also inhibited upon overexpression of Bcl- 
XL pointing to the role of the Bcl-2 family as pore forming regulators of cytochrome 
c release. Taken together these findings by Kojima et al. (1998) suggest that B c1-Xl 
plays an important role in the development of multidrug resistance and by directly 
affecting the activity of the apoptotic machinery -  caspase-3 and cytochrome c.
Overexpression of B c1-Xl  was shown by Nagata et al. (1998) to inhibit caspase-3 
like protease activation in drug-resistant human glioblastoma cells. McConkey et al. 
(1996) originally found that elevated Bcl-2 levels correlated with increased metastatic 
potential of cells, presumably through modulation of caspase activities. Many other 
reports exist documenting the effect which Bcl-2 overexpression has on caspase 
activation an its subsequent contribution to drug resistance.
1.5.13.3 Contribution of CD95/CD95-L to Drug Resistance
Defective activation of the CD95/ CD95-L system in cells has been linked to drug 
resistance. Friesen et al. (1997) and Los et al. (1997) demonstrated that disruption of 
the CD95/CD95-L system leads to resistance of tumour cells to drug treatment. 
CD95 levels were found to be much lower in drug resistant cells, and CD95-L levels 
were not upregulated after drug treatment, unlike the case in parental cells. This 
highlights the importance of an intact CD95 signaling system for efficient apoptosis in 
anticancer therapy. Studies by Fulda et al. (1998a, 1998b) implicate deficient 
activation of the CD95 system in drug resistance, and found that in vitro 
chemosensitivity of solid tumour cells was directly related to a functional CD95 
signaling pathway.
1.5.13.4 P-glycoprotein and Resistance to Apoptosis
Recent studies have implicated the drug-efflux pump P-glycoprotein (Pgp) in 
resistance to apoptosis. Smyth et al. (1998) and Johnstone et al. (1999)
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demonstrated that P-glycoprotein additionally protected cells from apoptosis induced 
by a variety of stimuli including chemotherapy drugs and CD95. Resistance could be 
circumvented if the activity of Pgp was inhibited using a variety of blockers such as 
verapamil or antagonistic antibodies. Reduced caspase activation was seen as the 
major effect of Pgp activity, and the reduction in caspase-3 activity and apoptosis 
induction was not attributable to MDR effects.
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1.6 Aims of the Thesis
The main aim of this thesis was to investigate the effects of doxorubicin on the cell 
cycle and apoptosis induction in variants of a human lung carcinoma cell line DLKP. 
This study was carried out to identify any alterations there may be in resistant cells 
compared to sensitive cells in their response to drug treatment. DLKP-SQ is a clonal 
population of DLKP which is sensitive to doxorubicin and other chemotherapeutic 
drugs, DLKP-A250 10p#7, DLKP-A5F and DLKP-A2B are variants with varying 
levels of resistance to doxorubicin and other chemotherapeutic drugs.
Analysis revealed differences in the response of resistant variants to doxorubicin 
treatment compared to the sensitive cells, particularly in the cell cycle response. The 
resistant variants exhibited an abrogation of the G2/M arrest, raising the possibility of 
a defective DNA damage-induced G2 checkpoint in resistant cells. This theory was 
further investigated by looking at the controllers of the G2/M transition in the 
sensitive and resistant DLKP cell lines.
The apoptotic pathway was also investigated in the DLKP cells following 
doxorubicin treatment. Apoptosis induction occurred in all four cell lines following 
drug treatment, but higher doxorubicin concentrations were used in the resistant 
cells. Numerous studies in the literature implicate defects in the key apoptotic 
executioners, caspases as a mechanism of resistance. This theory was investigated in 
the resistant cells, to determine if, in their resistance development, DLKP resistant 
variants acquire defects in their apoptotic pathways which could contribute to the 
resistant state.
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2.0 Materials and Methods
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2.1 Preparation for Cell Culture
2.1.1 Ultrapure W ater
Ultrapure water, (UHP) was used for the preparation of all media and solutions. This 
water was purified to a standard of 12-18 Mil / cm resistance by a reverse osmosis 
system (Millipore Milli-RO 10 Plus, Elgastat UHP). A conductivity meter in the 
system continuously monitored the quality of the UHP.
2.1.2 Glassware
The solutions utilised in the various stages of cell culture were stored in sterile glass 
bottles. These sterile bottles and other glassware required for cell culture related 
applications were prepared as follows: glassware and lids were soaked in a 2% 
solution of RBS-25 (AGB Scientific) for 1 hour. After this time they were cleaned 
and rinsed in tap water. The glassware was washed in an industrial dishwasher, using 
Neodisher detergent and rinsed twice with UHP. The materials were finally sterilised 
by autoclaving as described in Section 2.3.
2.1.3 Sterilisation Procedures
All thermostable solutions, water and glassware were sterilised by autoclaving at 
121°C for 20 min at 15 p.s.i.. Thermolabile solutions were filtered through 0.22(im 
sterile filters (Millipore, Millex-GV SLGV025BS). Large volumes, (up to 10 litres) 
of thermolabile solutions were filter sterilised through a micro-culture bell filter 
(Gelman, 12158).
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2.1.4 Preparation of cell culture media
The basal media used during cell culture were prepared as follows: 10X media were 
added to sterile UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazine- 
N-(2-ethanesulfonic acid)) and NaHC03 as required and adjusted to pH 7.5 using 
sterile 1.5 N NaOH and 1.5 N HCL. The media were then filtered through sterile 
0.22pm bell filters (Gelman, 12158) and stored in sterile 500mL bottles at 4°C. 
Sterility checks were performed on each bottle of media by inoculating samples of the 
media on to Colombia blood agar plates (Oxoid, CM217), Thioglycollate broths 
(Oxoid, CM173) and Sabauraud dextrose (Oxoid, CM217) and incubating the plates 
at 37°C and 25°C. These tests facilitated the detection of bacteria, fungi and yeast 
contamination.
Basal media were stored at 4°C for up to three months. The HEPES buffer was 
prepared by dissolving 23.8g HEPES in 80mL UHP water and this solution was then 
sterilised by autoclaving. Then 5mL sterile 5N NaOH was added to give a final 
volume of lOOmL. NaHC03 was prepared by dissolving 7.5g in lOOmL UHP water 
followed by autoclaving. Complete media was then prepared as follows: supplements 
of 2mM L-glutamine (Gibco, 11140-0350) and 5% foetal calf serum (Sigma, F-7524) 
were, in the majority of cases, added to volumes of lOOmL basal media. lmL 100X 
non-essential amino acids (Gibco, 11140-035) and lOOmM sodium pyruvate (Gibco, 
11360-035) were also added to MEM. Complete media were maintained at 4°C for 
up to a maximum of 1 week.
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2.2 Cell Culture procedures
All cell culture work was carried out in a class II laminar air-flow cabinet (Nuaire 
Biological Laminar Air-Flow Cabinet). All experiments involving cytotoxic 
compounds were conducted in a cytogard laminar air flow cabinet (Gelman Sciences, 
CG series). Before and after use the laminar air-flow cabinet was cleaned with 70% 
industrial methylated spirits (IMS). Any items brought in to the cabinet were also 
cleaned with IMS. At any time, only one cell line was used in the laminar air-flow 
cabinet and upon completion of work with any given cell line the laminar air-flow 
cabinet was allowed to clear for at least 15 minutes so as to eliminate any possibilities 
of cross contamination between the various cell lines. The cabinet was cleaned 
weekly with industrial detergents (Virkon or TEGO) and these detergents were 
alternated every month.
2.2.1 Cell lines
Details pertaining to the cell lines used for the experiments detailed in this thesis are 
provided in table 2.2.1. All cells were grown in complete medium consisting of 
ATCC or RPMI with 1% L-Glutamine and 5% foetal calf serum. Cells were 
incubated at 37°C and where required, in an atmosphere of 5% CO2. Cells were fed 
with fresh media or subcultured (see section 2.5.1) every 2-3 days in order to 
maintain active cell growth.
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CELL LINE BASAL
MEDIUM*
CELL TYPE SOURCE**
DLKP-SQ ATCC Clonal subpopulation of 
DLKP (Human Lung 
squamous carcinoma)
NCTCC
DLKP-A2B ATCC Clonal population of 
adriamycin-selected cell 
line DLKP-A
NCTCC
DLKP-A5F ATCC Clonal population of 
adriamycin-selected cell 
line DLKP-A
NCTCC
DLKPA25010p ATCC Adriamycin-selected 
variant of DLKP SQ
NCTCC
DLKP-A250
10p#7
ATCC Clonal population of 
DLKP-SQ/A250 lOp
NCTCC
HL-60 RPMI-1640 Human Leukaemia cell line Dr. Melvin Center
* ATCC basal media consists of a 1:1 mixture of DMEM and Hams F12,
**NCTCC = National Cell and Tissue Culture Centre.
RPMI 1640 media supplied as a IX stock (Gibco, 52400-025)
Table 2.2.1 Source description and media requirements of cell lines used in 
experiments described in this thesis
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2.2.2 Subculturing of adherent cell lines
The waste cell culture medium was removed from the tissue culture flask and 
discarded into a sterile bottle. The flask was then rinsed out with 1ml of 
trypsin/EDTA solution (0.25% trypsin (Gibco, 043-05090), 0.01% EDTA (Sigma, 
E9884) solution in PBS (Oxoid, BRI4a)) to ensure the removal of any residual 
media. 5mls of trypsin was then added to the flask, which was then incubated at 
37°C, for approximately 5 minutes, until all of the cells detached from the inside 
surface of the flask. The trypsin was deactivated by adding an equal volume of 
complete media to the flask. (For subculturing of suspension cells, trypsin was not 
used). The cell suspension was removed from the flask and placed in a sterile 
universal container (Sterilin, 128a) and centrifuged at lOOOrpm for 5 minutes. The 
supernatant was then discarded from the universal and the pellet was suspended in 
complete medium. A cell count was performed and an aliquot of cells was used to 
reseed a flask at the required density.
2.2.3 Cell counting
Cells were trypsinised, pelleted and resuspended in media as described in section 
2.2.2.. An aliquot of the cell suspension was then added to trypan blue (Gibco, 525) 
at a ratio of 5:1. The mixture was incubated for 3 minutes at room temperature. A 
10(0,1 aliquot of the mixture was then applied to the chamber of a glass coverslip 
enclosed haemocytometer. Cells in the 16 squares of the four grids of the chamber 
were counted. The average cell numbers per 16 squares were multiplied by a factor 
of 104 and the relevant dilution factor to determine the number of cells per ml in the 
original cell suspension. Non-viable cells stained blue, while viable cells with intact 
membranes excluded the trypan blue dye, and remained unstained. On this basis, 
percentage viability could be calculated.
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2.2.4 Cell freezing
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described in section 2.2.3. Cell pellets were resuspended in a suitable volume of 
serum. An equal volume of a 10 % DMSO/serum solution was added dropwise to the 
cell suspension. A total volume of 1ml of this suspension (which should contain 
approximately 7x106 cells) was then placed in cryovials (Greiner, 122278). These 
vials were then placed in the vapour phase of a liquid nitrogen container, which was 
equivalent to a temperature of -80°C. After a period of three-four hours, vials were 
removed from the vapour phase and transferred to the liquid phase (-196°C) for 
storage.
2.2.5 Cell Thawing
The cryopreserved cells were removed from the liquid nitrogen and thawed at 37°C. 
A volume of 9ml of fresh growth medium was added to a sterile universal. The cells 
were removed from the vials and transferred to the medium in the universal. The 
resulting cell suspension was centrifuged at 1,000 rpmfor 5 minutes. The supernatant 
was removed and the pellet resuspended in fresh culture medium. An assessment of 
cell viability on thawing was then carried out (Section 2.2.3). Thawed cells were then 
added to an appropriately sized tissue culture flask with a suitable volume of growth 
medium and allowed to attach overnight. Cells were fed with fresh medium the next 
day to ensure complete removal of any residual DMSO that may be present
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2.2.6 Monitoring of sterility of cell culture solutions
Sterility testing was performed for all cell culture media and cell culture related 
solutions. Samples of prepared basal media were inoculated on to Colombia blood 
agar plates (Oxoid, CM331), Thioglycollate broths (Oxoid, CM173) and Sabauraud 
dextrose (Oxoid, CM217) and incubating the plates at 37°C and 25°C. These tests 
facilitated the detection of bacteria, fungus and yeast contamination. Complete cell 
culture media were sterility tested a least four days prior to use, using Columbia 
blood agar.
2.2.7 Mycoplasma analysis of cell lines
All cell lines were tested for possible Mycoplasma contamination at the National Cell 
and Tissue Culture Centre, Glasnevin, Dublin 9.
The protocol used is detailed in the following Sections 2.2.7.1 and 2 2 .1 .2 .
2.2.1A  Indirect staining procedure for Mycoplasma analysis
Mycoplasma negative NRK (Normal rat kidney fibroblast) cells were used as an 
indicator cells for this analysis. The cells were incubated with a sample volume of 
supernatant from the cell lines in question and then examined for Mycoplasma 
contamination. A fluorescent Hoechst stain was used in this analysis. The stain binds 
specifically to DNA and so stains the nucleus of the cell in addition to any 
Mycoplasma present. Mycoplasma infection was indicated by fluorescent bodies in 
the cytoplasm of the NRK cells.
2.2 .1 .2  Direct staining procedure for Mycoplasma analysis
Direct staining for Mycoplasma analysis involved inoculating samples on to a 
Mycoplasma culture broth (Oxoid, CM403). This was supplemented with 16%
serum, 0.002% DNA (BDH, 42026), 2(ig/mL fungizone (Gibco, 042 05920), 2xl03
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units penicillin (Sigma, Pen-3) and lOmL of a 25% yeast extract solution. Incubation 
was carried out at 37°C for a period of 48 hours. Samples of this broth were then 
streaked onto plates of Mycoplasma agar base (Oxoid, CM401) which had been 
supplemented as described above. The plates were incubated for three weeks at 37°C 
while exposed to 5% C02. The plates were examined microscopically every 7 days. 
The appearance of small oval shaped colonies indicated the presence of Mycoplasma 
infection.
2.2.8 Safe handling of cytotoxic drugs
Cytotoxic drugs were handled with extreme care at all times to minimise any risks of 
exposure. Risks include carcinogenic and teratogenic effects as well as severe 
cytoxicity. All work involving cytotoxic drugs was carried out in Gelman 
“Cytoguard” laminar air flow cabinets (CG series) and nitrile gloves or double latex 
gloves were worn when dealing with concentrated stocks and drug wastes. All drugs 
were stored in designated areas at room temperature, 4°C or -20°C. Table 2.2.8.1 
details storage and disposal of cytotoxic drugs used in this thesis.
CYTOTOXIC AGENT STORAGE OF CONC. 
STOCK
DISPOSAL
Doxorubicin 4°C in darkness Inactivate with 1% hyperchlorite, and 
neutralise with sodium thiosulphate
Taxol Room temperature in 
darkness
Incineration
5-Fluorouracil Room temperature in 
darkness
Incineration
Table 2.2.8.1 Storage and Disposal of cytotoxic drugs
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2.3 Establishment of clonal populations from the DLKP-SQ/A250 lOp cell 
line
The DLKP-A250 lOp cell line was established by pulse exposure of doxorubicin on 
the DLKP-SQ cell line (Nicamhlaoibh, 1997). Clonal populations were isolated from 
this cell line to facilitate flow cytometrical analysis of the cells.
To propagate a clonal population from the DLKP-A250 lOp, individual cells were 
plated into wells of a 96-well plate and allowed to grow as an individual clonal 
population. A single cell suspension of DLKP-A250 lOp was prepared at a density of 
1 cell per 300^1 of media. The cell suspension was then added to a 96 well plate, at 
lOOfal per well, so that only one in three wells should have one cell. The plates were 
incubated at 37°C and 5% CO2 and monitored for cell growth. Any wells identified 
with just one cell after 3 days were marked, and monitored for growth. This resulted 
in the development of a population derived from just one cell, i.e. a clonal population. 
When a clonal population had reached 80% confluency in a well, it was trypsinised as 
described in 2.2.2. and transferred to a 24-well plate (Greiner; 662160), and 
transferred again to a 25cm2 flask once 80% confluency had been reached in the 24- 
well plate. Clonal populations were then frozen to maintain stocks, as described in 
2.2.4.
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2.4 Cytotoxic treatment of cells
2.4.1 Preparation of cells for drug treatment and sampling
Cells were set up at a density of 2x105 cells/ 25cm2 flask 2 days before treatment. The 
media was removed and 5ml of lx concentration of drug was then added for 2 hours. 
After this time the drug was removed and the flask was washed twice with 37°C sterile 
PBS and refed with fresh media.
Cells were analysed at various timepoints for effects of chemotherapeutic drugs on the 
cell cycle and apoptosis as follows: At the selected timepoints the media was removed and 
placed in sterile labelled universals to retain any floating or detached cells. The adherent 
cells were then trypsinised as described in section 2.2.2., and trypsinised cells were pooled 
with the corresponding medium. Cells were spun at 1000 rpm for 5 minutes. Pellets were 
washed twice with sterile ice-cold PBS and used for further analysis as required. Drugs 
and other reagents used throughout the course of this thesis are listed in table 2.4.1.
REAGENT CONCENTRATION USED SUPPLIER
Doxorubicin (Adriamycin) O.ópg/ml - 100ng/ml Farmitalia
Taxol 40ng/ml - 80ng/ml Bristol Myers-Squibb
5-Fluorouracil 0 - 50ng/ml David Bull Laboratories, 
Ltd.
zVAD.fmk lOOmM Calbiochem
zDEVD.fmk lOOmM Calbiochem
YVAD lOOmM Calbiochem
CD95 (CH-11) 100ng/ml Pharmingcn
ZB4 500ng/ml 250ng/ml Pharmingen
NOK-2 2ng/ml l|ig/ml Pharmingen
Table 2.4.1 Drugs and inhibitors used in experiments
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2.4.2 Inhibitor treatments
Cells required for experiments investigating the role of caspase inhibitors and CD95 
inhibitors were set up as described in 2.4.1, the appropriate concentration of inhibitor 
was added for 1 hour before doxorubicin treatment. Inhibitor was then removed, and 
drug added as a 2x concentration with 2x concentration of inhibitor. Cells were 
incubated either for 2 hours for 72 hours with this drug-inhibitor combination, after 
which time cell viability was determined using either crystal violet or acid 
phosphatase assays.
2.4.3 Serum Starvation
Cells were seeded at a density of 2 xl 04/ml one day prior to treatment. Cells were 
carefully washed with sterile PBS three times and then incubated in serum-free 
medium (ATCC with 1% L-Glutmaine and no foetal calf serum) for 72 hours after 
which time cell viability was determined.
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2.5 In vitro toxicity assays
2.5.1 In vitro toxicity assay -96 well plate
Cell suspensions containing 1 xlO4 cells/ml were prepared in cell culture medium. 
Volumes of 1 OOjal of these cell suspensions were added in to 96 well plates (Costar, 
3599) using a multichannel pipette. The first column of the plate was not seeded with 
cell suspension and was used as a control containing only medium. Plates were 
agitated gently in order to ensure even dispersion of cells over the wells. Cells were 
then incubated overnight at 37°C in an atmosphere containing 5% C 02. Cytotoxic 
drug dilutions were prepared at 2X their final concentration in cell culture medium, 
100(il of the drug dilutions were then added to each well using a multichannel pipette 
in replicas of eight. Plates were then mixed gently as above. Cells were incubated for 
6 days at 37°C and 5% C02 or until control wells had reached approximately 80-90% 
confluency. Assessment of cell survival in the presence of drug was determined by 
acid phosphatase assay (section 2.5.2). The concentration of drug which caused 50% 
cell kill ( IC 5 0  of the drug) was determined from a plot of the % survival (relative to 
the control cells) versus cytotoxic drug concentration.
2.5.2 Assessment of cell viability - Acid Phosphatase assay
Following the incubation period of 6 days, media was removed from the plates. Each 
well on the plate was washed with 100|il PBS. This was then removed and 100|il of 
freshly prepared phosphatase substrate (lOmM¿»-nitrophenol phosphate (Sigma 104- 
0) in 0.1M sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), pH
5.5) was added to each well. The plates were then incubated in the dark at 37°C for 2 
hours. The enzymatic reaction was stopped by the addition of 50|al of IN NaOH. The 
plate was read in a dual beam plate reader at 405 nm with a reference wavelength of 
620 nm.
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2.5.3 Toxicity Assay - 25cm2 flask
25cm2 flasks were set up as described in section 2.4.1. After drug treatment cells 
were re-fed with complete medium and incubated for 72 hours. At this time media 
was removed from the flasks which were then washed twice with PBS and viability 
was analysed using crystal violet elution assay in 2.5.4.
2.5.4 Crystal Violet Elution assay
Crystal violet toxicity assays were carried out on cells growing in 25cm2 flasks. The 
medium was removed and cells washed twice with PBS, fixed for 10 minutes in 10% 
formalin and allowed to air-dry. The cells were then stained with crystal violet for 10 
minutes, excess dye removed by washing and allowed to air-dry. The dye was eluted 
by addition of 1ml of 33% glacial acetic acid, and the absorbance measured at 570nm 
with a reference of 620nm.
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2.6 Protein Analysis
2.6.1 Protein Extraction - Total cell extract
At the selected timepoints, the cells were trypsinised and pooled with any floating cells 
and spun to obtain pellets. The resulting pellet was washed twice with ice-cold PBS. All 
procedures from this point forward were performed on ice. The pellet was 
resuspended in 200-400(fl NP-40 lysis buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 
0.5% NP-40 (Sigma, N6507), 50mM NaF) to which was added immediately before use, 
lx stock of the following: lOOmM NasVCU (Sigma, 6508) (in UHP stored at 4°C), 100 
mM DTT (Sigma, D9779) (in UHP stored at -20°C), 100 mM PMSF (Sigma, P7626) (in 
100% ethanol stored at 4°C), 25 x protease inhibitors (Boehringer Mannheim, 1 697 498) 
(in UHP stored at -20 °C). Samples were left on ice for 20 minutes and checked 
microscopically for lysis. If cells were not lysed at this stage they were then sonicated with 
8 pulses lasting 0.7 sec, and then checked for lysis. The sample was centrifuged at 
13,000rpm for 30 min at 4°C in a benchtop microfuge. The supernatant was removed, 
aliquotted and stored at -80 °C. Protein concentration was quantified as detailed in 
sections 2.6.3 (BioRad).
2.6.2 Protein extraction - Cytosolic extracts
Cytosolic extracts were used for fluorometric caspase assays which are detailed in section 
2.9. Cells were set up as described in section 2.4.1. The pellet was then resuspended in 
buffer C (25mM HEPES, pH 7.5 at 4°C, 5mM MgCl2 (Sigma, M-8266), ImM EGTA 
(Sigma; E4378) with ImM PMSF (Sigma, P7626), 25x protease inhibitors (Boehringer 
Mannheim, 1 697 498) immediately before use, and kept on ice. The cells were then 
stored at -80 °C or lysed directly by sonication as before. The samples were centrifuged at 
13,000rpm for 15 min at 4°C in a benchtop microfuge. The supernatant was carefully 
removed, supplemented with 5mM EDTA and centrifuged at 40,000 rpm for lhour at 
4°C in a 70. IT rotor (Beckman). The supernatant was removed using a 32-gauge needle
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and supplemented with 2mM DTT (Sigma, D9779). The samples were frozen at -80 °C. 
Protein concentration was quantified as detailed in section 2.6.4.
2.6.3 Protein Quantification - BioRad Method
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 500- 
0006) as follows. A 2mg/ml bovine serum albumin (BSA) solution (Sigma, A9543) 
was prepared in NP-40 lysis buffer, and frozen in aliquots at -20°C. A protein 
standard curve (0, 0.2, 0.4, 0.6. 0.8 and lmg/ml) was prepared from the BSA stock 
with dilutions made in UHP. The Bio-Rad reagent was diluted 1:5 in UHP water and 
filtered through Whatman paper before use. A lOjil volume of protein standard 
dilution or sample (diluted 1:5 in UHP) was added to 490|al of diluted dye reagent 
and the mixture vortexed. After 5 minutes incubation, absorbance was assessed at 
570nm although samples could be read within 1 hour of preparation. The 
concentration of the protein samples was determined from the plot of the absorbance 
at 570nm versus concentration of the protein standard.
2.6.4 Protein Quantification - BCA Method
Components in buffer C for cytosolic extracts interfered with the BioRad reagent, so 
an alternative protein assay was used for determination of protein concentrations of 
cytosolic extracts. Protein levels were determined using the BCA protein assay kit 
(Pierce, 23220) as follows. A 2 mg/ml bovine serum albumin (BSA) solution 
(supplied with kit) was used to create a standard curve, with dilutions made in UHP. 
A working reagent was prepared by combining 50:1 BCA reagents. 10|j.l of each 
standard or sample (diluted 1:50 or 1:100 in UHP) was added to a 96-well plate, and 
200jxl working reagent was added to each well. Blanks were set up using 10|il UHP 
with 200|rl of working reagent. The plate was mixed for 30 seconds and then 
incubated for 30 minutes at 37°C. Absorbance was measured at 562 nm, and protein
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concentrations determined from plotting a graph of absorbance at 562nm against 
protein concentration.
2.6.5 Immunoprécipitation
Immunoprécipitations were carried out using 100[ig extracted protein (detailed in 
section 2.6.1) as estimated using the BioRad assay in section 2.6.3. All steps were 
carried out on ice. 100|rg protein was centrifuged at 13,000rpm at 4°C for 15 
minutes in a benchtop microfuge. The supernatant was transferred to an eppendorf 
and precleared by addition of 1 (j.g of normal mouse IgG (Sigma, 15381) and shaking 
for 1 hour at 4°C. 20^1 protein A agarose (Santa Cruz, sc2001) was added and 
samples shaken for a further 30 minutes at 4°C, after which time they were spun at 
5000rpm for 5 minutes at 4°C in a benchtop microfuge. The supernatant was 
carefully transferred to eppendorfs, taking care not to carry over any beads (high 
source of background). Primary antibody was added (10p.l cyclinB; 2\i\ weel; 4 1^ 
cdc25C) to the supernatant, and eppendorfs were shaken gently for at least 2 hours 
or overnight at 4°C. 12pl protein A agarose was added to each sample, and shaken 
for 2-4 hours (30mins for weel) at 4°C. Samples were spun at 5000rpm for 15 
minutes and supernatants discarded. The pellets were washed four times with NP-40 
lysis buffer (without protease inhibitors), and spun each time at 5000rpm for 10 
minutes. Pellets were resuspended in a total volume of 15|il lysis buffer and 5X 
loading buffer and boiled for three minutes. Samples, including beads were loaded on 
polyacrylamide gels, and western blotting carried out as described in section 2.6.6 
and 2.6.7.
2.6.6 Gel electrophoresis
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE). The stacking and resolving gels were prepared as
79
illustrated in table 2.6.6.1. The gels were set in clean 10cm x 8cm gel cassettes, 
which consisted of a glass plate and an aluminium plate, which were separated by 
1mm spacers. The gels resolving were overlaid with 0.1 % SDS or water-saturated 
butanol whilst polymerising to exclude air and ensure a smooth surface on which to pour 
the stacking gel. The gel was allowed to polymerise for 1 hour. Once set, the 0.1% SDS 
was removed and the stacking gel was then added, combs inserted and left to 
polymerise for 30 minutes.
Resolving Gel Stacking Gel
7.5% 10% 12% 15% 5%
30% Acrylamide 
stock
3.8 ml 5.0ml 6 ml 7.5 ml 0.8 ml
Distilled Water 8.0 ml 6.8 ml 5.8 ml 4.3 ml 3.6 ml
1.875M Tris-HCl 
pH 8.8
3.0 ml 3.0 ml 3.0ml 3.0ml
1.25M Tris-HCl 
pH6.8
0.5 ml
10% SDS 150 nl 150 Ml 150 m1 150 m1 50 Ml
10%NH4-(S2O3)2 60 pi 50 Ml 50 Ml 50 Ml 17 Ml
TEMED 9.0 Ml 7.5 Ml 7.5 Ml 7.5 Ml 6 m1
Table 2.6.6.1 Recipes for preparation of polyacrylamide-SDS gels
30 % acrylamide stock solution was made by dissolving 29.1 g acrylamide (Sigma, 
A8887) and 0.9g NN-methylene bis-acrylamide (Sigma, N7256) in 60 ml UHP and 
made up to 100ml. The solution was stored at 4°C in the dark for up to one month.
Before sample loading, protein was diluted in 5X loading buffer (2.5mL 1.25 M Tris- 
HC1, l.Og SDS, 2.5mL mercaptoethanol (Sigma, B6250) 5.8mL glycerol (BDH, 
44305) and 0.1% bromophenol blue (Sigma, B8026) and made up to 20mL with 
distilled water). The molecular weight markers (New England Biolabs, 7708S) and 
protein samples were boiled for three minutes. Following heating, equal amounts of
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protein were added in to each well, and 8 jj.1 of molecular weight markers were used. 
The gels were run at 250V and 45mA until the bromophenol blue dye front was 
found to have reached the end of the gel, or when sufficient resolution of the 
molecular weight markers was achieved.
2.6.7 Western Blotting
Once electrophoresis had been completed, the SDS-PAGE gel was equilibrated in 
transfer buffer (25mM Tris (Sigma, T8404), 192mM glycine (Sigma, G7126) pH 8.3-
8.5 without adjusting) for 20 minutes. Protein was transferred from the gel to 
Hybond ECL nitrocellulose membranes (Amersham, RPN 2020D) by semi-dry 
electroblotting. Seven sheets of Whatman 1mm filter paper were soaked in freshly 
prepared transfer buffer. These were then placed on the cathode plate of a semi-dry 
blotting apparatus (Bio-rad) and air pockets removed from between the filter paper 
by rolling with a glass pipette. Nitrocellulose was also soaked in the transfer buffer 
and placed over the filter paper on the cathode plate. Air pockets were once again 
removed. The acrylamide gel was layered gently on top of the nitrocellulose. Seven 
sheets of transfer buffer soaked filter paper were placed on top of the gel and again 
air pockets removed. The proteins were transferred from the gel to the nitrocellulose 
at a constant current of 34mA with 15V for 30 minutes.
When protein had transferred, membranes were removed and stained with Ponceau 
(Sigma) for 5 minutes or until protein bands were visible. Membranes were washed 
with PBS until the background was clear, and stained proteins were either 
photographed or copied using a scanner for future reference. Membranes were 
destained by washing three times in PBS for 10 minutes.
Membranes were blocked using 5% milk powder (Cadburys; Marval skimmed milk) 
in TBS (125mM NaCl, 20mM Tris pH 7.5) with 0.1% Tween at room temperature 
for two hours. Membranes were treated with the appropriate dilution of primary 
antibody in TBS- 0.1% Tween overnight at 4°C. The antibodies used are listed in
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table 2.6.7.1 with the appropriate dilutions. All antibodies were diluted appropriately 
in TBS-0.1% Tween. A negative control where the gel was exposed to antibody 
diluent or animal pre-bleed was also performed.
Antibody Supplier Dilution Antibody Supplier Dilution
cdkl Santa Cruz; 
sc-54
1:1000 caspase-4 Pharmingen;
66171A
1:1000
cdk2 Santa Cruz 
sc-163
1:1000 caspase-6 Santa Cruz ; 
sc-1232
1:1000
cdk4 Santa Cruz; 
sc-601
1:1000 caspase-2 Transduction 
Labs.; 129120
1:1000
cyclin B Santa Cruz; 
sc-245
1:1000 caspase-3 Transduction 
Labs;C31720
1:1000
cyclin E Santa Cruz 
sc-247
1:1000 caspase-7 Transduction
Labs;M64620
1:1000
cyclin D Pharmingen;
14561A
1:1000 caspas e-8 Pharmingen; 
66231A
1:1000
cdc25B I.Hoffmann* 2.5(ig/ml caspase-9 Merck Frosst* 
MF445
1:5000
cdc25C I.Hoffmann* 2.5(ig/ml Fodrin Chemicon;
MAB1662
1:1000
weel Santa Cruz; 
sc-325
1:1000 PARP#1
(C-210)
Transduction
Labs.;SA-250
1:5000
P-glycoprotein
(C-219)
Centocor;
800-661
1:40 PARP#2 Boehringer 
Mannheim; 
1 835 238
1:2000
CD-95
(CH-11)
Upstate
Biotech.;
05-201
1:1000 PARP#3 Santa Cruz; 
sc-1561
1:1000
* These antibodies were received as gifts
Table 2.6.7.1 Source of and dilutions of antibodies used in western blotting
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Primary antibody was removed after this period and the membranes rinsed three times 
with TBS-0.1% Tween for a total of 30 minutes. Membranes were incubated with the 
appropriate secondary antibody (1:000 dilution of anti-mouse IgG peroxidase 
conjugate (Sigma, A6782) or 1:000 dilution of anti-rabbit IgG peroxidase conjugate 
(Sigma, A4914) in TBS-0.1% Tween for 1 hour at room temperature.The 
membranes were washed three times in the wash buffer (TBS containing 0.5% Tween 
(Sigma, P7949)) for 15minutes.
2.6.8 Enhanced chemiluminescence (ECL) detection
Immunoblots were developed using an Enhanced Chemiluminescence kit (Amersham, 
RPN2109). The procedure was carried out according to manufacturers instructions as 
follows. The nitrocellulose membrane was placed on a plate which was covered with 
layer of parafilm. 3ml of a 1:1 mixture of ECL reagents were applied to completely cover 
the nitrocellulose. The ECL reagent mixture was removed after a period of one minute 
and the membrane wrapped in clingfilm. All excess air bubbles were removed. The 
nitrocellulose was exposed to autoradiographic film (Kodak, X-OMATS) for various 
times (from 1 to 15 minutes depending on the signal). The exposed autoradiographic film 
was developed for 3 minutes in developer (Kodak, LX-24). The film was then washed in 
water for 15 seconds and transferred to a fixative (Kodak, FX-40) for 2 minutes. The film 
washed with water for 5-10 minutes and left to dry at room temperature.
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2.7 Flow Cytometry analysis of DLKP cells
Cells were set up and treated with doxorubicin as described in section 2.4.1. At the 
appropriate time medium was removed from flasks and reserved; cells were trypsinised 
and added to the medium to ensure collection of floating cells. Cells were washed twice in 
ice-cold PBS. Pellets were resuspended dropwise in 250(il ice-cold ethanol-PBS (70%- 
30% ) and stored at 4°C for up to four weeks until time of analysis. Before analysis, fixed 
cells were pelleted and resuspended in 40|ig/ml propidium iodide (Sigma, P4170) in PBS 
with 100|ig/ml RNase (DNase-free, Boehringer Mannehim, 1 119 915).
Samples were analysed on a FacScan (Becton Dickinson) using 488nm argon ion laser 
(FL2 detector) measuring forward and orthogonal light scatter with the lysis program to 
create histograms depicting the cell cycle distribution of the sample.
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2.8 Caspase Activity Assays
Caspase enzyme activity was investigated using cytosolic extracts (section 2.6.2) and 
the ability of the extract to cleave a fluorometric substrate was measured, according 
to a method described by Martins et al. (1997). Caspase activity is represented by the 
fluorescence of a particular sample.
Cytosolic protein was diluted to 50[rg/50pl in buffer C (see section 2.6.2). The 
protein was then diluted with 225^1 of freshly prepared assay buffer (25mM HEPES, 
pH 7.5, 0.1% CHAPS (Sigma; C3023), lOmM DTT (Sigma, D5545), lOOU/ml 
aprotinin (Boehringer Mannheim Al 153, ImM PMSF)) containing 100p.M 
DEVD.AMC substrate (Calbiochem, 235425). The reaction mixture was incubated 
for 2 hours at 37°C in darkness. The reaction was terminated by addition of 1.225ml 
of ice-cold assay buffer. Blanks were set up using 50|rl buffer C with 225pi assay 
buffer incubated at 37°C for 2 hours and then diluted with ice-cold assay buffer.
Fluorescence was measured using an excitation wavelength of 380nm and emission 
wavelength of 460nm. An AMC standard curve was prepared using 0-3000pmol of 
AMC (Sigma, A9891) per sample, to determine the amount of fluorochrome 
released.
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2.10 Cdkl Kinase assay
Cdkl kinase assays were carried out using a MESACUP cdkl kinase assay kit 
(MBL, 5235; Stratech, UK). Cells were set up in 75cm2 flasks at 4xl04cells/ml (total 
10ml) two days before doxorubicin addition. Cells were drug-treated and samples 
taken 24, 48 and 70 hours after drug treatment, as described in section 2.4.1. Cell 
pellets were resuspended in 400jrl of ice-cold sample buffer (50 mM Tris-Hcl, pH 
7.5, 0.5 M NaCl, 5mM EDTA, 2mM EGTA (Sigma, E4738), 0.01% Brij35 
(Sigma,P1254), ImM PMSF (Sigma, P7626) 0.05mg/ml leupeptin (Sigma, L2884), 
50mM 2-mercaptoethanol (Sigma, M6250), 25mM betaglycerophosphate (Sigma, 
M8266), ImM sodium orthovanadate (Sigma, S6508), and sonicated with ten 0.7sec 
pulses, 50% power, on ice. Cell extract was separated by centrifugation at 13,000rpm 
for 1 hour at 4°C in a benchtop microfuge.
200jj.l cell extract was then incubated with HCK-gel suspension (supplied with kit) 
gently shaking for 1 hour at 4°C. After incubation, the HCK-gel was washed three 
times with sample buffer and twice with 2nd wash buffer (25mM HEPES buffer 
pH7.5, lOmM MgCl2). The pellets were used as the cdkl enzyme source for the 
kinase assay.
The kinase assay was carried out on ice. 5|rl sample buffer, 5^ 1 lOx cdc2-reaction 
buffer, 5^ 1 biotinylated MV peptide and 30^1 distilled water were added to the HCK- 
gel pellets. The phosphorylation reaction was started by the addition of 5|il of 
ImMATP, and the reaction was carried out at 32°C for 45 minutes. The reaction was 
terminated by addition of 200|il of reaction stop buffer.
The kinase activity was then detected using ELISA. lOOfo.1 of terminated reaction 
mixture was transferred to microwell strips coated with Monoclonal antibody 4A4, 
which detects the phosphorylated peptide. The microwell strips were incubated at 
25°C for 80 minutes, and then washed five times with a wash solution supplied with 
the kit. 100|a.l peroxidase (POD)-conjugated streptavidin was added to each well and 
incubated at 25°C for 25 minutes. The wells were washed five times with wash
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solution. Following this step the wells were incubated with lOOp.1 POD substrate 
solution for 3-5 minutes, after which time lOOjrl 20% H 3 P O 4  was added. This 
resulted in a yellow colour development, and absorbance was measured at 492nm.
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2.11 Time-lapse videomicroscopy
Time-lapse videomicroscopy was performed using a Nikon Diaphot inverted 
microscope (Micron Optical, Bray, Ireland) equipped with phase-contrast optics, 
linked to a Mitsubishi CCD-100 colour video camera (Micron optical, Ireland). 
Images were recorded in S-VHS format using a Mitsubishi HS-S5600 video recorder 
with time-lapse capabilities. Recording speed was set at 3.22 sec/field (480hr mode) 
which resulted in an acceleration factor of 160 when played back at normal speed. 
Temperature was controlled using a perspex incubator hood (V-Jay Plastics, Dublin) 
and a Nikon warm air blower.
Cells were set up as described in 2.4.1. A random field in the flask was chosen, and 
recorded for 72 hours, after which time the tape was played back and kinetics of cell 
death or division were monitored. Cell death was classified as apoptosis on the basis 
of apoptotic morphology. Apoptotic events were scored when the classical apoptotic 
morphology first appeared; i.e. when cells rounded up just before chromosome 
condensation, membrane blebbing and apoptotic body formation. Mitosis was scored 
at the time of formation of septa between two daughter cells. Typically 100 cells in 
the field were monitored over 72 hours.
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2.12 Detection of Apoptosis
2.12.1 DNA Laddering
Cells were set up as described 2.4.1 and treated with daunorubicin. After 24 hours, 
cells were trypsinised, washed twice in ice-cold sterile PBS and resuspended in lysis 
buffer (20mM EDTA, 0.8% (w/v) sodium lauryl sarcosinate, lOOmM Tris, (pH 8.0) 
and 10 1^ RNase (Boehringer Mannheim, 1 119 915) (lOmg/ml), and incubated at 
37°C for 18 hours. Proteinase K (Boehringer Mannheim, 161 519) was added and 
samples incubated for a further 2 hours at 50°C. Samples were resolved on 0.8% 
agarose gels with EtBr at 50V for 2 hours. DNA in gels was visualised under UV 
light.
2.12.2 TUNEL analysis
Drug treated cells or untreated (control) cells, as described in section 2.4.1, were 
trypsinised at the desired times into a single cell suspension, and washed twice with 
sterile PBS. Cytospins were prepared using a cell suspension of 0.5 xlO5 cells/ml. 
Cytospins were analysed for the presence of apoptotic cells by TUNEL analysis. 
DNA strand breaks were identified using an In Situ Cell Death Detection Kit with a 
fluorescein tag (Boehringer Mannheim, 1 684 817).
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2.12.3 Phosphatidylserine analysis
The presence of phosphatidyl serine was detected using an antibody specific for 
phosphatidylserine. DLKP-SQ were set up in 25cm2 flasks as described in section 
2.4.1. Doxorubicin was added for 2 hours, and washed off. Cells were trypsinised 24 
hours later and pooled with the floating cells. Pellets were washed twice in sterile 
PBS. Cells were resuspended in PBS at a concentration of lxl06/ml, and 50^1 cell 
suspension was transferred to a sterile eppendorf. 50|rl of FITC-labelled annexin-V 
antibody suspension was added to the cell suspension. Tubes were incubated in 
darkness at 4°C for 30 minutes. Cells were washed three times in PBS by 
centrifuging at 2000rpm in a benchtop microfuge for 4 minutes to remove unbound 
antibody. The pellet was resuspended in 50jo.l PBS and one drop of Vectashield was 
added. The cells were placed on a glass slide and covered with a coverslip. Slides 
were viewed using a fluorescent microscope.
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2.13 RNA extraction, quantifiction and analysis by PCR
2.13.1 Total RNA extraction from cultured cell lines.
The four DLKP cell lines were grown in 75 cm2 flasks until approximately 80% 
confluent. Media was then removed and 1ml per 75cm2 flask of TRI reagent (Sigma, 
T-9424) was added to the flask for 5 minutes ensuring that all cells are covered with 
the solution. TRI reagent is a mixture of guanidine thiocyanate and phenol in a mono­
phase solution. It effectively dissolves DNA, RNA, and protein on lysis of cell culture 
samples. After addition of the reagent, the cell lysate was passed several times 
through a pipette to form a homogenous lysate. To ensure complete dissociation of 
nucleoprotein complexes, the sample was allowed to stand for 5 minutes at room 
temperature. 0.2ml of chloroform (not containing isoamyl alcohol or any other 
additive) per ml of TRI reagent was added to the cell lysate. The sample was covered 
tightly, shaken vigorously for 15 seconds and allowed to stand for 2-15 minutes at 
room temperature. The resulting mixture was centrifuged at 12,000rpm for 15 
minutes at 4°C in a benchtop microfuge. Centrifugation separated the mixture in to 
three phases: an organic phase (containing protein), an interphase (containing DNA) 
and a colourless upper aqueous phase (containing RNA). The aqueous phase was 
then transferred to a fresh tube and 0.5ml of isopropanol per ml of TRI reagent used 
in sample preparation, added and mixed. The sample was then allowed to stand for 5- 
10 minutes at room temperature, before being centrifuged at 12,000rpm for 10 
minutes at 4°C. The RNA precipitate formed a pellet on the side and the bottom of 
the tube. The supernatant was removed and the RNA pellet washed by adding 1ml of 
75% ethanol per 1ml of TRI reagent. The sample was vortexed and centrifuged at 
7,500rpm for 5 minutes at 4°C. Samples could be stored for up to one year at -20°C. 
The RNA pellet was air-dried briefly. Approximately 50ul DEPC treated H20  was 
added to the pellet. The RNA was then stored at -80°C until required for PCR 
analysis.
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2.13.2 RNA Quantitation
RNA was quantified spectrophotometrically at 260nm and 280nm. An optical density 
of 1 at 260nm is equivalent to 40mg/mL RNA. The A26o/A28o ratio is indicative of 
RNA purity. Partially solubilised RNA has a ratio of <1.6 (Ausubel et al., 1991). The 
yield of RNA from most lines of cultured cells is 100-200fog/90mm plate (Sambrook 
etal., 1989).
2.13.3 Reverse transcription of RNA isolated from cell lines
The following components were used in the reverse transcriptase (RT) reaction for 
RNA isolated from cell lines:
l(xl oligo (dT)i2-i8 primers (lfog/ml) (promega, Cl 101), 1 |og of total RNA (1 (J.g/M-l), 
and 3(j,l of DEPC-H20 were mixed together and heated at 70°C for 10 min and then 
chilled on ice to remove any RNA secondary structure formation and allow oligo 
(dT) primers to bind to the poly (A)+ tail on the mRNA. 4pi of a 5X buffer 
(consisting of 250mM Tris-HCL, pH 8.3, 375mM KC1 and 15mM MgCl2 ), 2(0,1 of 
DTT (lOOmM), 1 (0,1 of RNasin (40U/(ol) (Promega, N2511), lfol of dNTPs (lOmM 
each of dATP, dCTP, dGTP and dTTP), 6(ol of water and lfil of Moloney murine 
leukaemia virus-reverse transcriptase (MMLV-RT) (Gibco; 5108025 SA) was then 
added to the heat-denatured RNA complex and the mixture incubated at 37°C for 1 
hour to allow the MMLV-RT enzyme catalyse the formation of cDNA on the mRNA 
template. The enzyme was then inactivated and the RNA and cDNA strands 
separated by heating to 95°C for 2 min. The cDNA was used immediately in the PCR 
reaction or stored at -20°C until required for analysis.
92
2.13.4 PCR analysis of cDNA formed from mRNA isolated from cell lines
Typical PCR reactions were set up as 50|ol volumes using 5|ol of cDNA formed 
during the RT reaction (see section 2.13.3). Each PCR reaction tube contained 
26.5(0,1 of water, 5|ol 10X buffer (lOOmM Tris-HCL, pH 9.0, 50mM KC1, 1% Triton 
X-100), 2|ol 25mM MgCl2, l|ol of first strand target primer (250ng/|ol), 1 (0.1 of second 
strand target primer (250ng/[ol), 0.5(ol of first strand endogenous control primer (P- 
actin) (250ng/|ol), and 0.5|ol of second strand endogenous control primer (P-actin) 
(250ng/(il). 5(ol of cDNA (pre-heated to 95°C for 3 min. to separate strands and 
remove any secondary structure if the sample had been stored at -20°C) was added to 
the above and heated to 94°C for 5 min (reduces non-specific binding of primers to 
template). 8|ol of 1.25mM dNTP and 0.5fol (1 unit) of Taq DNA Polymerase enzyme 
(Promega, N1862) was then added to the above. The cDNA was then amplified by 
PCR using the following program:
94°C for 3 minutes (denature double stranded DNA);
35 cycles 94°C for 3 min. (denature double stranded DNA);
54°C for 1.5 min. (anneal primers to cDNA)
72°C for 3 min (extension)
72°C for 7 minutes (extension)
All reaction tubes were then kept at 4°C until analysed by gel electrophoresis 
followed by densitometry. A 10(ol aliquot of tracking buffer, consisting of 0.25% 
bromophenol blue (Sigma; B5525) and 30% glycerol in water, was added to each 
tube of amplified cDNA products. lOjol of cDNA products from each tube were then 
separated by electrophoresis for approx. PA - 2 hours at 70V through a 2% agarose 
(Promega, V3122) gel containing ethidium bromide (Sigma, E8751), using lx TBE 
(22.5mM Tris HC1, 22.5mM boric acid (Sigma, B7901), 0.5mM EDTA) as running 
buffer. Molecular weight markers "(])-X174" Hae III digest (Promega, G1761) were 
run, simultaneously as size reference. The gels were placed under UV light (UVP 
Transilluminator) and photographed.
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3.0 Results
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3.1 Constitutive protein level of cyclins and cdks in the DLKP cell lines
An investigation was carried out in order to compare protein levels of selected cell 
cycle-associated proteins in a range of cell lines displaying varying resistance to 
chemotherapeutic drugs. It has been shown that overexpression or deregulation of 
some cell cycle proteins frequently occurs in many tumours and can contribute to the 
malignancy of cancers. Western blotting was carried out to identify cyclins or cdks 
whose expression may be altered in the resistant variants of DLKP, DLKP-A250 lOp 
#7, DLKP-A2B and DLKP-A5F compared to the sensitive cell line DLKP-SQ, and 
may contribute to the resistant state. As can be seen from figures 3.1.1 - 3.1.6, there 
are no significant differences between the protein levels of cyclin E (figure 3.1.2), 
cyclin Bi (figure 3.1.1), cyclin Di (figure 3.1.3), cdkl (figure 3.1.4), cdk2 (figure
3.1.5), and cdk4 (figure 3.1.6) in the four cell lines, when protein loading is taken 
into account. Blots were stained with the reversible stain Ponceau to confirm equal 
protein loading in each case. From these results it was concluded that levels of 
protein expression in the four cell lines is equivalent.
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3.2 Effects of doxorubicin on the cell cycle of DLKP cell lines
Resistant cells have similar cyclins and cdks expression compared to DLKP-SQ. The 
effect the chemotherapeutic drug doxorubicin exerted on the cell cycle of the DLKP 
cell lines was studied to determine if sensitive and resistant cells exhibit a comparable 
response. An equitoxic drug dosage was used which gave approximately 50% kill 
after 3 days. Growth curves were carried out to determine these values, and 
representative data are illustrated in figure 3.2.1. The concentrations used are listed in 
table 3.2.1
CELL LINE CONC. IC50
DLKP- SQ 0.6 ng/ml
DLKP- A250 10p#7 2 ng/ml
DLKP- A2B 30 ng/ml
DLKP- A5F 100 (ig/ml
Table 3.2.1 IC50 values for the DLKP cell lines after 2 hr Doxorubicin pulse
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Toxicity profile of Doxorubicin on 
DLKP-SQ
Cone (pg/ml)
Toxicity profile o f Doxorubicin on 
DLKP-SQ/A250 10p #7
Cone (|ig/ml)
Toxicity profile of Doxorubicin on 
DLKP-A2B
Cone (pg/ml)
Toxicity profile o f Doxorubicin on 
DLKP-A5F
Cone (pg/ml)
Figure 3.2.1 Toxicity profiles of DLKP cell lines. Cells were treated for
2 hours with doxorubicin, after which time drug was removed and 
flasks refed. Viability was determined after 72 hours using crystal 
violet toxicity assay.
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3.3.1 Flow cytometric analysis of DLKP cell lines after Doxorubicin treatment
The effect of doxorubicin treatment on the cell cycle of the various cellular 
populations was initially investigated using flow cytometric analysis. Cell cycle 
distribution of cells at various times after drug treatment was analysed using 
propidium iodide (PI), which is a nucleic acid intercalator. Cells in G2 will have twice 
as much DNA as those in G1 and S, therefore G2/M cells will have a two-fold 
increase in PI levels over those in Gl. S phase cells will have intermediate PI levels 
according to the amount of DNA synthesised during replication. It is necessary to use 
clonal populations in order to obtain distinct peaks during analysis since most cancer 
cell lines contain subpopulations with various levels of ploidy. The effects of 
doxorubicin treatment on the DLKP cell lines compared to untreated controls are 
illustrated in figures 3.3.1 - 3.3.8, C refers to untreated control cells and T refers to 
doxorubicin treated cells at the indicated time following drug treatment. Figure 3.3.1 
illustrates the DNA profile of untreated DLKP-SQ cells over three days. The x-axis is 
a measurement of fluorescence at 488nm and is directly proportional to the DNA 
content of the cells. The y-axis measures the relative number of cells. 10,000 
individual cells were counted for each sample. The left hand peak represents cells in 
Gl phase of the cell cycle (2n DNA content) and the right-hand peak represents cells 
in G2 phase having 4n DNA content just before mitosis. S phase is represented by the 
area between the two peaks. The histograms in figures 3.3.1, 3.3.3, 3.3.5, and 3.3.7 
illustrate the unperturbed asynchronous cell cycles of untreated DLKP-SQ, DLKP- 
A250 10p#7, DLKP-A2B and DLKP-A5F respectively, in which the distribution 
remains unchanged as the cells progress through the cell cycle.
When DLKP-SQ cells are treated with 0.6|j.g/ml doxorubicin for 2 hours, alterations 
in the cell cycle become apparent by 12 hours after treatment, with a slower traverse 
of the S phase indicated by the increased population in the S phase at T16 and an 
eventual G2/M arrest at 36 hours (T36) after treatment. Apoptotic cells can be seen 
by the emergence of a sub Gl population at T36 and T45. These results are 
illustrated in figure 3.3.2. When the resistant clones were treated with doxorubicin 
similar results were not obtained. In figure 3.3.4 it can be seen that DLKP-A250 lOp 
#7 cells traverse the S phase much faster than the DLKP-SQ cells and begin to arrest
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in G2/M by T16, however this arrest is not permanent because cells begin to 
accumulate in G1 phase by T36. There is a similar effect seen in DLKP-A2B cells 
(figure 3.3.6) and DLKP-A5F (figure 3.3.8), in which the cells seem to transiently 
arrest in G2/M and then bypass the arrest.
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Figure 3.3.1 Cell cycle analysis of untreated DLKP-SQ cells.
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Figure 3.3.2 Cell cycle analysis of DLKP-SQ cells after 0.6jig/ml Doxorubicin
2hr pulse treatment.
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Figure 3.3.3 Cell cycle analysis of untreated DLKP-SQ/A250 10p#7 cells.
104
U3: C G L0£ 3\FL£-A \FLe -a re a U3 j COL0 £ 9 ^FL2-A ^FLe -ftr© a
T ib
A
260 400 600 800 1000
U3s COL0£0vFL£-AvFLS-Are«.
T£0
J
■ m
736
La
è ZÒ0 400 tèa 880 lee» V3l COt031-'FL2-«'R.2-Ai-»a
X.*»
1000
U31 COU03e'Fte-fi'fLa-Hf-ea
see 4O0 600 800 10O0
Figure 3.3.4 Cell cycle analysis of DLKP-A250 lOp #7 following 2.0 jig/ml
Doxorubicin 2 hour treatment
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Figure 3.3.5 Cell cycle analysis of untreated DLKP-A2B cells.
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Figure 3.3.6 Cell cycle analysis of DLKP-A2B cells after 30^ig/ml Doxorubicin
treatment
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Figure 3.3.7 Cell cycle analysis of untreated DLKP-A5F cells
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Figure 3.3.8 Cell cycle analysis of DLKP-A5F cells after lOOjig/ml Doxorubicin 
2 hour pulse treatment
109
3.3.2 Effect of caffeine on DLKP-SQ cells
Caffeine treatment is a well known means of bypassing a G2/M arrest in cultured cells, 
and its effect on the doxorubicin-treated DLKP-SQ cell line was investigated to establish 
if doxorubicin-induced G2/M arrest could be overcome. DLKP-SQ cells were treated 
with 4mM (non-toxic) caffeine in combination with doxorubicin, with some variations in 
the timing of caffeine addition in an attempt to mimic the effect seen in the resistant cells. 
Caffeine treatment alone had no effect on DLKP-SQ cells (seen in figure 3.3.11) and they 
cycled identically to the untreated control cells, as seen in figure 3.3.9. Doxorubicin 
0.6ug/ml treatment arrests the cells in G2/M by T36 in figure 3.3.10. Figure 3.3.12 
demonstrates that this arrest can be bypassed when 4mM caffeine is added directly after 
drug removal at TO, and cells appear to cycle through Gl and G2/M and undergo 
apoptosis (seen by Time-lapse videomicroscopy). If caffeine treatment is delayed until 18 
hour. a^fter drug removal the cells have arrested in G2/M, as seen in figure 3.3.13, upon 
addition of 4mM caffeine cells resume mitotic progression and the G2/M arrest is 
abrogated. In summary, it appears that DLKP-SQ cells treated with caffeine can mimic 
the action of the resistant variants after doxorubicin treatment.
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Figure 3.3.9 Cell Cycle Analysis of untreated DLKP-SQ cells
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Figure 3.3.10 Cell Cycle Analysis of DLKP-SQ cells after pulsing with 0.6jig/ml 
Doxorubicin for 2 hours.
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Figure 3.3.11 Cell Cycle analysis of DLKP-SQ cells after treatment with 4mM 
caffeine, samples were taken at the indicated times.
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Figure 3.3.12 Cell cycle analysis of DLKP-SQ cells following 0.6jig/ml 
Doxorubicin 2 hr pulse and 4mM caffeine added directly after drug removal.
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Figure 3.3.13 Cell cycle analysis of DLKP-SQ cells after 0.6^tg/ml Doxorubicin 
2hr pulse and 4mM caffeine added 18 hrs after drug removal. Controls were 
treated at 18 hrs with 4mM caffeine
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3.4 Time-lapse Videomicroscopy of cells
From section 3.3 it is evident that a certain sub-population of the resistant variants can 
progress through mitosis after doxorubicin treatment, whilst the sensitive DLKP-SQ cells 
remain arrested at G2/M. Further evidence for this phenomenon comes from time-lapse 
videomicroscopy which allows visualisation of dynamic cellular events of cells in culture. 
Kinetics of cell death and mitosis were monitored in each of the cell lines after drug 
treatment. 100 cells were randomly chosen in the field and the number of apoptotic and 
mitotic events were noted (as described in materials and methods). When DLKP-SQ are 
doxorubicin-treated there is no mitosis observed and cells die by apoptosis, this is seen in 
figure 3.4.1. In the case of the resistant cells however there is a significant level of mitosis, 
being highest in DLKP-A5F cells. Figure 3.4.2 illustrates the kinetics of apoptosis and 
mitosis in DLKP-A20 lOp #7 after drug treatment with 60 % apoptosis and 13 % mitosis 
in 100 cells over three days. DLKP-A2B cells exhibit 73 % apoptosis and 15 % mitosis 
seen in figure 3.4.3, and DLKP-A5F cells 70 % apoptosis and 58 % mitosis can be seen in 
figure 3.4.5. Table 3.4.1 summarises these results.
Cell Line % Apoptosis % Mitosis
DLKP-SQ 60% 0%
DLKP-A250 lOp #7 60% 13%
DLKP-A2B 73% 15%
DLKP-A5F 70% 58%
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Figure 3.4.1 Timelapse videomicroscopical analysis of 
doxorubicin 2-hour pulse on DLKP-SQ
Figure 3.4.2 Timelapse videomicroscopical analysis of 
2pg/ml doxorubicin 2 hour pulse on DLKP-A250 10p#7
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Figure 3.4.3 Timelapse videomicroscopical analysis of 
30 pg/ml Doxorubicin 2 hour pulse treatment on DLKP-A2B
Figure 3.4.4 Timelapse videomicroscopical analysis of 
lOOpg/ml Doxorubicin 2 hour pulse treatment on DLKP-A5F
3.5 Investigation of doxorubicin effect on cyclin and cdk levels
Flow cytometric analysis in section 3.3 demonstrated a G2/M arrest in doxorubicin 
treated DLKP-SQ cells, and a G2/M bypass in the resistant variants. This raises the 
possibility of a faulty or inefficient G2/M checkpoint in the resistant variants allowing 
some cells to over-ride the checkpoint even if their DNA is damaged. This likelihood led 
to an investigation of the proteins involved in the control of entry to mitosis, the m ain  
controller being cyclin B-cdkl kinase complex. As described in section 1, cyclin B-cdkl 
kinase is at the core of a complex control mechanism that allows the cell to sense any 
DNA damage and halt the cell cycle in order to repair any damage before the cell enters 
mitosis.
3.5.1 Cyclin B protein expression in DLKP cell lines following doxorubicin 
treatment
The effect of doxorubicin on cyclin B expression was investigated using Western Blotting. 
Any decrease in protein levels could indicate reduced protein synthesis or increased 
degradation rates, and any increase in protein levels could reflect either increased protein 
synthesis rates or decreased protein degradation. Blots were stained with the reversible 
protein stain Ponceau to confirm equal loading in each case. Results for cyclin B levels in 
DLKP-SQ are shown in figures 3.5.1.1 (controls) and 3.5.1.2 (drug treated). Controls are 
labelled C, at the time samples were taken, and drug-treated samples are labelled T at the 
time of sampling. There is no change in cyclin B protein levels after drug treatment. 
Figures 3.5.1.3 and 3.5.1.4, 3.5.1.5 and 3.5.1.6, 3.5.1.7 and 3.5.1.8 illustrate cyclin B 
protein levels in DLKP-A250 lOp #7, DLKP-A2B and DLKP-A5F respectively. Again 
doxorubicin had no effect on the protein levels of cyclin B in the resistant variants.
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CO C12 C16 C20 C24 C36 C45 Neg
-  83 kDa 
-6 2  kDa
<
-47.5 kDa
Cyclin B1
Figure 3.5.1.1 Western Blot showing cyclin B protein levels in DLKP-SQ 
untreated cells.
TO T12 T16 T20 T24 T36 T45 Neg
-  83kDa
-  62 kDa
<r-  47.5 kDa cyclin B1
Figure 3.5.1.2 Western Blot showing Cyclin B protein levels in DLKP-SQ cells 
after 0.6)ig/ml Doxorubicin 2hr pulse treatment.
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-  62 kDa 
<r- cyclin B1
-  47.5 kDa
Figure 3.5.1.3 Western Blot showing Cyclin B protein levels in DLKP-SQ/A250 
10p#7 untreated cells
CO C12 C16 C20 C24 C36 C45
mm mmm * —
TO T12 T16 T20 T24 T36 T45 Neg
=sto~ 83k Da
„  cyclin B1
■ 62 kDa
3-  47.5 kDa
Figure 3.5.1.4 Western Blot of Cyclin Bi protein levels in DLKP-SQ/A250 
10p#7 cells after Doxorubicin 2hr pulse treatment
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CO C12 C16 C20 C24 C36 C45 Neg
-  62 kDa
<—  cyclin B1
-  47.5k Da
Figure 3.5.1.5 Western blot of Cyclin B protein levels in untreated DLKP-A2B 
cells
TO T12 T16 T20 T24 T36 T45 Neg
-  62 kDa
<— cyclin B1
-  47.5 kDa
Figure 3.5.1.6 Cyclin B protein levels in DLKP-A2B cells after 30pg/ml 
Doxorubicin 2hr pulse treatment
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TO T12 T16 T20 T24 T36 T45 Neg
~ 62 kDa
-- 47.5 kDa
' cyclin B1
Figure 3.5.1.7 Cyclin B protein levels in untreated DLKP-A5F cells
TO T12 T16 T20 T24 T36 T45 Neg
-6 2 k D a <_ Cyc|jn B, 
-  47.5 kDa
Figure 3.5.1.8 Cyclin B protein levels in DLKP-A5F cells after lOOpg/ml 
Doxorubicin 2hr pulse treatment
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3.5.2 Cdkl expression following doxorubicin treatment
The catalytic partner of cyclin B, cdkl was studied, in terms of possible altered 
expression following drug treatment. Western blotting showed no differences in protein 
levels after drug treatment compared to control cells. Cdkl levels in DLKP-SQ can be 
seen in figures 3.5.2.1 and 3.5.2.2. The apparent increase in protein in figure 3.5.2.2 in 
DLKP-SQ after doxorubicin treatment is due to an unequal protein loading on this blot. 
DLKP-A250 10p#7 cdkl levels are shown in figures 3.5.2.3 and 3.5.2.4. DLKP-A2B 
and DLKP-A5F results are illustrated in figures 3.5.2.5, 3.5.2.6 and figures 3.5.2.7, 
3.5.2.8 respectively. In summary doxorubicin treatment does not alter expression of 
cdkl protein in either sensitive or resistant DLKP cell lines.
CO C12 Cl 6 C20 C24 C36 C45 Neg
i  wm -  32 kDa
Figure 3.5.2.1 Cdkl protein levels in DLKP-SQ untreated cells.
TO T12 T16 T20 T24 T36 T45 Neg
-  47.5 kDa
mm -  32 kDa
Figure 3.5.2.2 Cdkl protein levels in DLKP-SQ cells after 0.6^ig/ml Doxorubicin
2hr pulse treatment.
CO C12 C16 C20 C24 C36 C45 Neg
- 47.5 kDa
-  32 kDa
Figure 3.5.2.3 Cdkl protein levels in DLKP-SQ/A250 10p#7 untreated cells
TO T12 T16 T20 T24 T36 T45 Neg
-  32 kDa
Figure 3.5.2.4 Cdkl protein levels in DLKP-SQ/A250 10p#7 cells after 
Doxorubicin 2hr pulse treatment
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CO C12 C16 C20 C24 C36 C45 Neg
Figure 3.5.2.5 Cdkl protein levels in untreated DLKP-A2B cells
TO T12 TI 6 T20 T24 T36 T45 Neg
Figure 3.5.2.6 Cdkl protein levels in DLKP-A2B cells after 30pg/ml 
Doxorubicin 2hr pulse treatment
- 32 kDa
32 kDa
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CO C12 C16 C20 C24 C36 C45 Neg
Figure 3.5.2.7 Cdkl protein levels in untreated DLKP-A5F cells
TO T12 T16 T20 T24 T36 T45 Neg
Figure 3.5.2.8 Cdkl protein levels in DLKP-A5F cells after 100^g/ml 
Doxorubicin 2hr pulse treatment
32 kDa
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3.5.3 Cyclin B-cdkl complex formation
Section 3.5.1 and 3.5.2 demonstrated that doxorubicin did not affect the protein 
expression of cyclin B or cdkl in any of the four DLKP variants. Even though equal 
protein expression was observed, this does not necessarily indicate that that complex 
formation was unaffected by drug treatment. If either cyclin B or cdkl was altered 
by doxorubicin in such a way as to restrict its binding ability to its partner, yet 
unaffect protein expression, kinase activity would be prevented, thus arresting the 
cell cycle before mitosis onset. Conversely aberrant formation of cyclin B-cdkl 
complexes, if sufficiently active could be responsible for a G2/M override.
Immunoprécipitations were carried out using an anti-cdkl antibody. Samples were 
separated on SDS-page and probed with anti-cyclin B. In this way levels of cyclin B 
bound to cdkl could be investigated before and after drug treatment. Figure 3.5.3.1 
illustrates results, CO refers to untreated controls, and T48 refers to doxorubicin- 
treated samples 48 hours after drug treatment. It can be seen that doxorubicin 
treatment does not alter levels of cyclin B-cdkl complex in DLKP-SQ, DLKP-A250 
10p#7, DLKP-A2B or DLKP-A5F. The alteration in the doxorubicin-induced G2/M 
arrest seen in resistant variants is not due to deregulated cyclin B-cdkl complex 
formation.
DLKP-SQ DLKP- 10p#7 DLKP-A2B DLKP-A5F
CO T48 CO T48 CO T48 CO T48
Figure 3.5.3.1 Western blot showing levels of cyclin B-cdkl complex prior to 
and following doxorubicin treatment. Co refers to untreated controls, T48 
refers to cells 48 hours after drug treatment.
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3.6 Investigations on phosphorylation levels of specific residues on cdkl
Section 3.5 demonstrated that doxorubicin treatment did not affect protein levels of 
cyclin B or cdkl in either of the cell lines. If these proteins are unaffected at the 
protein synthesis level, then perhaps the enzyme activity of the complex may be the 
causative factor accounting for the G2/M over-ride in the resistant variants. The 
activity of cdkl is the key regulatory factor in the cyclin B-cdkl complex, and as 
described in 1.4.7 is tightly controlled by a phosphorylation and dephosphorylation 
mechanism. Three main residues are initially phosphorylated on cdkl when it binds to 
cyclin B; Thr 14, Tyr 15 and Thr 161. Thr 14 and Tyr 15 are inhibitory sites and 
when phosphorylated can render the complex inactive, these residues are thought to 
be phosphorylated by weel in vivo. The presence or absence of a phosphate residue 
on the Tyr 15 residue therefore will give an indication as to whether the cdkl kinase 
is active (absence of a phosphate on Tyr 15) or inactive (presence of a phosphate on 
Tyr 15).
Tyr 15 (Y15) phosphorylation of cdkl in DLKP-SQ cells after doxorubicin treatment 
was looked at using two methods. The first technique involved immunoprécipitation 
of 100 (.ig cdkl protein using an anti-cdkl antibody. After Western Blotting, an anti- 
phosphotyrosine antibody was used to visualise the levels of phosphorylated Tyr 15. 
The blots are shown in figure 3.6.1 and 3.6.2. Negative controls consisted of 
immunoprecipitated protein exposed to antibody diluent, and IgG controls consisted 
of 1 pg normal mouse IgG immunoprecipitated instead of cellular protein. As can be 
seen from the blots, drug treatment had little or no effect on the levels of 
phosphorylated Tyr 15 compared to the untreated controls. This result is a little 
surprising because the G2/M arrest seen in flow cytometry could be caused by a 
decrease in cdc2 kinase activity due to phosphorylation on Y15. But the bands 
obtained are quite weak, so a definitive comparison is difficult.
A more specific technique involved using a specific anti-cdkl Y15 monoclonal 
antibody which recognises the phosphorylated Y15 on cdkl. Results for DLKP-SQ 
cells are illustrated in figure 3.6.3, and the levels of phosphorylated Y15 seem to
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increase after drug treatment. Levels of tyrosine phosphorylation in the resistant 
variants were also investigated. This was carried out using the specific anti-cdkl Y15 
antibody. There was no change in levels of Y15 phosphorylation in DLKP-A250 
10p#7 treated cells compared to control levels (figure 3.6.5 and 3.6.6). This result 
was also seen in DLKP-A2B doxorubicin-treated cells (figures 3.6.7 and 3.6.8 ) and 
in DLKP-A5F doxorubicin treated cells (figure 3.6. 9 and 3.6.10).
To further corroborate these results, samples from the four cell lines were run on one 
gel together, and results are shown in figure 3.6.11. It can be clearly determined from 
this blot that DLKP-SQ experiences an increase in Y15 phosphorylation after 
doxorubicin treatment, and resistant variants seem to have a similar level of Y15 
phosphorylation when compared to controls. When analysed using densitometry and 
taking protein loading into consideration, the DLKP-SQ Y15 phosphorylation 
increased 1.58-fold compared to the untreated control The higher protein in the lane 
marked T48 #7 is due to much higher protein loading in this lane, as concluded from 
Ponceau staining.
From these results it seems that the G2/M bypass in the resistant cells is due to 
absence of an increase in Y15 phosphorylation levels. This suggests a consistent cdkl 
kinase activity which could push the cells through mitosis. This theory is further 
investigated by looking at the cdkl kinase activity in the cell lines following 
doxorubicin treatment.
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62 kDa -  
47.5 kDa -
32 kDa -  
(Y15)
CO C12 C24 C45 Neg
■ \v'" ‘» r . " - v
»
Figure 3.6.1 Untreated DLKP-SQ samples. Immunoprécipitations with anti- 
cdkl antibody, and then probed with antiphosphotyrosine to look at levels of 
Y15 phosphorylation before and after doxorubicin treatment
TO T12 T24 T45 IgG Neg
62 kDa -  
47.5 kDa -
32 kDa -  
(Y15)
Figure 3.6.2 Doxorubicin-treated samples. Immunoprécipitations with anti- 
cdkl antibody, and then probed with antiphosphotyrosine to look at levels of 
Y15 phosphorylation after doxorubicin treatment
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CO C12 C16 C20 C24 C36 C45 Neg
Figure 3.6.3 Untreated controls. Western blots showing levels of 
phosphorylated tyrosine 15 on cdkl before doxorubicin treatment in DLKP-SQ 
cells. Blots were probed using a cdkl-specific anti-phosphotyrosine 15.
TO T12 T16 T20 T2 T36 T45 Neg
32 kDa ■
Figure 3.6.4 Western blots showing levels of phosphorylated tyrosine 15 on 
cdkl after doxorubicin treatment in DLKP-SQ cells. Blots were probed using a 
cdkl-specific anti-phosphotyrosine 15.
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32 kDa -
Figure 3.6.5 Untreated DLKP-A250 10p#7 cells. Western blots showing levels 
of phosphorylated tyrosine 15 on cdkl before doxorubicin treatment in DLKF- 
A250 10p#7 cells. Blots were probed using a cdkl-specific anti-phosphotyrosine 
15,
TO T12 T16 T20 T24 T36 T45
Figure 3.6.6 Doxorubicin treated DLKP-A250 lOp #7cefls Western blots 
showing levels of phosphorylated tyrosine 15 on cdkl after doxorubicin 
treatment in DLKP-A250 10p#7 cells. Blots were probed using a cdkl-specific 
anti-phosphotyrosine 15.
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CO C12 C16 C20 C24 C36 C45
32 kDa —
Figure 3.6.7 Untreated DLKP-A2B cells. Western blots showing levels of 
phosphorylated tyrosine 15 on cdkl before doxorubicin treatment in DLKP- 
A2B cells. Blots were probed using a cdkl-specific anti-phosphotyrosine 15.
Figure 3.6.8 Doxorubicin treated DLKP-A2B cells. Western blots showing 
levels of phosphorylated tyrosine 15 on cdkl after doxorubicin treatment in 
DLKP-A2B cells. Blots were probed using a cdkl-specific anti-phosphotyrosine
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CO C12 C16 C20 C24 C36 C45
Figure 3.6.9 Untreated DLKP-A5F cells. Western blots showing levels of 
phosphorylated tyrosine 15 on cdkl before doxorubicin treatment in DLKP- 
A5F cells. Blots were probed using a cdkl-specific anti-phosphotyrosine 15.
TO T12 T16 T20 T24 T36 T45
Figure 3.6.10 Doxorubicin treated DLKP-A5F cells. Western blots showing 
levels of phosphorylated tyrosine 15 on cdkl after doxorubicin treatment in 
DLKP-A5F cells. Blots were probed using a cdkl-specific anti-phosphotyrosine 
15.
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DLKP-SQ DLKP- 10p#7 DLKP-A2B DLKP-A5F
C48 T48 C48 T48* C48 T48 C48 T48
32kDa -
*T48, much higher protein loading, when ponceau staining was carried out.
Figure 3.6.11 Western blot showing levels of Y15 phosphorylation in the four 
DLKP cell lines. CO refers to untreated controls, T48 refers to doxorubicin 
treated samples 48 hours after treatment.
DLKP-SQ DLKP- 10p#7 DLKP-A2B DLKP-A5F
C48 T48 C48 T48 C48 T48 C48 T48
Figure 3.6.12 Ponceau-stained membrane showing levels o f protein loading for 
Y15 phosphorylation Western seen in 3.6.11.
3.7 Cdkl kinase activity assays
A cdkl kinase activity assay in the cells was assessed by two methods. A radioactive 
method was initially employed to look at kinase activity associated with the cyclin B- 
cdkl complex after drug treatment. Unfortunately results were difficult to interpret 
due to high background and uneven loading of beads on the gels. An alternative assay 
procedure was obtained in the form of an ELISA-based kit. The kit uses a synthetic 
biotinylated peptide modelled on the phosphorylation sequence surrounding the Y15 
phosphorylation site on cdkl. The peptide, when phosphorylated can be picked up by 
an antibody (which recognises the phosphorylated form of the peptide) coated on the 
ELISA strip. Streptavidin-labeled peroxidase is then used to detect any bound 
peptides. Substrate solution is added and the intensity of colour is measured at 
492nm.
This ELISA method was used to measure kinase activity in DLKP-SQ, DLKP-A250 
10p#7, DLKP-A2B and DLKP-A5F. Results are illustrated in figure 3.7.1. The 
DLKP-SQ cells seem to experience a slight decrease in cdkl kinase activity following 
doxorubicin treatment. This observation supports the finding in section 3.6 that cdkl 
becomes phosphorylated in DLKP-SQ cells after doxorubicin treatment, coinciding 
with the G2 arrest seen in section 3.2. The resistant variants, however follow a trend 
of elevated cdkl kinase activity following doxorubicin treatment, and this kinase 
activity rises with increasing time after doxorubicin treatment. This result indicates 
that a higher kinase activity in the resistant variants is responsible for their ability to 
overcome the G2/M arrest seen in sensitive cells. The results are not statistically 
significant but numerous repeat experiments produced similar trends of unaltered or 
decreased cdkl kinase activity following drug treatment in DLKP-SQ, with an 
increase in cdkl kinase activity in resistant variants following drug treatment.
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Figure 3.7.1 Cdkl kinase assay. Four DLKP cell lines were analysed 
at 18, 24 and 48 hours following doxorubicin treatment. Controls were 
also analysed at 18, 24 and 48 hours.Cell lines are arranged from 
from left to right, from sensitive to most resistant.
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Section 3.8 Analysis of cdc25B and cdc25C in cell lines after drug treatment
Cdc25B and cdc25C are members of the cdc25 phosphatase family, and as described 
in section 1.4.7 are critically involved in activation of cyclin B-cdkl and entry to 
mitosis. The level of expression of cdc25B and cdc25C represents an important 
control point in the activation of cdkl kinase. Any overexpression of cdc25C could 
lead to unscheduled activation of cdkl and a push past the G2 arrest, ultimately 
leading to unrestrained cell division and proliferation. Indeed cdc25C overexpression 
occurs in many human cancers and has been implicated as a potential oncogene 
(Galaktionov et al., 1995).
Levels of cdc25B and cdc25C were investigated in DLKP-SQ, DLKP-A250 10p#7, 
DLKP-A2B and DLKP-A5F before and after doxorubicin treatment to determine 
whether or not the G2/M override seen in the resistant variants was associated with 
an altered expression of cdc25B or cdc25C. Figure 3.8.1 and 3.8.2 show levels of 
cdc25B protein expression in the cells prior to and following drug treatment. Cdc25B 
protein expression does not vary after doxorubicin treatment in DLKP-SQ when 
compared to controls, as illustrated in figure 3.8.1. Equal protein loading was 
monitored by reversible staining with ponceau. Cdc25B was also investigated in the 
resistant variants before and after doxorubicin treatment. Results in figure 3.8.2, 
when protein loading is taken into account, indicate that cdc25B expression is not 
altered in resistant variants compared to the sensitive cell line, nor is its expression 
affected by doxorubicin treatment.
Cdc25C was also investigated in the resistant variants, and similar results were found. 
In figure 3.8.4 it can be seen that there are equal levels of cdc25C in resistant and 
sensitive DLKP cell lines, and expression is not altered by doxorubicin treatment. 
From figure 3.8.3 it seems as if there are higher levels of cdc25C expression in 
DLKP-SQ cells at T24, T36 and T45 but this is due to slightly higher protein loaded 
in these wells.
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The activity of cdc25C increases through phosphorylation, and the phosphorylation 
can be experimentally detected by altered mobility in SDS-page, Samples were 
immunoprecipitated using anti-cdc25C before and after doxorubicin treatment, and 
then run on 15% SDS-polyacrylamide gels. Results for DLKP-SQ are displayed in 
figure 3.8.5, DLKP-A250 10p#7 in figure 3.8.6, DLKP-A2B in figure 3.8.7 and 
DLKP-A5F in figure 3.8.8. Inactive hypophosphorylated cdc25C migrates at 55kDa, 
and when activated (hyperphosphorylated) it migrates at 66kDa. However the 55kDa 
and 66kDa bands can be seen in all the samples, with no difference in the level of 
expression of either band following drug treatment. This questions the role of cdc25C 
in the G2/M override in the resistant cells. Possible reasons explaining this result are 
discussed in section 4.8.
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Figure 3.8.1 Effect of doxorubicin on cdc25B expression in DLKP-SQ (C refers 
to controls, T refers to drug-treated samples).
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Figure 3.8.2 Effect of doxorubicin on cdc25B expression in DLKP cell lines (C 
refers to controls, T refers to drug-treated samples).
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CO T12 T18 T24 T36 T45 Neg
Figure 3.8.3 Effect of doxorubicin on cdc25C expression in DLKP-SQ (C refers 
to controls, T refers to drug-treated samples).
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Figure 3.8.4 Effect of doxorubicin on cdc25C expression in DLKP cell lines (C 
refers to controls, T refers to drug-treated samples).
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62 kDa -  
47 kDa -
C24 C48 T24 T48
Figure 3.8.5 Immunoprécipitation of cdc25C in DLKP-SQ cells before and 
after doxorubicin treatment. C24 and C48 refer to untreated controls, T24 and 
T48 refers to drug-treated cells.
C24 C48 T24 T48
62 kDa -
47 kDa-
Figure 3.8.6 Immunoprécipitation of cdc25C in DLKP-A250 10p#7 cells 
before and after doxorubicin treatment. C24 and C48 refer to untreated 
controls, T24 and T48 refer to drug-treated cells.
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C24 C48 T24 T48
62 kDa -
47 kDa -
Figure 3.8.7 Immunoprécipitation of cdc25C in DLKP-A2B cells before and 
after doxorubicin treatment. C24 and C48 refer to untreated controls, T24 and 
T48 refer to drug-treated cells.
SQ #7 A2B A5F
47 kDa -
Figure 3.8.8 Immunoprécipitation of cdc25C in DLKP-A5F cells before and 
after doxorubicin treatment. C24 and C48 refer to untreated controls, T24 and 
T48 refer to drug-treated cells.
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3.9 Investigation of w eel levels and activation in DLKP cell lines
Weel is responsible for the inhibitory phosphorylation of cdkl, and therefore can 
co-ordinate onset of mitosis by inactivating cyclin B-cdkl complex activity until 
required conditions for mitosis are present. In section 3.6, it appears that DLKP-SQ 
have higher Y15 phosphorylation levels compared to resistant variants after 
doxorubicin treatment. It was observed in section 3.7 that DLKP-SQ experience a 
slight decrease in cdkl kinase activity, when compared to the response of resistant 
variants following drug treatment. It is necessary to investigate the involvement of 
weel in the G2 arrest of DLKP-SQ, in the override experienced by the resistant 
variants and to determine if weel is responsible for the higher Y15 phosphorylation 
levels seen in DLKP-SQ. If weel is responsible, then it is plausible to suggest that 
perhaps weel activity is lower in resistant variants, thus allowing them to progress 
through mitosis.
Weel protein expression in the four cell lines was investigated to see if weel 
downregulation was associated with the G2/M override seen in resistant variants. 
Results in figure 3.9.1 demonstrate that weel is expressed to a similar extent in 
resistant and sensitive DLKP cells, suggesting that weel expression is not linked to 
the G2/M override.
The activity of weel before and after doxorubicin treatment in each of the four cell 
lines was investigated by immunoprécipitation with an anti-weel antibody, running 
samples on SDS-polyacrylamide gels and probing with anti-wee 1, as described in 
section 2.6.7. Weel runs at approximately 94 kDa, and when inactived by 
phosphorylation it should run slightly higher («5kDa) on the gel. Results are shown 
in figure 3.9.2 for DLKP-SQ, 3.9.3 for DLKP-A250 10p#7, figure 3.9.4 for DLKP- 
A2B and figure 3.9.5 for DLKP-A5F. It can be seen from these results that active 
weel runs at approx. 94 kDa. In DLKP-SQ the upper band is reduced in the drug 
treated samples, particularly by 48 hours after drug treatment. This suggests that the 
level of inactive weel in these cells is lower, which would tie in well with a G2 
arrest. The higher levels of weel would be required to prevent cdkl kinase activity. 
The weel levels in the resistant variants do not vary and therefore must be activated
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to an equal extent in all three resistant cell lines, before and after doxorubicin 
treatment, perhaps suggesting that the unaltered weel is responsible for the unaltered 
Y15 phosphorylation levels seen in cdkl. The problems associated with using 
asynchronous cells, and difficulties with detection of changes in weel 
phosphorylation are discussed in section 4.9.
Figure 3.9.1 Levels of w eel protein in the four DLKP cell lines. There was 
slightly less protein loaded in DLKP-SQ and DLKP-A2B.
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C24 C48 C70 T24 T48 C70
170 kDa -
83 kDa-
Inactive phosphorylated
■ 94 kDa active 
unphosphorylatd
Figure 3.9.2. Immunoprécipitation of w eel protein in DLKP-SQ before and 
after doxorubicin treatment. Two arrows indicate two forms of w eel, upper 
band represents hyperphosphorylated inactive w eel, lower band represents 
active w eel.
83 kDa-
-Inactive phosphorylated
-94 kDa active 
unphosphorylated
Figure 3.9.3. Immunoprécipitation of w eel protein in DLKP-A250 10p#7 before 
and after doxorubicin treatment. Two arrows indicate two forms of w eel, 
upper band represents hyperphosphorylated inactive wee, lower band 
represents active weel.
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C48 C70 T24 T48 T70
83 kDa—
^  Inactive phosphorylated
M  94 kDa active 
unphosphorylated
Figure 3.9.4. Immunoprecipitation of w eel protein in DLKP-A2B before and 
after doxorubicin treatment. Two arrows indicate two forms of w eel, upper 
band represents hyperphosphorylated inactive wee, lower band represents 
active w eel.
C24 C48 C70 T24 T48 T70
I—  94 kDa active 
unphosphorylated
Figure 3.9.5. Immunoprecipitation of w eel protein in DLKP-A5F before and 
after doxorubicin treatment. Arrow indicates active form of w eel.
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Section 3.10 MDR characteristics of DLKP cell lines
3.10.1 P-glycoprotein status in DLKP cell lines
Expression of P-glycoprotein (Pgp) in cells is closely associated with the 
development of multiple drug resistance (MDR). Cells that overexpress Pgp 
frequently exhibit the MDR phenotype, becoming resistant to a wide variety of 
structurally unrelated and mechanistically distinct chemotherapy drugs.
The resistant DLKP cell lines were originally selected for resistance by a pulse 
(DLKP-A250 10p#7) or a continuous (DLKP-A2B, DLKP-A5F) stepwise increase in 
exposure to doxorubicin. Extensive characterisation has revealed MDR 
characteristics in these cell lines, including overexpression of Pgp (Heenan et al., 
1998). To confirm that these cells are stable in their MDR status, the Pgp levels were 
compared using western blotting with C219-antibody specific for Pgp, although it 
may also cross-react with c-erbB2 at around 170kDa. Results are shown in figure 
3.10.1. DLKP-SQ cells do not express detectable levels of Pgp because these are a 
sensitive clonal population isolated from the sensitive parental population (McBride 
et al., 1997). DLKP-A250 10p#7 express low levels of Pgp; and DLKP-A2B and 
DLKP-A5F express higher levels of Pgp. The DLKP-A2B and DLKP-A5F display 
much higher resistance levels than the DLKP-A250 10p#7, and this is mainly 
conferred through their higher Pgp expression. However, DLKP-A5F are 100-fold 
more resistant than DLKP-A2B, yet both express a comparable level of Pgp 
expression, so there must be alternative resistance mechanisms in the DLKP-A5F cell 
line to account for the increased resistance without an accompanied increase in Pgp 
expression.
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SQ #7 A2B A5F
175 kDa- » » » PgP
Figure 3.10.1 Western blotting showing P-glycoprotein levels in DLKP cell 
lines
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3.10.2 Doxorubicin toxicity profile on the DLKP cell lines
Doxorubicin was the original selecting drug used in generating the DLKP resistant 
variants. Resistant cells were developed by exposing the cells to a continuous 
increasing drug concentration until a resistant population emerged with the ability to 
proliferate in the presence of high drug concentrations. DLKP-A2B and DLKP-A5F 
are clonal populations isolated from the original resistant population DLKP-A, which 
was developed by exposing DLKP to continuous increasing concentrations of 
doxorubicin (Heenan et al., 1998). DLKP-A250 10p#7 is a clonal population derived 
from DLKP-A250 lOp, as described in materials and methods. DLKP-A250 lOp are 
a cell line exhibiting a low level of resistance which was developed by pulsing the 
clonal DLKP-SQ cell line 10 times (lOp) with 250ng/ml doxorubicin (A250) for four 
hours (NicAmhlaoibh, 1997). The relative resistance of each of these cell lines to 
each other in the experimental setting used in this thesis (25 cm2 flasks, 2 hour drug 
pulse and viability determined after 72 hours) was examined, and representative data 
are in figure 3.10.2. It was concluded from numerous toxicity assays that DLKP-A5F 
is approximately 300-fold resistant, DLKP-A2B is 30-fold resistant and DLKP-A250 
10p#7 are 2-3-fold resistant to DLKP-SQ cells. These are at slight variance with 
previous results of 300-fold, 30-fold and 10-fold respectively to DLKP, but these 
values represent resistance in 96-well plates after 6 days with continuous drug 
exposure, compared to 25cm2 flasks, 2 hour drug incubation and 72 hour viability 
estimates being used in this study. Therefore the discrepancies in results can be 
attributed to different experimental conditions such as cell density, drug exposure 
times and length of time before viability was determined. Toxicity was assessed after 
72 hours because this was the period of time over which the effects of doxorubicin on 
the cell cycle were monitored. Apoptosis was also monitored over this period of time, 
and approximately 50% of the cells died over 72 hours.
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Toxicity profile o f Doxorubicin on 
DLKP-SQ
Cone (|ig/ml)
Toxicity profile o f Doxorubicin on 
DLKP-A2B
Cone (|ig/ml)
Toxicity profile o f Doxorubicin on 
DLKP-A5F
Cone (|ig/ml)
Figure 3.10.2 Toxicity profiles of DLKP cell lines. Cells were treated for
2 hours with doxorubicin, after which time drug was removed and 
flasks refed. Viability was determined after 72 hours using crystal 
violet toxicity assay.
Toxicity profile of Doxorubicin on 
DLKP-SQ/A25010p #7
1 2 3
Cone (M9/ml)
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3.10.3 Drug Accumulation Analysis in drug resistant cell lines
The principal function of Pgp in MDR is to act as an energy-dependent efflux pump 
which effectively removes drug from the cell, resulting in a lower concentration of 
drug in the nuclei of resistant cells. One advantage of using doxorubicin is its innate 
fluorescence characteristics, it fluoresces under UV light and its cellular location can 
easily be determined.
DLKP cells were analysed for doxorubicin accumulation by preparing cytospins, 72 
hours after doxorubicin treatment, as described in materials and methods. Cytospins 
were examined under FITC filter. TUNEL staining was also carried out on the 
samples as an indicator of apoptosis, and is described in section 3.12.2.
Some representative photographs are illustrated in figure 3.10.3. The doxorubicin is 
identified as the yellow-brown staining in the cytoplasms of cells. The nucleus 
remains as a dark sphere in the resistant variants, with no yellow staining indicating 
that no drug has entered the nucleus. However, in a subpopulation of the cells, 
doxorubicin has entered the nucleus and apoptosis has occurred. This situation can be 
seen in the cells with intense yellow staining in their nuclei, their nuclear material has 
condensed, characteristic of cells undergoing apoptosis. The intense yellow staining is 
TUNEL stained cells which stains the fragmented DNA in the nucleus of apoptotic 
cells. DLKP-A250 10p#7 in particular contain a very good example of this, one cell 
that has undergone apoptosis as seen by the intense yellow staining of the fragmented 
DNA in the apoptotic bodies.
These results support the concept of an important role for Pgp in the resistant 
variants, and its ability to prevent doxorubicin from remaining in the nucleus. The 
drug concentrations chosen, however induce approximately 50% apoptosis in the 
cells over 72 hours, so the drug concentration used is sufficient to overcome the 
efflux activity of Pgp and induce apoptosis, as evidenced by toxicity assays and 
presence of apoptotic cells in the photographs.
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Figure 3.10.3 Accumulation of 2hour doxorubicin in DLKP cells 72 hours after 
treatment; DLKP-SQ (a), DLKP-A250 10p#7 (b), DLKP-A2B (c) and DLKP- 
A5F (d). Apoptotic cells (stained with TUNEL) are indicated with a white 
arrow.
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3.10.4 Non-Pgp-mediated apoptosis in DLKP cell lines
5-Fluorouracil is an antimetabolite frequently used in chemotherapy. One of the 
advantages of 5-FU use in this study is that it is not a substrate of Pgp, and so cannot 
be efiluxed from cells as efficiently as doxorubicin. The toxicity of 5-FU on DLKP 
cell lines was investigated and results are in figure 3.10.4. The cell lines are equally 
sensitive to induction of apoptosis by 5-FU, and this is in agreement with previously 
published reports (NicAmhlaoibh et al., 1999; Heenan el al., 1998 ).
Another apoptotic stimulus used was serum starvation. Serum starvation-induced 
apoptosis represents a pathway not involving DNA damage, but rather damage 
inflicted through absence of growth factors and mitogens. Cells were treated as 
described in section 2.4.1. Results in figure 3.10.5 indicate that the resistant variants 
are more resistant to serum-starvation thanDLKP-SQ, albeit only 1.3-1.5 fold.
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Figure 3.10.4 The effect of 5-Fluorouracil on the four DLKP cell lines. Viability 
was determined after 72 hours using end point acid phosphatase 
toxicity assay.
Serum Starvation 72 hours
90 r 
80 
70
HDLKP-SQ 
ED DLKP-A250 10p#7 
HDLKP-A2B 
E3 DLKP-A5F
Figure 3.10.5 The susceptibility of DLKP cell lines to cell death induced 
by serum starvation for 72 hours.
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Section 3.11 Kinetics of cell death in DLKP cell lines
Time-lapse videomicroscopy was carried out to monitor the cell death kinetics of the 
DLKP variants following doxorubicin treatment. Cells were recorded over 70 hours. 
Cell death events were identified when the classic apoptotic morphology appeared; 
cell rounding up, membrane blebbing, chromatin condensation and break up into 
apoptotic bodies. These events usually occurred very rapidly so that it was difficult to 
distinguish different timing of one event from the next. The time when cells rounded 
up, as seen by the emergence of a “phase- halo” when viewed using a phase contrast 
microscope was noted as the time of death for that particular cell. 100 cells were 
followed in the field for the duration of the experiment. An example of such a field is 
shown in figure 3.11.1, in which cells are monitored over 72 hours and time of 
apoptotic onset noted; examples of apoptotic cells are marked with arrows.
The extent of apoptosis is dependent on the drug concentration used, and also the 
time of exposure of drug to the cells. When DLKP-SQ are treated with varying drug 
concentrations, the percentage and rate of apoptosis also varies. If DLKP-SQ cells 
are treated with 5(ag/ml Doxorubicin continuous exposure there is a rapid induction 
of apoptosis with 50% of the cells dead by 5 hours and by 30 hours only 10% of the 
population remain. At a lower concentration of doxorubicin the rate of apoptosis is 
slower with 0% dead at 5 hours, 10% dead at 30 hours and 50% viable cells 
remaining at 72 hours. These results are shown in figure 3.11.2. From these graphs it 
can be seen that there are no mitotic events in the cell population.
The resistant variants DLKP-A250 10p#7, DLKP A2B and DLKP-A5F also undergo 
apoptosis when treated with Doxorubicin. Equitoxic drug concentrations were used 
on the cell lines, a 2 hour Doxorubicin dose which gave approximately 50 % kill after 
3 days was used. The growth curves used can be seen in figures 3.10.2. The rates of 
apoptosis differ between the cell lines however.
DLKP-A250 10p#7 cells have a similar rate of apoptosis to DLKP-SQ after 2 hours 
treatment with 2 fig/ml Doxorubicin (see figure 3.11.3) when compared to DLKP-SQ
apoptosis rate after 0.6 jig/ml 2 hour pulse. A very small percentage of cells have
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died by 5 hours, and by 30 hours 10 % cell death has occurred. The apoptosis rate 
increases after the initial lag and by 72 hours 48 % of the cells are dead.
DLKP-A2B calls have a high initial rate of apoptosis, in the first five hours following 
treatment up to 25 % of the cells undergo apoptosis, the rate slows at 12 hours when 
60 % of the cells have died, and by 72 hours 42 % of the original field remain. This is 
illustrated in figure 3.11.4. It can also be seen from this kinetic curve that there is 
mitosis occurring after Doxorubicin treatment (this interesting phenomenon is 
discussed in section 3 .4) and the majority of cells that divide lose at least one of their 
daughter cells by apoptosis. Quite a high level of mitotic events occur in which the 
parent cell divides into more than two daughter cells. Up to five daughter cells 
formed from a parent cell at one instant but all five died within an hour of mitosis.
When DLKP-A5F are treated with 100 i^g/ml Doxorubicin less than 50 % kill is seen 
over three days. Yet when time-lapse is used to analyse cell kinetics it can be seen 
from figure 3.11.5 that 70 % apoptosis occurs in 80 hours. There is a high rate of 
mitosis seen also and this compensates for the loss in number due to apoptosis. There 
were some incidences of post- mitotic apoptosis observed in DLKP-A5F cells, similar 
to DLKP-A2B cells.
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Figure 3.11.1 Timelapse videomicroscopy analysis of apoptosis in DLKP-SQ over 72 hours 
following 0.6 pg/ml 2 hour Doxorubicin treatment. Examples of individual cells undergoing 
apoptosis are marked with arrows.
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Figure 3.11.2 Timelapse videomicroscopical analysis of 
0.6pg/ml doxorubicin 2-hour pulse on DLKP-SQ
Figure 3.11.3 Timelapse videomicroscopical analysis of 2pg/ml doxorubicin 
2 hour pulse on DLKP-A250 10p#7
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Figure 3.11.4 Timelapse videomicroscopical analysis of 30 pg/ml Doxorubicin 
2 hour pulse treatment on DLKP-A2B
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Figure 3.11.5 Timelapse videomicroscopical analysis of 100pg/ml Doxorubicin 
2 hour pulse treatment on DLKP-A5F
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3.12 Morphological features of apoptosis in DLKP-SQ cells
A number of morphological features specific to apoptotic cells were looked at in 
DLKP-SQ cells in an attempt to give a comprehensive study of the apoptotic process 
in DLKP cells. Based on the many morphological and biochemical features in 
apoptotic cells, there are a variety of techniques that can be utilised to identify cells 
undergoing apoptosis. Timelapse videomicroscopy was routinely used to confirm that 
cell death was occurring via apoptosis by identifying the cells with characteristic 
apoptotic morphology. The morphological features chosen were DNA fragmentation 
which is assayed using DNA gel electrophoresis, and also TUNEL analysis. The 
biochemical feature chosen was the externalisation of the membrane phospholipid 
phosphatidyl serine, using annexin V as an indicator.
3.12.1 DNA fragmentation analysis in Doxorubicin-treated DLKP-SQ cells
One of the main cellular events in apoptosis involves the condensation of chromatin 
as discussed in section 1. Endonucleolytic activity is responsible for cleavage of the 
DNA first into large fragments (50 - 300 kb) and then into smaller fragments of 180 
bp, or mutiples of 180 bp. It is thought that this 180 bp corresponds to the size of 
linker DNA between two nucleosomes. The 180bp multiples are visible on an agarose 
gel as “ladders”. DLKP-SQ cells were set up as described in materials and methods. 
A typical DNA gel can be seen in figure 3.12.1. No DNA laddering occurs in the 
untreated DLKP-SQ control wells (no DNA fragmentation). DLKP-SQ cells treated 
with varying concentrations of daunorubicin underwent apoptosis and the distinctive 
ladders were seen.
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Figure 3.12.1 DNA fragmentation analysis in DLKP-SQ after Daunorubicin 
treatment. Lanes were loaded as follows; Lane 1: Mr markers. Lane 3 and 4: 
controls (untreated). Lane 5: lOpg/ml. Lane 6: 5jig/ml. Lane 7: 1 fig/ml.
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3.12.2 TUNEL analysis
DNA fragmentation can also be detected by staining the 3’-end of the fragments in 
apoptotic cells. TUNEL staining involves the incorporation of dUTP to the 3’-end of 
the “nicked” or fragmented DNA formed during apoptosis. It is a sensitive technique 
that allows visual semi-quantitive detection of apoptotic cells. DLKP cells were set 
up as described in materials and methods, and treated with equitoxic doxorubicin 
doses for 2 hours. Samples were taken at 24, 48 and 72 hours after drug treatment 
and cytospins were prepared as described in materials and methods. Analysis was 
carried out as in materials and methods, and representative photographs for each cell 
line can be seen in figures 3.12.2.1, 3.12.2.2, 2.12.2.3 and 2.12.2.4. Each photograph 
represents a random field of 50-100 cells. It is difficult however to see the 
background unstained cells in some photographs. Photographs were also taken of 
untreated control cells, and no TUNEL staining was visible in these (not shown)
TUNEL staining confirmed that all cells died by apoptosis at the doxorubicin 
concentrations used, and there was negligible background apoptosis in untreated 
controls. The TUNEL staining shows the classical condensation of the nucleus and its 
fragmentation. The earlier onset of apoptosis seen by timelapse analysis is also seen 
by TUNEL staining, a higher level of apoptotic cells are present at earlier times in 
figure 3.12.3 than in the other cell lines.
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Figure 3.12.2.1 TUNEL analysis of DLKP-SQ cells (a) 24, (b) 48 and (c) 72 
hours after doxorubicin treatment.
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Figure 3.12.2.2 TUNEL analysis of DLKP-A250 10p#7 cells (a) 24, (b) 48 and
(c) 72 hours after doxorubicin treatment.
166
3.12.3 Phosphatidylserine exposure on DLKP-SQ induced by Doxorubicin 
treatment
Phosphatidylserine in a membrane phospholipid that is transiently exported to the 
outer plasma membrane during the early stages of apoptosis (Fadok et al. 1992) and 
this can be monitored using annexin-V-FITC (fluorescein isothiocyanate) which is a 
Ca2+-dependent phospholipid-binding protein that has high affinity for phosphatidyl 
serine (van Engeland et al. 1996). DLKP-SQ cells were treated with Doxorubicin for 
2 hours and monitored for annexin V binding, which is indicative of 
phosphatidylserine externalisation. Untreated controls exhibited no annexin V binding 
when looked at under FITC filter as seen in figure 3.12.3.1. Doxorubicin-treated cells 
however were positive for annexin V staining as seen in figure 3.12.3.2. This is 
indicated by the intense green staining on the membranes of DLKP-SQ cells about to 
undergo apoptosis. A low background fluorescence can be seen in the Doxorubicin- 
treated cells and this is due to the fluorescence of Doxorubicin under FITC filter.
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(2)
Figure 3.12.3.1 Untreated DLKP-SQ cells stained with annexin V looked at 
under (1) FITC filter and (2) white light
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(1)
Figure 3.12.3.2 DLKP-SQ cells treated with 0 .6  jig/ml Daunorubicin for two 
hours and labeled with annexin V. Cells were viewed using (1) FITC filter and 
(2) white light.
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3.13 Investigation of Caspase involvement in DLKP apoptosis
Caspases constitute one of the key components in the apoptotic pathway, and their 
role in apoptosis is discussed in section 1. It is currently proposed that caspases 
function as part of a cascade and redundancy may exist between a certain subset of 
the fourteen currently known caspases. Extensive research has been carried out to 
study the involvement of the various caspases in apoptosis in numerous cell lines. It 
was therefore decided to investigate which caspases were involved in apoptosis in 
DLKP cell lines. One other important reason to look at caspase activation in the 
DLKP cell lines stems from recently published reports in which resistant cell lines 
have defective caspase activation (Los et al., 1997, Kojima et al., 1998). This raises 
the possibility that there may be reduced or altered caspase levels, activation or 
activity in the DLKP resistant variants during apoptosis and this could in part 
contribute to the resistant state.
3.13.1 Investigation of caspase-2 involvement in DLKP apoptosis
Caspase-2 levels were investigated using an antibody that recognises the proform of 
caspase-2 at approx. 48 kDa (Transduction Labs.). Human endothelial cell lysate 
was used a positive control. Cells were set up as already described and 10 ug protein 
was loaded on each lane and blots were stained with the reversible protein stain Ponceau 
to confirm equal loading in each case. Figure 3.13.1.1 illustrate procaspase-2 levels in 
DLKP-SQ cells before and after a 0.6 ng/ml doxorubicin exposure for 2 hours. Clearly 
there is no reduction in the levels of pro-caspase-2 after drug treatment. This seems to 
indicate that caspase-2 does not play a role in DLKP-SQ apoptosis.
Caspase-2 protein levels in the resistant variants were then compared to DLKP-SQ 
levels. Results are shown in figure 3.13.1.2. Interestingly, very low levels of caspase-2 
were detected in control and drug treated DLKP-A250 10p#7, DLKPA2B and DLKP- 
A5F. 10 ug protein was loaded on each lane and blots were stained with the reversible 
protein stain Ponceau to confirm equal loading in each case. From the blot it can be seen
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that there are high levels of caspase-2 in DLKP-SQ, low levels in DLKP-A250 lOp #7, 
no detectable levels in DLKP-A2B and very low levels in DLKP-A5F.
CO C50 TO T4 T10 T24 T50 Pos Neg
47.5 kDa -
32.5 kDa --
Figure 3.13.1.1 Western blots showing caspase-2 levels in DLKP-SQ before and 
after doxorubicin treatment
D LKP -SQ  DLKP-A250-10P #7 D LKP -A2B  DLKP-A5F
-I' -!•
CO T45 CO T45 CO T45 CO T45 Pos
45 kDa -
32 kDa -
Figure 3.13.1.2 Caspase-2 Levels before and after drug treatment in the four 
cell lines. CO refers to untreated cell extracts and T45 refers to drug treated 
cells 45 hrs after treatment
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3.13.2 Investigation of caspase-3 involvement in DLKP apoptosis
Caspase-3 levels were looked at initially in untreated and doxorubicin treated cells 
using an antibody which recognises pro-caspase-3 at 32kDa. The positive control 
used was a Jurkat cell lysate (Transduction labs.) lOug protein was loaded on each lane 
and blots were stained with the reversible protein stain Ponceau to confirm equal loading 
in each case. Results are shown in figure 3.13.2.1, and it can be seen that there is no 
decrease in levels of pro-caspase-3 in apoptotic DLKP-SQ cells. It was shown in section 
3.9 and 3.10 that the cells under apoptosis over this timescale, so it appears that pro- 
caspase-3 is not proteolytically cleaved to form active pl7 and pl2 subunits in the 
apoptotic process of these cells.
Figure 3.13.2.2 compares levels of pro-caspase-3 in untreated and drug treated samples 
from each of the DLKP cell lines. There seems to be an increase in the T45 drug-treated 
DLKP-SQ sample compared to CO sample, but using ponceau staining it was obvious that 
the DLKP-SQ T45 lane had higher protein levels than all the other lanes which were 
equally loaded. There were low levels of pro-caspase-3 in DLKP-A250 lOp #7 similar to 
the situation for caspase-2. Caspase-3 could not be detected in either DLKP-A2B or 
DLKP-A5F extracts, yet protein bands of equal intensity were seen on the membrane 
when stained with ponceau. Perhaps the caspase-3 protein levels in these cell lines are too 
low to be detected using the ECL detection system.
Caspase-3 levels after doxorubicin treatment in DLKP-A250 10p#7 cells were also 
investigated over time points as shown in figure 3.13.2.3. The protein loading was 
approximately equal in this blot except for the lane labelled T4. As can be seen from this 
result there is no significant decrease in pro-caspase-3 levels after 50 hours in doxorubicin 
treated cells.
From these results it may be speculated that neither caspase-2 or caspase-3 play a role in 
doxorubicin-mediated apoptosis in the DLKP cell lines. The possibility that caspase-3 
would not have an involvement in doxorubicin-mediated apoptosis is surprising because it 
is the most widely studied caspase to date and is implicated in apoptosis in the majority of 
cell lines and in vitro models studied.
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CO C50 TO T4 TIO T24 T50 Pos
Figure 3.13.2.1 Western blots showing procaspase-3 levels in DLKP-SQ before 
and after doxorubicin treatment
D LKP -SQ  DLKP-A250-10P #7 D LKP -A2B  DLKP-A5F
•I1 ■I' >1’
CO T45 CO T45 CO T45 CO T45 Pos
45 kDa -
32 kDa — —  — * * "  * *
Figure 3.13.2.2 Procaspase-3 Levels before and after drug treatment in the 
four cell lines. CO refers to untreated cell extracts and T45 refers to drug 
treated cells 45 hrs after treatment
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45 kDa -
Figure 3.13.2.3 Western blots showing Caspase-3 levels in DLKP-A250 lOp #7 
before and after doxorubicin treatment
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3.13.3 Caspase-7 involvement in apoptosis
Caspase-7 is a group-II caspase, has similar substrate preference to caspase-3 and is 
involved in apoptosis in various cell lines induced by diverse stimuli. It is a 45kDa 
protein which is cleaved into 17 kDa and 28 kDa fragments during apoptosis.
Procaspase-7 protein levels were looked at in the four DLKP cell lines, before and 
after doxorubicin treatment to investigate its role in doxorubicin-induced apoptosis. 
Looking at treated cells (CO) in figure 3.13.3.1, it can be seen that when protein 
loading is taken into account, there are approximately equal levels of procaspase-7 in 
all four cell lines. It seems as if there is a lower level of procaspase-7 in DLKP- 
A25010p#7 and DLKP-A5F but ponceau staining confirmed that this is due to 
slightly less protein in these lanes, and repeat westerns confirmed that there are equal 
levels of procaspase-7 in the four cell lines.
In figure 3.13.3.1, the effect of doxorubicin on procaspase-7 can be seen. There is no 
reduction in procaspase after doxorubicin treatment in any of the cell lines, the p45 
intact caspase remains at comparable levels to the untreated controls. Furthermore 
there was no detection of pi 7 fragments in the drug-treated samples, indicating that 
procaspase-7 is not activated in doxorubicin-induced apoptosis in any of the DLKP 
cell lines.
D LKP-SQ
I
DLKP-A250-1 OP #7
I
DLKP-A2B
4
DLKP-A5F
I
CO T45 CO T45 CO T45 CO T45
Figure 3.13.3.1 Western blots showing caspase-7 levels in DLKP-SQ before and 
after doxorubicin treatment
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3.13.4 Investigation of procaspase-6 in DLKP apoptosis
Procaspase-6 protein levels before and after drug treatment are shown in figure
3.13.4.1. Procaspase-6 is a 40 kDa protein and the antibody used should pick up both 
procaspase and the active 24 kDa active fragment. Caspase-6 is the caspase 
responsible for lamin cleavage during apoptosis, and is a downstream caspase which 
can be activated by caspase-3 (Orth et al., 1996).
There are relatively equal amounts of procaspase-6 in the four DLKP cell lines, 
however levels in DLKP-A250 10p#7 CO seem to be higher on this blot due to 
unequal protein loading, also DLKP-A2B CO is less than T45 due to decreased 
protein loading, when ponceau staining is taken into account. After doxorubicin 
treatment there is no decrease in the procaspase-6, and active p24 fragments could 
not be detected using Western blotting (this part of the gel not shown). These results 
suggest that caspase-6 does not play a role in doxorubicin-induced apoptosis in 
DLKP cells lines.
D LK P -SQ  DLKP-A250-10P #7
CO T45 CO T45
warn
DLKP-A2B
4
45 kDa —
32 kDa —
DLKP-A5F
4
CO T45 CO T45
Figure 3.13.4.1 Western blots showing procaspase-6 levels in DLKP cell lines 
before and after doxorubicin treatment
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3.13.5 Investigation of caspase-8 involvement in DLKP apoptosis
Caspase-8 plays an important role in the CD95-mediated apoptotic pathway, being 
the first caspase to be activated. It had a unique DED domain, absent in other 
caspases (but also in caspase-10) which allows it to bind directly to FADD, the 
double adaptor protein, linking it to the CD95 receptor. Given the wealth of evidence 
existing for doxorubicin-induced activation of the CD95 pathway, the levels and 
timely activation of procaspase-8 represent critical factors in maintaining an intact 
CD95 signalling pathway.
Levels of procaspase-8 in sensitive and resistant cell lines is investigated in figure
3.13.5.1. There is equal protein loading on this blot, except for DLKP-SQ T45 lane 
which has higher protein loaded. There is a definite, though small decrease in 
procaspase-8 expression in the resistant variants, particularly in DLKP-A5F. This 
result may have important implications in the ability of these cells to resist apoptotic 
induction, at doxorubicin concentrations which effectively induce apoptosis in the 
three other cell lines. Looking at doxorubicin treated cells in figure 3.13.5.1 there 
was no decrease in procaspase-8 levels, and also absence of caspase-8 activation, 
judged by the absence of caspase fragments. This result questions the involvement of 
caspase-8 activation in the doxorubicin-induced apoptosis in DLKP cell lines.
D LKP -SQ  DLKP-A250-10P #7 D LKP-A2B  DLKP-A5F
4 4 4 4
CO T45 CO T45 CO T45 CO T45
45 kDa —
32 kDa -
Figure 3.13.5 Western blots showing procaspase-8 levels in DLKP cell lines 
before and after doxorubicin treatment
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3.13.6 Investigation of caspase-4 in DLKP apoptosis
Caspase-4 was investigated also, it has been shown on a number of occasions to be 
activated and involved in apoptosis induced by such stimuli as CD95 (Kamada et a l ,  
1997). However results in figure 3.13.6 demonstrate that procaspase-4 is not 
activated in either of the DLKP cells lines during doxorubicin-induced apoptosis. 
The antibody used picks up the intact procaspase-4 at 43 kDa, and no reduction of 
this band was seen in the apoptotic samples.
Figure 3.13.6 Western blots showing procaspase-4 levels in DLKP cell lines 
before and after doxorubicin treatment
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3.13.7 Involvement of caspase-9 in DLKP apoptosis
Caspase-9 is a critical factor at the apex of the apoptotic pathway involving 
cytochrome c release and apaf-1. It is activated through autocatalysis when it binds 
to apaf-1, cytochrome c and dATP during initiation of apoptosis. Caspase-9, when 
active, has been shown to activate all the other known caspases (Harte et al., 1999), 
and so has a key role to play in transducing the death signal to the downstream 
machinery to bring about destruction of the cell. Any reduction in or faulty caspase-9 
could lead to a defective induction of apoptosis. Figure 3.13.7 illustrates levels of 
procaspase-9 in the four DLKP cell lines. Clearly resistant variants do not have 
reduced procaspase-9, but the effect of doxorubicin treatment on the cells has not 
been looked at. Even though the sensitive and resistant variants express caspase-9 to 
an equal extent, it remains to be seen if the resistant variants have alterations in the 
activation of procaspase-9.
D LKP -SQ  A250-10P #7 A2B A5F DLKP -SQ  A250-10P#7 A2B  A5F
45kDa -
Figure 3.13.7 Western blots showing procaspase-9 levels in DLKP cell lines 
(untreated)
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3.14.1 STAT proteins
STAT proteins are critically involved in many signal transduction pathways, and 
some recent studies have linked caspase expression to STAT-1 protein expression 
(Kumar et al., 1997; King et ah, 1998). Levels of STAT protein expression were 
investigated in DLKKP-SQ, DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F using 
western blotting. Results in figure 3.14.1 indicate that there is equal expression in 
resistant and sensitive DLKP cell lines. The effect of doxorubicin on STAT-1 
expression was also investigated in figure 3.14.1. From the Western blot there is no 
difference in STAT-1 protein expression in doxorubicin-treated cells compared to 
the untreated controls.
D LKP -SQ  DLKP-A250-10P #1 DLKP-A2B  DLKP-A5F
4- 4 'I-
CO T45 CO T45 CO T45 CO T45
Figure 3.14.1 STAT-1 protein levels in DLKP cell lines, before and after 
doxorubicin treatment
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3.14.2 mRNA levels of procaspase-3
Results in section 3.13.2 indicate that procaspase-3 protein expression is much 
reduced in the DLKP resistant variants. Therefore it was necessary to also 
investigate the mRNA levels of procaspase-3 to establish if there was a 
corresponding decrease in procaspase-3 expression, which would suggest that the 
procaspase-3 is controlled in resistant cells at a transcriptional level. There is no 
decease in procaspase-3 in western blotting, perhaps the activation of procaspase-3 
could be masked by increased transcription of the protein in drug-treated cells; 
analysis of mRNA levels before and after drug treatment would clarify this 
possibility (this analysis will be carried out in the future).
RT-PCR was carried out to look at mRNA levels of procaspase-3 in the four 
untreated DLKP cell lines. The forward and reverse procaspase-3 primers used were 
5' AAC CAC CAA CCA ACC ATT TCT 3' and 5' AAG GTA TCC ATG GAG 
AAC ACT GAA AAC 3'. Interestingly results in figure 3.14.2 show equal 
expression on procaspase-3 in DLKP-SQ, DLKP-A250 10p#7, DLKP-A2B and 
DLKP-A5F. A posttranscriptional control must exist that prevents translation of the 
mRNA into the protein, or results in increased deregulation of mRNA or protein.
Figure 3.14.2 mRNA levels of procaspase-3 in DLKP-SQ (untreated)
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As described in section 1, there is extensive protein cleavage during apoptosis and 
many specific substrates of caspases have been identified which are preferentially 
cleaved by the different subfamilies of caspases. Poly-(ADP)-ribose polymerase is an 
abundant 116 kDa nuclear protein involved in DNA repair, which is activated by 
DNA breaks. Lazebnik et al. (1994) showed that PARP was cleaved during 
apoptosis into two signature fragments of 85 kDa and 27 kDa by an ICE-like 
protease which was subsequently identified as caspase-3. Caspase-7 and caspase-2 
may also be candidates for cleaving PARP.
DLKP-SQ cells were treated as previously described in materials and methods and 
Western blotting was carried out to look at PARP cleavage over time. It can be seen 
in figure 3.15.1 that the intact 116 kDa band does not decrease over time as the cells 
are undergoing apoptosis, even at T50 there is no reduction in 116 kDa intact PARP 
although it can be seen from time-lapse analysis that 40 % cells have undergone 
apoptosis at this stage. There is a band on the blot corresponding to « 85 kDa but 
this band is present in controls and does not increase as cells die, so perhaps it is an 
unspecific background band.
HL-60 cells were used as a control for PARP cleavage to validate the detection 
system, and to confirm that the absence of PARP cleavage is a DLKP-associated 
phenomenon, and not a result of the experimental techniques used for protein 
extraction and detection. It has previously been shown that PARP is cleaved from 
116kDa to 85kDa in apoptotic HL-60 cells (Lazebnik et al., 1994). In this 
experiment HL-60 cells were treated with (ig/ml doxorubicin and protein extracted 
after 0, 1, 2 and 5 hours. These samples were analysed for PARP cleavage by loading 
10|ag protein on each lane and running them on the same gel with apoptotic DLKP- 
SQ samples. It can be seen in figure 3.15.2 that PARP is cleaved completely in the 
apoptotic HL-60 cells, even after 1 hour exposure to doxorubicin. However, 
apoptotic DLKP-SQ cells have intact PARP comparable to untreated controls, even 
48 hours after treatment, and at a time when 50% of the cells are apoptotic.
184
3.15 PARP cleavage - Investigation of caspase substrate cleavage in DLKP cell
lines
PARP cleavage was also investigated in the resistant variants. DLKP-A250 10p#7 
do not show PARP cleavage after doxorubicin treatment, this is evident from the 
consistent 116 kDa band present in drug treated samples in figure 3.15.3. When 
DLKP-A2B cells were investigated there was a slight decrease in the 116 kDa intact 
PARP by 50 hours after Doxorubicin treatment, this is illustrated in figure 3.15.4. 
DLKP-A5F cells did not show PARP cleavage after Doxorubicin treatment, see 
figure 3.15.4. There results are surprising because PARP cleavage is seen in the 
majority of cells undergoing apoptosis. The results do however agree with caspase-3 
westerns where pro-forms of caspase-3 are not decreasing after Doxorubicin 
treatment indicating that caspase-3 is not activated during apoptosis in DLKP cell 
lines. Taken together these results tentatively suggest that the Doxorubicin induced 
apoptosis in DLKP cell lines might be caspase-3 independent but further 
experimental evidence needs to be provided to substantiate this, (described in 
forthcoming sections)
CO C50 TO T4 TIO T24 T50
116 kDa -
85 kDa ■
Figure 3.15.1 PARP protein levels before and after Doxorubicin treatment in 
DLKP-SQ
185
DLKP-SQ HL-60
C24 C48 T24 T48 CO T1 T2 T5
Figure 3.15.2 Analysis of PARP cleavage in DLKP-SQ and HL-60 cell lines 
after Doxorubicin treatment
CO C24 C36 T12 T18 T24 T36 T45 Neg
116 kDa -  
85 kDa -
Figure 3.15.3 PARP protein levels before and after Doxorubicin treatment in 
DLKP-A250 lOp #7
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CO C24 C45 TO T12 T18 T24 T36 T45
Figure 3.15.4 PARP protein levels before and after Doxorubicin treatment in 
DLKP-A2B
CO C24 C45 TO T12 T18 T24 T36 T45
1 i 6kDa - * i *•*
85 kDa -
Figure 3.15.4 PARP protein levels before and after Doxorubicin treatment in 
DLKP-A5F
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Fodrin is a cytoskeletal protein found in all eukaryotic cells and has been shown to 
undergo cleavage during apoptosis (Martin etal., 1995). Fodrin is a 240 kDa protein 
and is cleaved to 150 kDa and 120 kDa bands in cells undergoing apoptosis. 
Caspase-3 recently was shown to be the key protease involved in fodrin cleavage 
into the 120kDa fragment (Janicke et al, 1998). It is thought that the 150 kDa 
fragment is generated by calpains.
Fodrin cleavage was compared in untreated and Doxorubicin treated samples from 
the four DLKP cell lines. Cells were set up as described in materials and methods. 
Drug treated samples were extracted 50 hours after drug treatment, and control 
samples were taken from untreated cells growing exponentially. Results are shown 
in figure 3.16.1. Fodrin is cleaved to some extent in all of the control samples, as 
seen by the presence of a band at 150 kDa, and a faint band at 120 kDa. The 150kDa 
band present in all the samples suggests some calpain activity in the cells. The faint 
120kDa band is due to background apoptosis. At any instant in an entire cell culture 
population, at least 5% of the cells will die by apoptosis. These cleavage bands, 
particularly the 120 kDa band are much weaker in untreated cells than in drug 
treated cells. There is a strong 120 kDa band in the four drug treated cell lines 
indicative of fodrin cleavage during Doxorubicin-mediated apoptosis. The extent of 
cleavage appears equal in each of the four cell lines suggesting that protease activity 
in the four cell lines is comparable. Fodrin is efficiently cleaved in each of the four 
cell lines implying activation of caspase-3. Yet active caspase-3 could not be 
detected in section 3.13.2 as judged by the consistent levels of pro-caspase-3 protein 
in DLKP-SQ and DLKP-A250 10p#7 cells during apoptosis.
3.16 Fodrin Cleavage - Investigation of caspase substrate cleavage in DLKP
cell lines
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D LK P -SQ  DLKP-A250-10P #7 DLKP-A2B DLKP-A5F
' ¿ ■ 4 '  4 4
CO T45 CO T45 CO T45 CO T45
Figure 3.16.1 Fodrin Levels in DLKP-SQ, DLKP-A250 10#7, DLKP-A2B, 
DLKP-A5F before and after doxorubicin treatment. CO refers to untreated 
cells, T45 refers to Doxorubicin treated cells 45 hrs after treatment.
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3.17 Effects of caspase inhibitors on Doxorubicin-mediated apoptosis in 
DLKP cell lines
The development of synthetic caspase inhibitors has allowed extensive research to 
progress in attempt to further clarify the roles of specific caspases in the apoptosis 
pathway. In the introduction, 1.5.4, the design of these inhibitors was discussed; in 
brief if the inhibitor amino acid sequence is identical to the cleavage site in a 
substrate, then a caspase will bind to this recognition sequence in the inhibitor and 
further activity is prevented due to sequestration of the active caspase by the 
inhibitor.
Irreversible inhibitors were chosen to investigate their effect on apoptosis induction in 
DLKP cell lines. The first inhibitor used was zVAD.fmk, this is a general cell 
permeable caspase inhibitor having the Asp residue in the PI position of the cleavage 
sequence that is common to all caspases. A relatively non-toxic (<10 % apoptosis) 
inhibitor concentration of 100 pM was used in experiments, and cells were pre­
incubated with inhibitor to ensure the inhibitor enters the cells prior to exposure to 
apoptotic stimuli. Three inhibitor treatments were used; the first involved pre­
treatment with the inhibitor and removal just before drug addition. The second 
involved pre-treatment with inhibitor and continuous incubation during drug 
treatment, and the third consisted of pre-treatment, continuous incubation during 
drug exposure and a further addition of inhibitor 24 hours after drug treatment. The 
three different treatments attempted to cover all inhibition possibilities. Pre­
incubation alone was carried out with the assumption that the irreversible inhibitor 
should inhibit all caspase activity in the cell, and this irreversible inhibition would be 
maintained when the cells were exposed to drug. If drug treatment could induce new 
caspase activation, this should be blocked by the second treatment, continuous 
inhibitor presence which should serve to block any new caspase activation. The 
possibility of inhibitor degradation at 37°C existed however, and to overcome this 
fresh inhibitor was added to the cells 24 hours after drug treatment. A 24 hour 
treatment was chosen as the optimum addition time because it was seen in section
3.10.1 that the majority of DLKP-SQ cells did not undergo apoptosis until at least 24 
hours after drug treatment. Results of the inhibitor experiments can be seen in figure
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3.17.1. All treatments were carried out in duplicate and percentage kill was estimated 
using the crystal violet elution end point assay. Control cells were untreated and after 
3 days were considered to represent 100% viability. The concentration of zVAD.fmk 
used was 100 [iM, and this alone resulted in 0 - 30 % apoptosis. zVAD.fmk was 
incubated either for 2 hours or for 72 hours in DLKP-SQ cells as a control for the 
doxorubicin and inhibitors used. This high level of apoptosis is not ideal, but is 
nonetheless sufficiently low when compared to the percentage kill seen after 
Doxorubicin treatment. It can be seen from figure 3.17.1 that zVAD.fmk treatment 
provided no survival enhancement in any of the combinations used, when standard 
deviations were taken into account. Continuous Doxorubicin treatment which gave a 
kill of 80% was also used in combination with zVAD.fmk but no protection from 
apoptosis was seen. The experiment was repeated and similar results were obtained.
The microtubule inhibitor taxol was then used in combination with zVAD.fmk to 
look at the effects on apoptosis induction in DLKP-SQ. Taxol was chosen because 
apoptosis is induced over a much shorter time-scale of 6 hours compared to 24 hours 
with Doxorubicin. Two taxol concentrations were used, 80ng/ml for two hours 
resulted in 85% apoptosis and 50ng/ml for two hours resulted in 90% apoptosis after 
6 hours. zVAD was again pre-incubated with the cells and then either removed or 
remained during drug treatment. From figure 3.17.2 it can be seen that the 
zVAD.fmk had no cytoprotective effect on DLKP-SQ.
zVAD.fmk was then used in combination with doxorubicin treatment to see whether 
apoptosis could be prevented in DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F, or 
if similar results to the situation in DLKP-SQ would be obtained. It can be seen in 
figures 3.17.3, 3.17.4, 3.17.5 and 3.17.6 that the four cell lines respond in a similar 
manner to doxorubicin treatment and zVAD.fmk; no protection from cell death is 
achieved.
The ability of the specific inhibitors zDEVD.fmk and YVAD.fmk to block 
doxorubicin-induced apoptosis was also investigated in the four DLKP cell lines. 
Again, cells were preincubated for 1 hour with inhibitor before doxorubicin 
treatment. zDEVD.fmk specifically inhibits the caspase-3-like family of caspases
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including caspase-2, -6 and -7, but no protection from cell death occurred in its 
presence in any of the doxorubicin-treated DLKP cell lines, and results can be seen in 
figure 3.17.3, 3.17.4, 3.17.5 and 3.17.6. YVAD.fmk is a specific inhibitor of caspase- 
1 (ICE)-like caspases but failed to inhibit apoptosis induced by doxorubicin in the 
four DLKP cell lines, as seen by the results in figures 3.17.3, 3.17.4, 3.17.5 and 
3.17.6.
Timelapse videomicroscopy was carried out to analyse the kinetics of apoptosis in 
DLKP-SQ treated with doxorubicin and the general caspase inhibitor zVAD.fink. 
Analysis in figure 3.17.7 revealed a similar rate of apoptosis in the doxorubicin- and 
inhibitor-treated cells compared to DLKP-SQ treated with doxorubicin alone, 
indicating that the presence of zVAD.fink did not alter the rate of apoptosis induced 
by doxorubicin.
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I 1 i 1 I I 1 ‘H - 1 1 >■
3 4 5 6 7
Treatment
lOOuM zVAD 2hrs 5: 0.8ug/ml Dox 2hrs + lOOuM zVAD ( 24hrs)
lOOuM zVAD const 6: 0.4ug/ml Dox const
0. 8ug/ml Dox 2hrs 7: zVAD const + 0. 4ug/ml Dox const
zVAD 2hrs + 0.8ug/ml Dox 2hrs 8: 0.4ug/ml Dox const + lOOuM zVAD ( 24hrs)
Treatments 
1
2
3
4
Figure 3.17.1 Effect of zVAD.fmk and doxorubicin on DLKP-SQ
1: lOOuM zVAD 2his 
2: lOOuM zVAD const 
3: 80ng/ml Taxol 2hrs
5: 5()ng/ml Taxol const
6: 50ng/ml Taxol const + lOOuM zVAD 2hrs
7: 50ng/ml Taxol const + lOOuM zVAD const
4: 80ng/ml Taxol 2hrs + lOOuM zVAD 2hrs
Figure 3.17.2 Effect of zVAD.fmk and Taxol on DLKP-SQ
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%Surviva %St Dev
Ctrl 100 0
DoxH 36.13 2.35
Dox M 54.60 2.5
HzVAD 39.59 2.06
M zVAD 58.72 2.64
HDEVD 35.39 3.09
M DEVD 57.54 3.46
H YVAD 36.57 2.65
M YVA 63.87 3.83
Figure 3.17.3 DLKP-SQ treated with doxorubicin and 
lOOpM caspase inhibitors.
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%Survival %St Dev
Ctrl 100 0
Dox H 38.02 3.73
Dox M 47.30 2.3
HzVAD 39.60 3.57
MzVAD 49.29 6.43
H DEVD 31.27 3.57
M DEVD 42.78 7.78
H YVAD 31.51 6.27
M W AD 42.78 9.13
Figure 3.17.4 DLKP-A250 10p#7 treated with doxorubicin 
and lOOjiM caspase inhibitors.
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%Survival %St Dev
Ctrl 100 0
DoxH 24.75 1.73
Dox M 40.21 6.62
MzVAD 40.79 4.12
M DEVD 38.67 2.35
M YVA 34.90 2.28
Figure 3.17.5 DLKP-A2B treated with doxorubicin 
and lOOpM caspase inhibitors.
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% Survival St Dev
Control 100 0
DoxH 72.15 4.78
Dox M 72.07 5.48
HzVAD 70.60 7.71
MzVAD 79.01 2.43
HDEVD 69.06 4.86
MDEVD 80.86 5.09
HYVAD 69.29 6.4
MYVA 83.41 6.94
Figure 3.17.6 DLKP-A5F treated with doxorubicin 
and lOOpM caspase inhibitors.
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Figure 3.17.7 Timelapse videomicroscopical analysis of apoptosis in 
DLKP-SQ cells, comparing kinetics of cell death in 
doxorubicin-treated cells with cells treated with doxorubicin and 
the caspase inhibitor zVAD.Cells were monitored over 72 hours, 
and the time of apoptotic induction noted.
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3.18.1 Caspase-3 fluorometric assays
Fluorometric substrate assays were carried out in order to measure caspase-3 activity 
using the specific fluorogenic substrate AcDEVD-AMC. This enzymatic assay 
quantitates the cleavage of the fluorogenic peptide as a measurement of caspase-3 
activation. Cytoplasmic extracts were prepared as described in section 2.x, and 
protein concentration was estimated using the BCA assay. Figure 3.18 illustrates one 
set of data from the fluorogenic assay, repeat assays followed similar trends.
In DLKP-SQ there is an increase in caspase-3 activity following doxorubicin 
treatment of approximately three-fold, but the basal activity in untreated DLKP-SQ 
cells seems to be active to an equal extent. DLKP-SQ cell extracts which had been 
treated with the caspase inhibitor zVAD.fmk exhibit a decreased caspase-3 activity 
indicating that the caspase inhibitor is cell permeable and can efficiently inhibit 
caspase-3 activity.
DLKP-A250 10p#7 cells exhibit an increase in caspase-3 activity after doxorubicin 
treatment with highest activity seen 60 hours after treatment. Caspase-3 activity was 
almost completely abolished in pre-treated zVAD.fmk and doxorubicin-treated 
extracts. DLKP-A5F also exhibits increased activity, with levels peaking at 45 hours 
after doxorubicin treatment, but results are not shown in this graph. There is 
significant decrease in the pre-treated VAD.fmk samples in the resistant cells at 60 
hours after drug treatment, in contrast to the sensitive which do not show as much of 
a decrease in inhibitor-treated extracts.
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Caspase-3 Fluorometric Assay
□  DLKP-SQ 
HA 250 10p #7 
IDLKP-A5F
C24 C45 C60 TO T24 T45 T60 T60+I T60
50:50
Figure 3.18.1 Caspase-3 enzyme activity as measured using 
fluormetric DEVD.AMC substrate
2 0 0
3.19 CD95 receptor levels
CD95/CD95-L interaction plays an important role in apoptotic signalling, and is 
involved in apoptosis induced by chemotherapy drugs, amongst other stimuli. Upon 
receipt of an apoptotic signal, the CD95 receptors trimerise, allowing CD95-L to 
bind and a death signal to be transduced. Therefore the amount of CD95 present is an 
important factor for efficient signalling to occur. It has previously been reported that 
cells resistant to apoptosis induced either by CD95-L or doxorubicin have altered 
regulation of CD95, resulting in reduced CD95 expression (Fulda et al., 1998). Also, 
CD95 expression is upregulated after doxorubicin treatment in some cell lines, such 
as neuroblastoma cells (Friesen et al., 1998, Fulda et al., 1998).
CD95 receptor levels were looked at using Western blotting in the four DLKP cell 
lines before and after doxorubicin treatment. In figure 3.19 it can be seen that CD95 
is expressed to the same extent in sensitive and resistant cell lines, with no 
downregulation of CD95 in the resistant variants. After doxorubicin treatment, there 
is no upregulation of CD95 in any of the cell lines. It had been thought that if after 
doxorubicin treatment, DLKP-SQ cells upregulated CD95 perhaps the resistant 
variants would not upregulate CD95 to the same extent, and this failure to upregulate 
CD95 after doxorubicin treatment could be an additional resistance mechanism in the 
resistant variants. However results show that there is no upregulation of CD95 in any 
of the cell lines. After doxorubicin treatment, DLKP-A2B seem to have an upper 
band, but the significance of this is not known.
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DLKJP-SQ DLKP-A250-I0P #7 DLKP-A2B DLKP-A5F
4 4 4 4
CO T45 CO T45 CO T45 CO T45
Figure 3.19 Western Blot showing CD95 receptor protein levels in DLKP cell 
lines before and after doxorubicin treatment
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3.20 Effect of CD95 blockers on doxorubicin-induced apoptosis
In figure 3.19 it was shown that doxorubicin treatment did not affect the CD95 
receptor levels in either sensitive or resistant cell lines. The involvement of the CD95 
pathway was further investigated using specific inhibitors of the CD95 pathway. ZB4 
is a CD95 antibody that binds to cellular CD95 and prevents CD95L binding, and 
consequently signal transduction. NOK-2 is a CD95-L antibody which has a 
neutralising effect on CD95-L action, by binding to CD95-L and preventing its 
association with CD95. Both these antibodies were used in combination with 
doxorubicin treatment on DLKP-SQ, DLKP-A250 10p#7 and DLKP-A2B (DLKP- 
A5F was not used). Three drug concentrations were used for each cell line which 
gave a high, medium and low cell kill after 72 hours. Cells were preincubated with 
inhibitor for 1 hour before doxorubicin addition, at which time fresh inhibitor was 
also added. Cell viability was determined after 72 hours using an in vitro acid 
phosphatase toxicity assay, as described in materials and methods.
Results are shown in figures 3.20.1, 3.20.2 and 3.20.3 for ZB4 and doxorubicin 
combinations. It can be seen that ZB4 offered no protection to the cells from 
doxorubicin-induced apoptosis, approximately the same number of cells died when 
treated with ZB4 and doxorubicin, as those treated with doxorubicin alone. The 
effect of NOK-2 on doxorubicin-induced apoptosis can be seen in figures 3.20.4, 
3.20.5 and 3.20.6 for DLKP-SQ, DLKP-A250 10p#7 and DLKP-A2B respectively. 
NOK-2 also has no protective effect against doxorubicin-induced apoptosis.
These results, although unexpected, are quite novel because they raise questions 
about the involvement of CD-95 pathway in doxorubicin-induced apoptosis in the 
DLKP cell lines. The ZB4 antibody was tested for its ability to block CD95-induced 
apoptosis, to ensure that it was capable of inhibiting apoptosis mediated by the CD95 
signalling pathway and to confirm that the ZB4 antibody is effective in entering the 
DLKP cell models. Cells were preincubated with ZB4 for 1 hour and then treated 
with a CD95 activating antibody (CH-11). Results are illustrated in figure 3.20.7. 
CH-11, even though it had to be used at much higher concentrations than those
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recommended in the literature, induced a low level of apoptosis in DLKP-SQ. When 
co-treated with the ZB4 blocking antibody the 37% kill decreased to 8 %, indicating 
that the ZB4 is active in blocking the CD95 signalling pathway.
In section 3.17 cell permeable inhibitors of caspases were tested for their ability to 
block doxorubicin-induced apoptosis in the DLKP cell lines, without success. The 
CD95 blockers also failed to inhibit doxorubicin-induced apoptosis, as seen in figures 
3.20.1-3.20.6. A further combination was then employed, consisting of the CD95 
blocker ZB4 and the general caspase inhibitor zVAD.fmk, in attempt to discover if 
both inhibitors together could prevent DLKP-SQ from apoptosis. Cells were 
preincubated with both inhibitors for 1 hour before doxorubicin addition, and again at 
the time of drug addition. Results in figures 3.20.8, 3.20.9 and 3.20.10 demonstrate 
that doxorubicin-treated DLKP cells can still die even in the presence of both CD95 
blockers and caspase inhibitors. To further corroborate these results, DLKP-SQ cells 
were closely monitored after this inhibitor and drug combination using timelapse 
videomicroscopy. The kinetics of apoptosis of the combination treatment were 
compared to kinetics of apoptosis induced by doxorubicin alone in figure 3.20.11. 
From the graph in figure 3.20.11 it is clear that the inhibitors have no effect on the 
rate of apoptotic induction in doxorubicin-treated cells. Apoptosis in inhibitor-treated 
cells has slightly faster initial rate, if anything, but the two rates closely mirror each 
other over the 72 hours monitored.
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%Survival % S t  Dev
Control 100 0
DoxH 6.59 0.493
Dox M 10.67 1.16
Dox L 38.9 3.63
H ZB4 6.91 0.36
MZB4 12.15 1.83
LZB4 47.3 2.96
Figure 3.20.1 DLKP-SQ treated with doxorubicin 
and the CD95 blocker ZB4(250ng/ml)
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%Survival %St Dev
Control 100 0
Dox H 9.74 0.924
Dox M 36.47 3.17
Dox L 79 4.65
HZB4 10.46 1.12
MZB4 32.34 0.825
LZB4 79.9 5.08
Figure 3.20.2 DLKP-A250 10p#7 treated with doxorubicin 
and the CD95 blocker ZB4 (250ng/ml)
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%Survival %St Dev
Control 100 0
DoxH 10.9 0.91
Dox M 18.42 2.75
Dox L 30.42 3.3
HZB4 9.99 1.19
MZB4 14.2 2.57
LZB4 28.1 5.22
Figure 3.20.3 DLKP-A2B cells treated with doxorubicin 
and the CD95 blocker ZB4 (250ng/ml)
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%Survival %St Dev
Control 100 0
Dox H 10.15 0.377
Dox M 15.27 0.892
Dox L 64.34 2.78
H NOK- 9.13 0.27
M NOK- 17.67 1.41
L NOK-2 49.77 2.265
Figure 3.20.4 DLKP-SQ cells treated with doxorubicin and 
the CD95L neutralising antibody, NOK-2 (lp,g/ml).
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%Survival %St Dev
Control 100 0
DoxH 13.39 1.59
Dox M 40.83 2.24
Dox L 87.34 3.79
H NOK-2 12.52 1.03
M NOK-2 35.64 4.02
L NOK-2 83.06 11.25
Figure 3.20.5 DLKP-A250 10p#7 cells treated with doxorubicin and 
the CD95L neutralising antibody, NOK-2 (1 fig/ml).
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%Survival %St Dev
Control 100 0
Dox H 9.38 1.77
Dox M 15.49 1.86
Dox L 30.9 5.67
H NOK-2 8.41 0.79
M NOK-2 12.83 5.22
L NOK-2 23.2 2.48
Figure 3.20.6 DLKP-A2B cells treated with doxorubicin and 
the CD95L neutralising antibody, NOK-2 (ljig/ml).
2 1 0
% Survival %St Dev
Control 100 0.0
500ng/ml 63.38 15.21
ZB4 H 93.72 15.21
ZB4 L 96.41 15.09
250ng/ml 90.42 8.68
ZB4 H 95.57 12.75
ZB4 L 99.94 12.04
100ng/ml 98.50 8.80
ZB4 H 97.01 8.68
ZB4 L 91.86 10.90
Figure 3.20.7 Effect of ZB4 on CD95 (CH-ll)-induced  
apoptosis after 72 hours. CD-95 concentrations used were 
500ng/ml, 250ng/ml and lOOng/ml. ZB4 H was 500ng/ml 
ZB4 L was 250ng/ml
2 1 1
%Survival %St Dev
Control 100 0
Dox H 6.83 0.36
Dox M 10.9 0.81
Dox L 43.6 4.47
H ZB4/zVAD 8.37 0.53
M ZB4/zVAD 17.53 1.01
L ZB4/zVAD 53.25 3.9
Figure 3.20.8 DLKP-SQ cells treated with doxorubicin and 
a combination of caspase inhibitor zVAD (IOOjiM) and 
the CD95 blocker ZB4(250ng/ml)
2 1 2
%Survival %St Dev
Control 100 0
Dox H 13.77 1.14
Dox M 41.55 3
Dox L 87.46 6.02
H ZB4/zVAD 25.39 6.61
M ZB4/zVAD 53.98 6.57
L ZB4/zVAD 85.02 3.09
Figure 3.20.9 DLKP-A250 10p#7 cells treated with doxorubicin and 
a combination of the caspase inhibitor zVAD (lOOpM) and the 
CD95 blocker ZB4 (250ng/ml)
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%Survival %St Dev
Control 100 0
DoxH 9.46 1.24
Dox M 17 2.1
Dox L 31.34 4.2
H ZB4/zVAD 12.32 0.95
M ZB4/zVAD 20.35 2.1
L ZB4/zVAD 33.25 2.87
Figure 3.20.10 DLKP-A2B cells treated with doxorubicin and 
a combination of the caspase inhibitor zVAD (lOOpM) and 
the CD95 blocker ZB4 (250ng/ml)
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4.0 Discussion
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4.1 Constitutive protein levels of cell cycle regulatory proteins in DLKP cell lines
The cell cycle is a tightly regulated process governing cellular growth and proliferation, 
and any defects in cell cycle control may lead to unrestrained growth and proliferation, a 
feature frequently seen in tumourigenesis. Abnormalities in cyclins and cdks have now 
been implicated in several human tumours (Bartkova et al., 1997). One of the earliest 
examples was the finding that the cyclin A gene was the site for integration of the hepatitis 
B virus in a human hepatocellular carcinoma, but this abnormality appears rarely in liver 
cancer (Motokura and Arnold, 1997). The cyclin E gene is often dysregulated and 
overexpressed in a variety of human carcinomas (Keyomarsi et al., 1994). Cdks have also 
been reported to be overexpressed or dysregulated in many cancers, cdk4 is frequently 
amplified in glioblastomas (Schmidt et al., 1994) and altered regulation of cdk2 occurs in 
glioblastoma (Pykett et al., 1997).
Cyclin Di has an important role to play in cell cycle progression and proliferation, due to 
its association with Rb and the E2F family of transcription factors. Therefore any 
overexpression of cyclin Di would have important implications for tumour growth 
resulting in enhanced transcription of many genes required for the S phase. Cyclin Di has 
been mapped to the 1 lql3 locus close to the BCL1 region which is frequently amplified 
in many tumours (Motokura and Arnold, 1997). Abnormalities in the cyclin D gene have 
been associated with numerous human cancers such as carcinomas of the breast, 
oesophagus, head and neck, lung, liver and bladder (Jiang et al., 1993; Gillett et al., 1996, 
Zhang et al., 1993). Overexpression of cyclin Di is associated with poor prognosis of 
patients with breast cancer (Borg et al., 1992, Michalides et al. 1996) and human 
pancreatic carcinoma (Gansauge et al. 1997). Recently Arber et al. (1997) reported that 
antisense cyclin Di can decrease cyclin Di levels and prevent tumorigenicity in human 
colon carcinoma cells. Hochhauser et al., (1996) investigated the chemosensitivity 
profiles of human fibrosarcoma cell lines expressing high and low levels of cyclin Di with 
doxorubicin (as well as other chemotherapeutic drugs taxol and cytarbine). It was 
demonstrated that cells with higher cyclin Di protein expression were equally sensitive to 
Doxorubicin when compared to cell lines with low levels of cyclin Di, but clones with
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high cyclin Di levels were more resistant to antimetabolites such as methotrexate. This 
finding implies that cyclin Di levels have no role to play in resistance to Doxorubicin. It 
was expected therefore that the Doxorubicin-resistant cells and Doxorubicin-sensitive 
DLKP-SQ should not have any significant differences in cyclin Di protein levels and this 
was the case.
An investigation was undertaken to study the levels of the main cell cycle regulating 
proteins cyclins and cyclin dependent kinases, in the sensitive DLKP-SQ and also the 
resistant variants DLKP-A250 lOp #7, DLKP-A2B and DLKP-A5F. Cyclin B protein 
levels in the asynchronous cell lines were of approximately equal intensity. There are no 
reports of altered cyclin B levels in association with drug resistance, and results in figure
3.3.1 are in agreement with this. Cyclin E protein levels were equal in the four cell lines. It 
can also be seen that there is an equal level of expression of cyclin Di in both resistant 
and sensitive cell lines.
There was no variation in protein levels of the cyclin dependent kinases cdkl, cdk2, and 
cdk4 among the four cell lines. It can therefore be concluded that the multidrug resistant 
cell lines have a similar cell cycle to the sensitive DLKP-SQ with equal levels of the cell 
cycle regulatory proteins under study.
The fact that protein expression levels of cyclins and cdks do not change does not give a 
true reflection of the action of these proteins during the cell cycle however. A cyclin-cdk 
complex must form to initiate cdk kinase activity, which has a profound effect on the 
subsequent cell cycle events in the cell. Therefore even if protein levels remain at 
comparable levels, it is still possible that resistant cells may have alterations in activation 
of cdk complexes or deregulated kinase activity. This assumption holds true for any drug 
treatments on the cells, the drug may not affect the protein expression, but rather its 
kinase activity is altered.
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4.2 Effect of Doxorubicin treatment on the cell cycle of DLKP cell lines
In section 3 .1 it was demonstrated that cell cycle regulatory protein levels in both resistant 
and sensitive cell lines were comparable. The resistant cell lines DLKP-A250 10p#7, 
DLKP-A2B and DLKP-A5F differ in their sensitivity to Doxorubicin treatment, and the 
main contributory factor to this resistance is the presence of p-glycoprotein, the ATP- 
dependent membrane transport protein whose main function is to act as a drug efflux 
pump (for review see Germann, 1998). The possibility that cell cycle regulatory proteins 
may also contribute to this resistance had not been investigated however, and a study was 
undertaken to clarify this.
Equitoxic concentrations were chosen, rather than equal intracellular concentrations. 
Some experiments were carried out in an attempt to relate drug dose to intracellular 
concentration but this was complicated by the fact that Doxorubicin can be sequestered 
into vesicles and away from their target site in the nucleus (Cleary, I., 1995 ). DLKP-A5F 
cells therefore gave an abnormally high doxorubicin intracellular reading even though 
there are very high levels of p-glycoprotein in this cell line (Heenan at al., 1998).
When compared to DLKP-SQ, drug resistant DLKP-A250 10p#7 cells were 
approximately 3.5 fold resistant, DLKP-A2B cells were 50 fold resistant and DLKP-A5F 
cells were 160 fold resistant. These results vary slightly from previously reported values in 
which the cell lines were compared to the parental DLKP cell line, but this discrepancy is 
due to different seeding density (25 cm2 flasks as opposed to 96-well plates) and different 
drug exposure times (2 hour pulse compared to continuous exposure over 3 days)
Drug treatment usually results in DNA damage, and the cell is equipped with checkpoints 
that sense DNA damage, and alter the cell cycle so as to prevent further progression 
which could be lethal for the cell. Numerous chemotherapy drugs affect the cell cycle, 
mainly through the instigation of an arrest before entry to mitosis, one of the critical 
events in the cell cycle. Early studies by Tobey et al. (1972) demonstrated that the 
antitumour drug bleomycin caused Chinese hamster ovary cells to arrest in G2. Tobey et 
al. (1975) subsequently identified a number of other chemotherapeutic drugs which could
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inhibit cell cycle traverse and cause an accumulation of cells in G2. Krishan and Frei, 
(1976) carried out a study investigating the effects of exposure of CCRF-CEM cells to 
doxorubicin, and concluded that cells accumulated in G2 phase and cell cycle traverse was 
inhibited. A G2 arrest occurs irrespective of the phase the cells are in during doxorubicin 
exposure, for instance cells exposed in late S and G2 experience an immediate arrest, cells 
in Gl will arrest more slowly in G2, but if they do manage to divide in M, their progeny 
will arrest in the subsequent G2 phase (Barlogie and Drewinko, 1978). Many other 
chemotherapy agents cause cells to arrest and accumulate in G2 and M, and these are 
summarised in table 2.1.
CHEMOTHERAPEUTIC AGENT REFERENCE
Actinomycin D Dewey and Highficld, 1976; Kinder et al., 
1978
Azacytidine Tobey et al., 1972
Bleomycin Tobey, 1972;
Camptothecin Tobey et al., 1972; Tsao et al., 1992
Cis-diamminedichloroplatinum (II)(CDDP) Nishio et al., 1993
Doxorubicin Krishan and Frei, 1976, Barlogie et al.,
1976
Etoposide Barlogie and Drewinko, 1978; Lock and 
Ross, 1990
Irradiation Lock and Ross, 1990
Lucanthone Kinder ef a/., 1978
Melphalan Barlogie and Drewinko, 1978
Mitomycin C Kinder et al., 1978
Table 2.1 Chemotherapeutic agents capable of inducing G2/M arrest
The effect of Doxorubicin treatment was initially investigated using flow cytometry. 
Doxorubicin or adriamycin is a member of the anthracycline group of chemotherapeutic 
drugs and exerts its effects by DNA intercalation and topoisomerase II inhibition (Pratt et 
al. 1994). The effect of doxorubicin treatment on DLKP-SQ cells was investigated. At 12
hours after treatment there is an increased number of cells in S phase, and this increases at 
16 hours and 20 hours. An accumulation in late S and G2 phase is seen at 24 hours with a 
definite G2/M arrest by 36 hours. Apoptotic cells are evident by the sub-Gl peak at 68 
hours. Doxorubicin is widely reported to cause a G2/M arrest in cycling cells. Krishan and 
Freii (1976) demonstrated that Doxorubicin treatment resulted in a G2/M arrest in 
asynchronous CCRF-CEM cells, and the situation in DLKP-SQ cells mirrors these 
results.
Doxorubicin treatment of DLKP-A250 10p#7 cells resulted in the cells accumulating in 
G2/M phase at 12 hours, peaking at 24 hours. After this time cells can be seen to increase 
in G1 phase with a decrease in G2/M population. The G1 cells seem to arrest at this point, 
and there is no increase in the S phase population. It is apparent from the histograms that 
the DLKP-A250 10p#7 cells cycle much faster than the DLKP-SQ cells. DLKP-A2B 
cells also exhibit a G2/M arrest, but the effect is not as prominent as for the DLKP-A250 
10p#7 cells and there seems to be a partial block in G1 in a small percentage of cells as 
evident by the small G1 peak still present at 24 hours. DLKP-A5F cells accumulate in 
G2/M by 16 hours, again evidence for a faster cell cycle traverse in resistant cell lines 
compared to DLKP-SQ. By 24 hours the G2/M arrest has peaked and after this time the 
increase in G1 peak occurs, as previously seen in DLKP-A250 lOp #7 and DLKP-A2B.
Barlogie et al. (1976) concluded that a G2 arrest was dependent on the doxorubicin 
concentration used and drug exposure time, with higher concentrations and longer 
exposure times causing a G1 arrest, delay in S phase transit and an irreversible G2/M 
arrest. The effect in DLKP-SQ cells reflects this “classic” effect (with arrest seen only at 
very high Doxorubicin concentrations) and contrasts sharply with the weak G2/M arrest, 
override of this arrest and subsequent G1 accumulation seen in the resistant variants. This 
difference is not due to a concentration effect because equitoxic doses were used to 
minimise any variation due to the higher concentrations used in resistant cells. Exposure 
times used for the four cells lines were of equal duration thus ruling out the possibility of 
the difference in effect being due to unequal exposure times. Therefore the possibility of a 
drug-specific effect being responsible for the G2/M override in the resistant variants seems 
unlikely.
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It is obvious from these results that there must be some alteration in the controller 
complex cyclin B-cdkl whose activity is critical for entry of the cells to mitosis. The 
activation and regulation of this complex is tightly controlled by phosphorylation levels 
(Parker et al., 1992). The resistant cells that bypass the G2/M arrest may have 
deregulated control of entry to mitosis, or may not be able to sense the damage that the 
sensitive DLKP-SQ experience; whatever the difference, it is significant because it allows 
the resistant variants to over-ride the G2/M arrest in response to doxorubicin treatment.
When taken together, these results imply that resistant cells must possess a defective 
checkpoint which empowers them to override the G2/M arrest seen in sensitive cells after 
doxorubicin treatment. The G2/M arrest seen is due to a cell cycle checkpoint that delays 
progression from G2 into mitosis in response to DNA damage, to allow time for repair of 
any damaged DNA before entry to mitosis. DLKP cells were investigated for p21 
induction following doxorubicin treatment but no p21 could be detected, suggesting that 
wild type p53 is absent in these cells. Current studies suggest that the G2 checkpoint 
occurs independently of p53; p53 is responsible for inducing p21 and consequently a Gl/S 
arrest, and it is thought that p53 does not play a role in the DNA-damage-induced G2/M 
arrest. p53 is involved in bringing about a Gl/S arrest in response to DNA damage 
(Westphal, 1997). Furthermore, Waldman et al (1996) reported that cells lacking p53 did 
not arrest in Gl, but could arrest in G2 following doxorubicin treatment. The current 
model for the G2/M checkpoint is outlined in figure 4.1.
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Figure 4.1 Outline of the G2/M Checkpoint
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The G2/M checkpoint is discussed in detail in section 1.4.12. Briefly, when DNA damage 
is inflicted, the DNA damage-sensor chkl protein kinase is activated through 
phosphorylation. This active kinase then phosphorylates cdc25C phosphatase on a 
specific residue (serine 216 in humans), resulting in the sequestration of the 
phosphorylated cdc25C protein by 14-3-3 proteins, resulting in inhibition of its 
phosphatase activity. This inhibition of cdc25C phosphatase activity in turn prevents 
removal of the inhibitory phosphate on Tyrl5 of cdkl, and thus inhibits cdkl kinase 
activity and cell cycle arrest, to allow for DNA repair. From this checkpoint model it can 
be seen that there are various proteins whose activity is crucial for an intact G2/M 
checkpoint and arrest to occur and any disruption of these proteins would result in a 
bypass of G2/M.
There are a number of possibilities to explain why the resistant variants can override the 
arrest. These can be arranged in levels according to their proximity to the cdkl-cyclin B 
complex, as outlined in figure 4.2. The first level includes the components of the complex, 
cyclin B and cdkl protein expression after drug treatment, and their ability to form an 
active complex. Continuing from this is the presence of inhibitory phosphate on Tyrl5 of 
cdkl, and consequently kinase activity of the active complex, the effectors of 
phosphorylation are particularly important; cdc25C and weel. Following these levels are 
14-3-3 protein and phosphorylation levels, and co-immunoprecipitation with cdc25C 
(i.e,14-3-3-cdc25C complex) and finally chkl levels after drug treatment and its 
phosphorylation levels. Some of these G2/M checkpoint components were investigated in 
an attempt to explain the G2/M over-ride seen in the resistant variants following 
doxorubicin treatment, and are discussed in sections 4.5, 4.6, 4.7, 4.8 and 4.9.
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Figure 4.2 Components of the G2/M checkpoint possibly involved in the 
doxorubicin-induced arrest in DLKP cell lines
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4.3.1 Attenuation of cell cycle checkpoints - Cellular Implications
Cells which have an intact checkpoint will arrest and carry out any required DNA 
repair so to maintain integrity of the DNA in each round of cell cycle. Proliferating 
cells normally respond to DNA damage by delaying the transitions from G1 to S or 
from G2 to M. By delaying progression through the cell cycle, cells may gain 
additional time for repair processes to remove any potentially mutagenic or lethal 
lesions before the genome is replicated or divided. Cells without an intact checkpoint 
will continue to divide with DNA damaged or incorrectly repaired, and become 
further unstable and contain chromosomal deletions, rearrangements and 
multiplications perhaps further advancing their genomic instability. This instability is a 
key feature of cancer cells. It is possible that a cell with enhanced genomic instability 
would progress rapidly to form a metastatic tumour. If cell cycle control is missing or 
defective, progression towards malignancy is accelerated, and also increasingly 
chemoresistant phenotypes have potential to develop.
The G2 checkpoint is particularly important due to the segregation of the genome in 
mitosis. Progression past M phase in the presence of incompletely repaired DNA 
would result in the acquisition of damaged genomic material in the progenitor cells. 
Kaufmann et al. (1995) investigated the possibility that attenuation of the G2 
checkpoint may contribute to the genomic instability of immortal human cell lines. It 
was concluded that the G2 checkpoint attenuation preceded immortalisation, and 
plays a role in immortalisation of human fibroblasts. Immortal fibroblasts display 
aneuploidy and genetic instability and attenuation of the G2 checkpoint could allow 
cells to enter mitosis with levels of DNA damage that would normally arrest cells 
with a functioning G2 checkpoint. Therefore cells with the ability to bypass the DNA 
damaged-induced G2 checkpoint would be expected to have higher levels of 
chromosomal aberrations and aneuploidy. Indeed DLKP cells have shown tendencies 
to be aneuploid (McBride, 1995).
Defective G2/M checkpoints occur in many familial cancer syndromes such as Li- 
Fraumeni syndrome and AT (Paules et al, 1995). Some cells do however die by
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apoptosis, but those that do not die can continue to cycle and carry out DNA 
synthesis and mitosis resulting in proliferation of very unstable cells. So could 
resistant cells, when treated with doxorubicin become even more turn or i genic, by 
having highly unstable cells which have the ability to bypass G2/M checkpoint?
One important question is that of the cell cycle effect of doxorubicin treatment in the 
initial resistance selection of the cells. Resistant and sensitive cells have similar 
doubling times when growing exponentially, also cyclin and cdk protein levels are not 
altered in resistant cells. When sensitive cells are first exposed to doxorubicin, they 
arrest in G2/M as seen in DLKP-SQ. Resistance develops with continuing 
doxorubicin presence, and apart from MDR changes, the cell cycle in drug-treated 
cells also changes. Initially, doxorubicin-treated cells irreversibly arrest in G2/M, but 
after development of resistance the functional G2/M checkpoint is dismantled in some 
way. Perhaps in their development to resistance, their cell cycle has evolved so that 
the G2/M checkpoint is compromised allowing some of them to continue to divide in 
an attempt to create a survival advantage mechanism.
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4.3.2 Effect of caffeine on DLKP-SQ cells
Caffeine belongs to the methylxanthines which are known to sensitise cells to DNA 
damage (Busse el al., 1978). Musk et al. (1990) demonstrated that methylxanthines can 
induce an override of the G2/M block in human tumour cells after ionising radiation. Little 
evidence is available to date on the mechanisms of caffeine action on cell cycle delay, but 
it is thought that caffeine prevents the G2/M checkpoint from arresting the cell cycle in 
order to repair damaged DNA and this results in higher levels of cell kill.
Caffeine treatment on DLKP-SQ cells in various combinations with doxorubicin was 
investigated for its ability to overcome the G2/M arrest seen with doxorubicin alone. 
4mM caffeine treatment alone had no obvious effect on the cell cycle of DLKP-SQ cells. 
The doxorubicin-induced G2/M arrest in DLKP-SQ can be prevented by addition of 
4mM caffeine and if G2/M arrest has already occurred it can be reversed by caffeine 
addition. Ilialis et al. (1986) investigated the effects of doxorubicin on Chinese hamster 
V79 cells with caffeine and found that caffeine reduced doxorubicin-induced arrest, 
similar to the situation in DLKP-SQ cells. From these results it appears that DLKP-SQ 
cells can mimic the resistant variants in their response to doxorubicin treatment. Perhaps 
caffeine affects the G2 cell cycle checkpoint of DLKP-SQ cells a in similar mechanism to 
that of doxorubicin in the resistant variants, or the resistant variants may already have the 
cellular defects that caffeine produces in DLKP-SQ cells, thus enabling them to override 
the G2/M arrest seen in the sensitive DLKP-SQ.
Dunphy (Keystone Meeting, 1998) suggested that caffeine’s effect of bypassing the G2/M 
arrest may be due to its action on the G2/M checkpoint. The most likely candidate to be 
affected is chkl protein in some as yet unknown way. When chkl is inhibited, cdc25C is 
not phosphorylated on ser 216 and remains active, thereby resulting in unscheduled 
removal of the inhibitory phosphate on Tyrl5 on cdkl. The results discussed here provide 
further evidence for a faulty checkpoint as the cause of the G2/M override by the resistant 
variants.
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4.4 Time-lapse Yideomicroscopy analysis of Doxorubicin-induced mitosis and 
apoptosis
As seen in flow cytometry histograms in section 3.3.1, DLKP resistant variants have the 
ability to bypass the G2/M arrest seen in the sensitive cells after doxorubicin treatment. 
These results are further strengthened by the use of time-lapse videomicroscopy which 
allows visualisation of cell death and cell division events. It is possible to follow the 
dynamics of a certain population continuously over time. In section 3.4 the graphs 
indicate that mitosis occurs in the resistant cells but not in the sensitive cells, this was 
assessed by monitoring the morphological changes that took place after doxorubicin 
treatment.
In DLKP-A250 10p#7 cells there is 13 % mitosis, 15 % mitosis occurs in DLKP-A2B 
and a high 58 % mitosis occurs in DLKP-A5F cells, and this occurs over a 70 hour period 
following exposure of the cells to a concentration of doxorubicin that induced 50% cell 
kill, as determined by mini ature in vitro toxicity assays. The high rate of mitosis in DLKP- 
A5F is surprising but the majority of post-mitotic cells rapidly undergo apoptosis just after 
mitosis. This is also seen to a lesser extent in DLKP-A2B and DLKP-A250 10p#7 cells in 
which at least one of the daughter cells dies by apoptosis. The phenomenon of post­
mitotic apoptosis lends further weight to the suggestion that the resistant cells undergo 
mitosis with damaged DNA without an intact G2/M checkpoint. The cells with impaired 
DNA after division cannot survive and die by apoptosis. If these cells had a functional 
checkpoint the cells would possibly not be pushed into lethal mitosis.
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4.5 Cellular Effects of Doxorubicin in DLKP cells
4.5.1 Doxorubicin effects on cyclin B levels
Cyclin B and cdkl are critical elements of the G2/M transition in eukaryotic cells, and 
their regulation is important in maintaining proper control of the cell cycle. As cells 
progress through S and G2 phase, cyclin B protein levels begin to accumulate. When a 
certain threshold level of cyclin B is reached, it can form a complex with cdkl. Cyclin B 
accumulation is essential for activating cdkl and for cells to progress into mitosis. Any 
treatment that prevents cyclin expression would therefore result in reduced cdkl-cyclin B 
complex formation, if the levels of cyclin B were insufficient, and ultimately lead to a G2 
arrest. However if cyclin B levels are sufficiently high to activate cdkl, and a G2 arrest 
still occurs, then the possibility of an additional regulatory control exists, such as inhibition 
of cdkl kinase activity.
It has been previously shown that cyclin B accumulation decreases due to DNA damage 
induced by ionising radiation (Datta et al. 1992, Muschel el al. 1997). Muschel et al. 
(1993) investigated the effects of irradiation on cyclin A and cyclin B expression in HeLa 
cells, and found that expression of cyclin B mRNA and protein is delayed after irradiation 
and levels of cyclin B protein do not accumulate to the same extent in irradiated cells 
compared to controls. Studies investigating the effects of irradiation on HeLa cells 
revealed that lower cyclin B levels after irradiation may contribute to the G2/M block 
(Bernhard et al., 1994). Induction of high cyclin B levels through use of an inducible 
expression vector shortens the G2 delay after irradiation. This induction, however, does 
not eliminate the G2 block suggesting that the cyclin B depression contributes to the G2 
delay but other regulatory factors must exist (Kao et al., 1997). Recently Innocente et al. 
(1999) reported that cyclin B expression can be regulated by p53 during the G2/M arrest 
after DNA damage. They demonstrated that in the presence of p53, cyclin B protein 
levels are decreased due to attenuation of the cyclin B promoter.
In contrast to these reports, Nishio et al., (1993) demonstrated that during a CDDP- 
induced G2 arrest, cyclin B protein levels and degradation were not affected. In addition,
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Shimizu et al. (1995) reported that camptothecin treatment of HL-60 cells does not alter 
cyclin B protein levels. Camptothecin treatment of HeLa cells results in a G2 arrest and 
minimally affects cyclin B protein synthesis, and high levels of cyclin B accumulate in 
conjunction with the G2 arrest (Tsao el al., 1992). High cyclin B levels are most likely 
due to a reduced rate of degradation, consistent with the observation that cyclin B is 
rapidly degraded only after mitosis. Furthermore, Ling el al. (1996) demonstrated that 
cyclin B1 levels increased relatively constantly after Doxorubicin treatment, due to 
induction of cyclin B synthesis and inhibition of its degradation in synchronised P388 cells, 
and a constant cyclin B protein level was seen using western blotting.
The influence of doxorubicin on cyclin B expression in DLKP-SQ. DLKP-A250 10p#7, 
DLKP-A2B and DLKP-A5F was investigated in section 3.5.1. Doxorubicin treatment did 
not induce changes in cyclin B protein levels in any of the cell lines when compared to 
control levels in DLKP-SQ. Cyclin B protein levels remained constant over 45 hours after 
drug treatment, by which time a G2/M arrest had occurred. Results were similar for 
DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F. These results are similar to Ling’s
(1996) results in that the cyclin B levels remain constant when compared to controls (but 
rates of synthesis were not looked at in this thesis).
4.5.2 Doxorubicin effects on cdkl levels
Levels of cdkl do not oscillate enormously during the cells cycle, and the protein relies on 
the presence of cyclin B for its kinase activity, thus the cyclin acts as the regulatory 
subunit of the complex. Ling el a l (1996) reported that doxorubicin treatment did not 
influence cdkl protein synthesis in synchronised P388 cells which were G2/M arrested. 
The topoisomerase I inhibitor camptothecin has no effect on cdkl protein levels in HL-60 
cells when accompanied by a G2/M arrest (Shimizu el al. 1995).
Cdkl protein levels in DLKP-SQ, DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F 
before and after doxorubicin treatment were monitored in section 3.5.2. Clearly there is 
no change in cdkl protein expression after doxorubicin treatment when compared to
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controls. These results are similar to the published reports mentioned previously. 
Therefore the altered G2/M transition in the resistant variants is not due to deregulation of 
cyclin B or cdkl proteins, and cyclin B and cdkl in sensitive and resistant cells are 
unaltered in their responses to doxorubicin treatment.
4.5.3 Effects of Doxorubicin on cyclin B-cdkl complex forming ability
The ability of cyclins and cdks to form complexes represents one of the fundamental 
regulatory events in the cell cycle. Cdks are the catalytic subunits of the cyclin-cdk 
complex, and they require cyclins for activation. If cyclin is not present the cdk remains 
catalytically inactive so when cdkl is not complexed to cyclin B it remains inactive, and 
entry to mitosis will not occur. The complex-forming ability of DLKP-SQ, DLKP-A250 
10p#7. DLKP-A2B and DLKP-A5F was not affected by doxorubicin treatment, levels of 
cyclin B-cdkl complex after drug treatment were not altered, indicating that alterations in 
cell cycle response in the resistant variants are not due to deregulated cyclin B-cdkl 
complex formation, but may lie downstream from this.
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4.6 Phosphorylation of Tyr 15 on cdkl
The kinase activity of cdkl is the key regulatory factor in the cdkl-cyclin B complex and 
is controlled tightly by phosphorylation and dephosphorylation mechanisms. As discussed 
in section 1.4.2, 1.4.3 and 1.4.7., Thr 14 and Tyr 15 (Y15) are inhibitory sites, and the 
presence of a phosphate on Tyr 15 generally confers inhibition of the cdkl kinase activity. 
Numerous reports have demonstrated G2/M arrest caused by inhibition of cdkl kinase 
activity as a result of decreased Y15 dephosphorylation. Failure to dephosphorylate Y15 
has been reported after treatment with various chemotherapy agents; camptothecin (Tsao 
et al., 1992; Shimizu et al., 1995) and etoposide (Lock et a l, 1992) induced a G2 arrest, 
which was mediated through a failure to dephosphorylate Y15. G2 arrest induced by 
irradiation in HeLa cells was found to be due to an increase in phosphorylation on cdkl, 
and consequently a decrease in cdkl kinase activity (Metting and Little, 1995). The study 
by Lock et al. (1992) looked initially at asynchronous CHO cells after etoposide 
treatment and found a decrease in cdkl kinase activity and a G2 phase arrest. They 
subsequently studied synchronous cells to facilitate further analysis of the effect of Y15 
dephosphorylation in relation to the decrease in kinase activity. This report suggests that 
the use of synchronised cells would eliminate the difficulties associated with asynchronous 
cells. Ling et al. (1996) demonstrated that doxorubicin-induced G2/M phase arrest in 
synchronised murine leukaemia p388 cells is mediated by deregulation of cdkl kinase 
activity through prevention of Y15 dephosphorylation.
An investigation into the observed G2/M arrest in DLKP cell lines and its association with 
levels of Y15 phosphorylation on cdkl was carried out in an attempt to explain the altered 
G2 response seen in the resistant variants. Two methods of detection were employed to 
detect Y15 in the DLKP cell lines before and after doxorubicin treatment. Initially 
immunoprecipitated DLKP-SQ cells (with anti-cdkl antibody) were probed with anti- 
phosphotyrosine, and the second method involved using a specific anti-cdkl Y15 
antibody. Doxorubicin treatment influenced the levels of Y15 in DLKP-SQ cells (section 
3.6); there seems to be a slight increase in Y15 phosphorylation after drug treatment. This 
reflects the situation seen in the flow cytometry analysis; 45 hours after doxorubicin 
treatment the cells experience a distinct G2/M arrest and Western blotting analysis reveals
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a corresponding increase in Y15 phosphorylation levels compared to controls. The 
control levels of Y15 in untreated cells should remain constant because in an 
asynchronous population of exponentially growing cells, there should be a relatively 
constant number of cells undergoing mitosis at any instant, and this effect was also seen in 
control DLKP-SQ cell extracts.
The resistant variants did not show any changes in Y15 phosphorylation levels after 
doxorubicin treatment. Samples from all four cell lines before and after doxorubicin 
treatment were run on one gel to compare Y15 levels to untreated and drug-treated on 
one gel, a ponceau-stained photograph of the gel is illustrated in figure 3.6.12 for 
comparison in protein loading. When an untreated sample is compared to an extract from 
doxorubicin-treated cells, it can be seen that when the protein loading is taken into 
account, the DLKP-SQ experience a slight increase in Y15 phosphorylation levels, to a 
greater extent than the resistant variants, with an increase of 1.58 when analysed using 
densitometry.
These are the expected results for the resistant variants, when comparing them to the 
results seen by flow cytometrical analysis of cell cycle progression following doxorubicin 
treatment. The resistant cells can bypass the G2/M arrest, therefore the cdkl kinase 
activity should be active in order to allow the cells pass through mitosis and Y15 should 
be dephosphorylated to a similar level as control cells, as was seen in this study.
As already mentioned in section 3.6, one important point for consideration is the 
experimental design. The cells are asynchronous, so at any instant in cycling cells only a 
small percentage of cells would be mitotic, would have active kinase activity and in 
addition possess Y15 phosphorylation. Y15 phosphorylation only occurs during G2 phase 
however. Parker et al. (1992) demonstrated that Y15 is only phosphorylated by weel 
when cdkl and cyclin B are in a complex, and this complex only occurs during G2 when 
cyclin B levels rise above a threshold and bind to cdkl in anticipation of mitosis. Based on 
this theory G2/M arrested DLKP-SQ cells should have a higher Y15 phosphorylation 
level, and the resistant cells which can continue to cycle should have similar levels of Y15 
phosphorylation to untreated asynchronous cells. This assumption is in agreement with
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actual results found in section 3.6. The above findings indicate that the cdkl kinase 
activity is the key component allowing the resistant cells to over-ride the G2/M arrest. 
Therefore further analysis is necessary to elucidate the exact mechanism that effectively 
reduces the levels of Y15 phosphorylation on cdkl and triggers the resistant variants to 
enter mitosis. Further analysis would involve investigation of weel kinase activity and 
cdc25C phosphatase activity to determine their role in the regulation of cdkl kinase
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4.7 Cdkl Kinase Activity
Activation of cdkl kinase requires both cyclin B binding and removal of the inhibitory 
phosphates on cdkl. Alterations in both of these regulatory components may contribute 
to the diminished cdkl activity seen after irradiation or treatment with DNA damaging 
agents. Numerous studies report decreased cdkl kinase activity due to the presence of 
inhibitory phosphates associated with a G2/M arrest induced by such chemotherapeutic 
drugs as doxorubicin (Ling et al., 1996), etoposide (Lock and Ross, 1990) and 
camptothecin (Lock et a l, 1995; Tsao et al., 1992; Shimizu et al., 1995). Particularly 
relevant to this thesis is the study by Ling et al. (1996) on the effects of doxorubicin on 
p53-mutant murine leukaemia P388 cells. Findings indicated that doxorubicin induces a 
G2/M arrest due to a reduction in cdkl kinase activity, as a result of failure to remove the 
inhibitory phosphates on cdkl. In addition cdkl protein levels remained unchanged after 
doxorubicin treatment. In a cell-free system, doxorubicin did not affect in vitro cdkl 
kinase activity indicating that the reduction in kinase activity was not due to a direct drug 
effect on the cdkl enzyme.
Initial attempts to look at cdkl kinase activity of DLKP-SQ and resistant variants before 
and after doxorubicin treatment using the well known radioactive histone HI kinase assay 
were unsuccessful. A level of kinase activity was identified in DLKP-SQ untreated cells, 
but drug treated samples were difficult to interpret due to high background levels and 
seemingly unequal loading of beads, even though equal protein amounts were 
immunoprecipitated. In hindsight, the antibody used to immunoprecipitate cdkl may not 
have been ideal, judging from the high background obtained.
An alternative non-radioactive ELISA-based procedure was then employed to investigate 
the effects of doxorubicin on the DLKP cells in an attempt to discover the mechanism of 
G2/M over-ride in resistant cells. The cdkl kinase assay kit is based on enzyme-linked 
immunosorbent assay (ELISA) that utilises a synthetic peptide which is specifically 
phosphorylated by active cdkl kinase, and a monoclonal antibody recognising the 
phosphorylated form of the peptide.
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DLKP-SQ cells after doxorubicin treatment exhibited an unaltered or slight decrease in 
cdkl kinase activity. The control cells had quite a high kinase activity but this was 
probably due to the asynchronous populations being used in this study. In an 
asynchronous population, at any one instant at least 5% of the cells will be dividing. This 
number could be higher depending on the growth phase of the cells, so they will have a 
certain level of active cdkl kinase activity. Doxorubicin treatment results in a slight 
reduction in kinase activity in DLKP-SQ cells compared to doxorubicin treatment in the 
resistant variants. This result suggests a G2 arrest before entry to mitosis. This result is in 
keeping with previous observations that DLKP-SQ cells arrest in G2/M using flow 
cytometry analysis and the cdkl is phosphorylated on inhibitory Y15. Therefore the arrest 
in the sensitive cells is most likely due to the higher inhibitory phosphorylation on cdkl 
with a subsequent decrease in kinase activity.
The situation in the resistant variants is however quite different. Doxorubicin treatment on 
the resistant variants seems to induce a slightly elevated kinase activity compared to 
untreated controls. The asynchronous resistant variants also have a significant cdkl kinase 
activity before doxorubicin treatment, probably due to a small percentage of these cells 
undergoing mitosis. After drug treatment, a increase in cdkl kinase activity was observed, 
most significantly in the most resistant cell line DLKP-A5F. Taking earlier results into 
consideration, this amplified kinase activity is not due to enhanced cyclin B or cdkl 
protein expression, nor is it due to higher cyclin B-cdkl complex levels. The principle 
factor governing the higher kinase activity in the doxorubicin-treated resistant variants 
may be the unchanging levels of Y15 inhibitory phosphorylation, seen by Western 
blotting. This higher kinase activity in drug-treated resistant cells versus the drug-treated 
sensitive cells must be sufficient to push the cells into mitosis.
Taken together, these results prompted an investigation into mechanisms that control 
cdkl kinase activity. There are a number of possible control points in cdkl activation and 
inhibition; complex-forming ability of cdkl with cyclin B (also cyclin B levels), activity of 
the weel kinase which is responsible for the inhibitory phosphorylation on Y15 and 
activity of cdc25C, the phosphatase responsible for removal of the inhibitory phosphate 
and subsequent activation of the kinase. One other regulatory element possibly involved
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could be CAK (cyclin H-cdk7) which is responsible for the activating phosphate on Thr 
161 of cdkl. Inability of cdkl to form complexes with cyclin B can be precluded from this 
investigation because both sensitive and resistant variants are equally capable of forming 
cyclin B-cdkl complexes after doxorubicin treatment (detailed in section 3.5.3).
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4.8 Analysis of cdc25B and cdc25C phosphatase activity after Doxorubicin 
treatment
An early study by Strausfeld et al. (1991) identified a cdc25 gene product as a novel 
phosphatase that acts directly on cdkl-cyclin B complex to induce its activation by 
removing inhibitory phosphate groups on tyrosine, presumably Y15 in cdkl. Since this 
initial finding, further studies have provided evidence that phosphatase cdc25 plays a key 
role in the activation of cdkl-cyclin B complex by dephosphorylation of cdkl at Y15 
(Kumagi and Dunphy, 1991; Dunphy and Kumagi, 1991). Cdc25 phosphatase is activated 
directly by phosphorylation in mitotic cells, and activation depends on an active cyclin B- 
cdkl complex. When inactive, cdc25 remains underphosphorylated, and becomes active 
through phosphorylation. The cdc25 family comprises three homologues, cdc25A, 
cdc25B and cdc25C, with cdc25B and cdc25C being involved in onset of mitosis. 
Cdc25C plays an important role in maintaining a positive feed back loop; cdc25C is first 
phosphorylated and activated by a small amount of active cyclinB-cdkl. The cdc25C can 
then phosphorylate and activate the cellular pool of cyclin B-cdkl kinase. In this way 
cdc25C can amplify cdkl-cyclin B activity. Cdc25C also plays a role in the G2/M 
checkpoint (Hoffmann and Karsenti, 1994).
The importance of cdc25C in G2/M arrest and checkpoint was revealed by a study that 
demonstrated G2/M arrest due to an inactive cdc25C. O’Connor el al. (1994) found that 
cells arrested in G2/M by nitrogen mustard had very high levels of phosphorylated 
inactive cdkl-cyclin B complexes, and this was due to a failure to activate cdc25C. 
Cdc25C remained in its inactive underphosphorylated form and suppressed activation of 
cdkl kinase and mitosis onset. Barth and Kinzel (1994) reported that reduction in cdc25C 
activity was responsible for G2 delay in synchronised HeLa cells after treatment with the 
phorbol ester TPA. A decrease in cdc25C activity coincided with dephosphorylation of 
the enzyme. Cdc25C of mitotic cells is fully activated through phosphorylation by cdkl 
and this hyperphosphorylated form of cdc25C migrates as a 65 kDa band in SDS gels 
(Hoffmann et a l, 1993), whereas the dephosphorylated cdc25C (inactive) migrates at 
55kDa. From this study, cells arrested in G2 would be expected to have an inactive 
cdc25C and an increase in the 55 kDa form. Cells undergoing mitosis on the other hand
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should have constant levels of active 65 kDa phosphorylated cdc25C. Cdc25B is also 
involved in activation of cdkl in human cells (Hoffmann, pers. commun., Keystone 
Meeting, 1998) and when active is phosphorylated and migrates at 62 kDa in SDS gels, 
and a lower 50 kDa band when inactive, although this is only readily observed in SDS 
gradient gels (pers. commun., Hoffmann, 1998).
The effect of doxorubicin on cdc25C protein expression has previously been investigated 
by Ling et al. (1996) who found that doxorubicin treatment did not affect expression of 
cdc25C compared to control cells. However the activity status of cdc25C was not 
investigated in this study. The expression and activity state of cdc25B and cdc25C 
proteins were investigated in doxorubicin-treated DLKP-SQ in attempt to establish their 
role in the G2/M arrest. Western blotting was carried out to look at protein expression 
levels, and immunoprécipitation followed by Western blotting was utilised to determine 
the phosphorylation state of cdc25C. Immunoprécipitation was carried out to concentrate 
the cdc25C protein, which is present at very low levels in the cell. The expression of 
cdc25B and cdc25C before and after doxorubicin treatment were investigated, and it can 
be concluded from results that doxorubicin had no effect on the level of expression of 
either cdc25B or cdc25C in the DLKP cell lines. This result is similar to the findings by 
Ling et al. (1996).
Hoffmann et al. (1993) and O’Connor et al. (1994) demonstrated that asynchronous cells 
have mostly inactive cdc25C, and migrate at 55kDa with a weak band (sometimes absent) 
at 66kDa, indicative of the small percentage of cells in mitosis in the asynchronous 
population. Using synchronised populations they concluded that cells arrested in G2 phase 
have minimal active cdc25C and migrate in SDS gels at 55kDa with a weak 66kDa band. 
However cells arrested in mitosis have largely active cdc25C and so will migrate in SDS 
gels at 66kDa. These findings are illustrated in figure 4.2.
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Figure 4.2 Mobility of cdc25C in SDS gels
With these observations in mind, the phosphorylation state of cdc25C was investigated in 
the DLKP cells before and after doxorubicin treatment, using immunoprécipitation 
followed by western blotting. Results show no differences in phosphorylation of cdc25C 
in control compared to drug-treated DLKP-SQ, DLKP-A250 10p#7, DLKP-A2B or 
DLKP-A5F ceËs, thus questioning the role of altered cdc25C as a possible mechanism for 
the G2/M override seen in the resistant variants.
In putting these results in context it should be remembered that the DLKP cells are 
asynchronous so the cells are in different stages of the cell cycle and this will immediately 
reduce the clarity of the specific 55kDa or 66kDa bands that would be seen if the entire 
population were in interphase or mitosis, respectively, i.e. a synchronous population. It 
was expected that asynchronous control cells would be mainly in interphase and are 
represented by a 55kDa band, with a small proportion in mitosis, as seen by a faint 66kDa 
band. Resistant variants that over-ride the G2/M arrest following drug treatment begin to 
accumulate in G2, and then a small percentage enter mitosis, so this situation would also 
be represented by a strong 55kDa band (G2 cells) and a faint 66kDa (mitotic cells) band. 
A strong 66kDa and 55-57kDa band were detected in all four cell lines before and after 
doxorubicin treatment. The band intensity for resistant cells is equal and does not alter 
following doxorubicin treatment. Perhaps a different experimental setting utilising 
synchronous DLKP populations might reveal more distinct alterations in the sensitive 
compared to resistant variants.
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4.9 W eel involvement in DLKP response to doxorubicin
Initial studies in fission yeast by Paul Nurse identified weel as a gene that controlled the 
onset of mitosis (Nurse and Thuriaux, 1980), and weel could effectively prevent entry to 
mitosis in fission yeast (Russell and Nurse, 1987). The weel gene in fission yeast encodes 
a protein kinase with serine-, threonine- and tyrosine phosphorylating activities (Parker et 
al. 1993), but the human homologue, weelHU encodes a tyrosine-specific protein kinase 
(Parker and Piwnica-Worms, 1992). The human homologue directly inhibits the cdkl- 
cyclin B complex by phosphorylating cdkl on Y15, and this inhibition can be reversed by 
human cdc25C (McGowan and Russell, 1995; Parker and Piwnica-Worms, 1992). Weel 
is negatively regulated by the mitotic induced Niml kinase, which phosphorylates weel 
and inactivates it (Parker et al. 1993). When weel is phosphorylated, its ability to 
phosphorylate cdkl on Y15 is inhibited; therefore Niml kinase can promote mitosis by 
inactivating weel kinase (Wu and Russell, 1995).
Weel is thought to co-ordinate the transition between S phase and mitosis by inhibiting 
any cdkl in the nucleus until G2/M, when cyclin B and cdc25C enter the nucleus in 
preparation for mitosis onset (Heald et al. 1993). Watanabe et al. (1995) revealed that in 
human cells weel activity is increased during S and G2 phases, and during mitosis weel 
activity is strongly suppressed through transient hyperphosphorylation, coinciding with 
the activation of cdkl kinase. Therefore negative regulation of weel is required for cdkl- 
cyclin B activation to occur through the action of cdc25C (McGowan and Russell, 1995). 
It has been reported that during G2 arrest, weel activity increases, and an abrogation of 
this G2 arrest was associated with a decrease in weel protein levels and a lower weel 
kinase activity. The possibility that this situation may also occur in DLKP cell lines 
displaying a G2 override prompted investigation of weel in the DLKP cell lines.
The levels of weel protein were examined in DLKP-SQ, DLKP-A250 10p#7, DLKP- 
A2B and DLKP-A5F to determine if a decrease in weel protein was associated with the 
resistance in these cells. The fact that resistant cells can override the G2 arrest suggested 
that perhaps the higher cdkl kinase activity may be due to lower weel levels, However 
this was not the case. Both sensitive and resistant DLKP cells have similar weel
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expresssion.
Weel activity is decreased by phosphorylation, and this can be visualised by an altered 
mobility on SDS gels. Therefore the activity of weel in DLKP-SQ, DLKP-A250 10p#7, 
DLKP-A2B and DLKP-A5F was investigated before and after doxorubicin treatment 
using immunoprécipitation followed by Western blotting. In DLKP-SQ, both treated and 
untreated cells possess an active weel, as seen by the unchanging 94kDa band, but 
inactive weel is also present as the upper band. However this upper band seems to 
decrease over time after doxorubicin treatment in DLKP-SQ, suggesting a decrease in 
inactive weel with perhaps a concomitant increase in active weel. The doxorubicin- 
treated cells are arrested in G2, when weel activity should be high, so the elevated weel 
activity may be necessary to maintain the inactivation of cdkl kinase and G2 arrest.
Again the problem of using asynchronous cells arises here; the control cells also have 
active weel, presumably due to inhibition of mitosis during interphase, so it is difficult to 
distinguish between the G2-arrested population and the asynchronous population. In 
earlier discussion it was mentioned that the arrested cells have higher levels of Y15 
phosphorylation, so it was speculated that the arrested cells would have a higher levels of 
active weel responsible for this inhibitory phosphorylation, and the immunoprécipitations 
of weel in DLKP-SQ seem to agree with this. A weel kinase assay, which directly looks 
at its kinase activity in vitro could be used to confirm this observation.
The DLKP resistant variants exhibited similar levels of 94kDa weel compared to 
untreated controls, indicating that the activity was similar before and after drug treatment. 
It was seen earlier that resistant variants had similar amounts of Y15 phosphorylation on 
cdkl before and after doxorubicin treatment, indicating that weel may be active to an 
equal extent. Inhibition of weel activity was not observed using immunoprécipitation and 
altered mobility; such inhibition might have been anticipated in the resistant variants since 
they can override the G2/M arrest. Perhaps the level of inhibition was below the 
sensitivity of detection on the western blots, especially given that the population was 
asynchronous. A definitive conclusion could be obtained by using an in vitro weel kinase 
assay to directly measure the kinase activity of weel.
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4.9.1 Other mechanisms responsible for G2/M override
Investigations into the levels and activity of the principal cdkl regulators, cdc25C and 
weel failed to provide a complete explanation of the mechanism of G2 override in the 
DLKP resistant variants. Another possible mechanism is that involving localisation of 
cyclin B during the cell cycle, perhaps cyclin B in resistant variants have altered 
localisation during G2 arrest promoting cdkl-cyclin B kinase activity and entry to mitosis.
Entry to mitosis can be regulated by the subcellular localisation of cdkl-cyclin B. During 
late S and G2 cyclin B accumulates in the cytoplasm due to a specific sequence in its N- 
terminus called a cytoplasmic retention signal (CRS) (Pines and Hunter, 1994). Cyclin B 
contains in its CRS a nuclear export signal (NES) which can mediate nuclear export of the 
protein. At the onset of mitosis cyclin B-cdkl complexes are shuttled to the nucleus 
where they can act on substrates that promote mitosis. Therefore the exclusion of cyclin 
B-cdkl from the nucleus until mitosis acts as a control mechanism to limit its effects 
before mitosis. Cyclin B with a defective NES is restricted to the nucleus, and inhibition of 
NES-mediated transport can result in accumulation of cyclin B in the nucleus.
In response to DNA damage and a G2 arrest, cyclin B accumulates in the cytoplasm 
(Smeets et al. 1994; Toyoshima et al. 1998) and this exclusion of cyclin B from the 
nucleus may possibly prevent cells from entering into premature mitosis in G2-arrested 
cells. To test this hypothesis, Toyoshima et al. (1998) developed a mutant cyclin B with a 
disrupted NES (i.e. cyclin B cannot be exported from the nucleus) and found that in the 
presence of caffeine (caffeine alone did not abrogate the etoposide-induced G2 arrest in 
this case) the G2/M arrest was abrogated. Treatment of cells possessing normal cyclin B 
with the NES inhibitor leptomycin B also resulted in an abrogation of the etoposide- 
induced G2/M arrest, but again only in the presence of caffeine. The requirement of 
caffeine suggests that there might be other mechanisms active in the DNA damage- 
induced G2 checkpoint. In agreement with this report Jin et al. (1998) observed that 
nuclear targeting of cyclin B was effective in overcoming DNA damage-induced G2 
arrest, and the G2 arrest was almost completely abrogated.
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Taking these observations into consideration, it is plausible that a similar situation may be 
partly responsible for the doxorubicin-induced G2 arrest override seen in DLKP-A250 
10p#7, DLKP-A2B and DLKP-A5F. It may be possible that the resistant variants have 
altered NES sequences in their cyclin B protein, that restricts the protein to the nucleus 
after doxorubicin-induced DNA damage, resulting in the activation of cdkl kinase and 
consequently onset of mitosis. The sensitive DLKP-SQ, on the other hand, could perhaps 
actively export cyclin B from the nucleus following doxorubicin treatment, and thus 
premature activation of cdkl kinase cannot occur. This hypothesis would explain the 
higher cdkl kinase activity seen in the resistant variants following doxorubicin treatment, 
given that differences in activation of cdc25C phosphatase and weel kinase could not be 
detected.
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4.9.2 Chemotherapy effects - links between apoptosis and cell cycle
Since many chemotherapeutic agents that induce apoptosis also affect and perturb cell 
cycle progression, apoptosis may be linked to the cell cycle proteins affected during drug 
treatment. Numerous studies implicate inappropriate activation of cyclin B-cdkl in 
apoptotic cell death following treatment with anticancer agents.
Preliminary studies by Lock and Ross (1990) demonstrated a decrease in inhibition of 
cdkl kinase activity during an etoposide-induced G2 arrest, and an increase in cdkl 
kinase activity during the period in which cells underwent apoptosis. Shimizu et al. (1995) 
reported an unscheduled activation of cdkl kinase which was correlated with the DNA 
damage-induced apoptosis in leukaemia cells. Cdkl kinase activity transiently increased 
following camptothecin treatment and then rapidly decreased during onset of mitosis. Shi 
et al. (1994) demonstrated that premature activation of cdkl was required for apoptosis 
to occur, by using temperature-sensitive mutants, but Martin et al. (1995) concluded that 
cdkl activation was not required for apoptosis to occur, but may be a consequence of 
apoptosis. Furthermore Yao et al. (1996) demonstrated that cdkl kinase is a critical 
determinant of cell death mediated by Fas and caspases, and that Fas-induced apoptosis 
induced caspase activity as well as cdkl activation. Taxol treatment of HeLa cells also 
induced cdkl kinase activity which did not correlate with the timing of the G2/M arrest 
observed, but coincided with the onset of apoptosis (Donaldson et al. 1994).
There have also been reports linking cyclin A with apoptosis. Upregulation of mRNA 
levels and activation of cyclin A-cdkl occurred during apoptosis (Meikrantz el al. 1994; 
Hoang et al 1994). A study by Huang et al. (1997) revealed an increase in cdc25C 
phosphatase activity as the responsible factor for an inappropriate activation of cdkl 
during apoptosis induced by a podophyllotoxin.
Taken together, these reports generally implicate cdkl kinase as having a role in 
apoptosis, although this may be an essential or consequential one. The substrates acted on 
by cdkl kinase during mitosis are usually structural components of the cytoskeleton, 
which must be fragmented in order for cytokinesis to occur during mitosis, but these
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substrates may also be acted upon in apoptosis to promote structural degradation of the 
cells. However, the significance of this in the apoptotic process still remains 
undetermined.
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4.10 Cellular effects of chemotherapy and implications for resistance 
development
Treatment of cancer with chemotherapeutic drugs frequently results in the development of 
multiple drug resistance (MDR), in which the tumour cells exhibit resistance to a wide 
range of structurally and functionally unrelated chemotherapy drugs. In many cases the 
MDR phenotype is mediated by P-glycoprotein (Pgp). Pgp is 170kDa plasma membrane 
protein and is an energy-dependent pump with ability to transport cytotoxic agents out of 
the cell, resulting in reduced intracellular concentrations of drug and failure of the drug to 
reach an intracellular target. However recent identification of other mechanisms of drug 
resistance such as MRP and LRP demonstrate the ability of a tumour to adapt to diverse 
cytotoxic stimuli.
There is a lot of evidence that chemotherapeutic drugs, radiation and other clinically 
relevant therapies can induce apoptosis in their cellular targets. Any disruption of this cell 
death pathway may contribute to a failure to undergo apoptosis, resulting in continued 
proliferation, ultimately leading to tumour progression and metastasis. If tumour 
progression selects for apoptosis resistance, it is conceivable that apoptosis resistance may 
be an important cause of drug resistance.
Studies by Frankfurt et al. (1994) and Kataoka et al. (1994) demonstrated that cells with 
drug resistance, following exposure to a variety of cytotoxic agents, exhibit resistance to 
drug-induced apoptosis. Therefore deregulation of the apoptotic response may be an 
important evolutionary occurrence in development of drug resistance in tumours. 
Furthermore Landowski et al. (1997) reported that selection of CEM and human 
myeloma cells for drug resistance results in resistance to apoptosis mediated by the CD95 
system. These results indicate that as tumour cells develop mechanisms of drug resistance, 
they also develop mechanisms of resistance to physiological signals for apoptosis.
The Bcl-2 family is critically involved in the modulation of the apoptotic response, as 
described in section 1.5.9. Selection of tumour cells with chemotherapeutic drugs often 
results in modification of antiapoptotic Bcl-2 family members. Overexpression of Bcl-2
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can interfere with diverse triggers for apoptosis, including chemotherapeutic drugs and 
radiation. Ibrado et al. (1996) demonstrated that overexpression of Bcl-XL can interfere 
with caspase-3 activation.
4.10.1 P-glycoprotein levels in DLKP cell lines
Expression of p-glycoprotein (Pgp) in cells is closely associated with the
development of multiple drug resistance (MDR). Cells that overexpress Pgp 
frequently exhibit the MDR phenotype, becoming resistant to a wide variety of 
structurally unrelated and mechanistically distinct chemotherapy drugs. The resistant 
DLKP cell lines used in the work described in this thesis were originally selected for 
resistance by a pulsed (DLKP-A250 10p#7) or a continuous (DLKP-A2B, DLKP- 
A5F) stepwise increased exposure to doxorubicin. Extensive characterisation has 
revealed MDR characteristics in these cell lines, including overexpression of Pgp 
(Heenan e t a l ,  1998; NicAmhlaoibh el al. 1999).
The resistance in the DLKP cells can be overcome by interfering with the efflux 
activity of Pgp using the calcium channel blocker, verapamil. The principal mode of 
action of verapamil is through inhibition of the binding of various chemotherapeutic
drugs to Pgp. Verapamil can effectively block Pgp activity, resulting in higher
intracellular drug concentrations capable of reaching the cellular target, ultimately 
leading to a restoration of original sensitivity in the cells. Other Pgp blockers such as 
MRK-16 and UIC2 are anti-Pgp antibodies which can bind to and inhibit the action 
of Pgp.
Western blotting analysis detailed in section 3.10.1 investigated levels of Pgp in 
DLKP-SQ, DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F. DLKP-SQ cells do 
not express detectable levels of Pgp. This result is as expected because these are a 
sensitive clonal population isolated from the sensitive parental population (McBride 
et al., 1997). DLKP-A250 10p#7 express low levels of Pgp, and DLKP-A2B and 
DLKP-A5F express higher levels of Pgp. The difference in expression of Pgp
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between the DLKP-A250 10p#7 and DLKP-A2B/DLKP-A5F correlates with the 
levels of resistance of these cells lines to doxorubicin. The DLKP-A2B and DLKP- 
A5F display much higher resistance levels than the DLKP-A250 10p#7, and this is 
mainly conferred through their higher Pgp expression. However, DLKP-A5F are 
100-fold more resistant than DLKP-A2B, yet both express a comparable level of Pgp 
as detected by Western blot, so there is not an exact correlation between the P-170 
protein levels and the resistance to doxorubicin. This discrepancy suggests that there 
must be alternative resistance mechanisms in the DLKP-A5F cell line to account for 
the increased resistance without an accompanied increase in Pgp expression. It is 
possible that these alternative resistance mechanisms also occur in the DLKP-A250 
10p#7 and DLKP-A2B, but the Pgp-mediated resistance probably overshadows any 
other mechanisms present. Further analysis of the apoptotic pathway should identify 
any alterations that exist in the three resistant variants compared to the sensitive 
DLKP-SQ.
Smyth et al. (1998) investigated the possibility that Pgp may, in addition to its drug 
transport function, generally inhibit cell death. They demonstrated that Pgp could 
specifically inhibit caspase activity and apoptosis in drug-selected CEM cell lines that 
expressed Pgp. Inhibition of Pgp with verapamil or MRK-16 restored cleavage and 
activation of procaspase-3 on addition of an apoptotic stimulus. Furthermore cells 
expressing Pgp were resistant to CD95-mediated apoptosis, but this resistance was not 
due to a defect in the CD95 pathway given that resistant cells did not have alterations in 
CD95 receptor. Resistance to CD95-mediated apoptosis could be reversed by inhibiting 
Pgp function with verapamil or MRK-16. Caspase-independent forms of cell death such 
as perforin-induced apoptosis were not inhibited by Pgp. These results suggest that at 
least in some cell backgrounds, caspase-dependent apoptotic pathways may in some way 
be inhibited by Pgp function.
Recently this study was extended by Johnstone et al. (1999) to demonstrate that the 
protective effect of Pgp was not restricted to drug-selected cells. Pgp was introduced by 
retroviral transfer of the MRD1 gene. Drug-selected and retroviral-transduced Pgp+/ cells 
were resistant to CD95-mediated, caspase-dependent DNA fragmentation and membrane
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lysis. They were also resistant to UV-irradiation and TNF-mediated apoptosis. Yet when 
Pgp action was inhibited by verapamil or MRK-16, the cells were rendered sensitive to 
apoptosis induced by these stimuli. Several possible mechanisms of antiapoptotic action of 
Pgp have been suggested; It is possible that Pgp presence may alter intracellular ATP 
levels, ATP is a critical component required for caspase-9 activation (Li el al. 1997). Pgp 
is an ATPase, so perhaps it acts by decreasing the intracellular ATP pool to below a level 
sufficient for caspase-9 activation. However the Pgp inhibitor verapamil may also 
decrease intracellular ATP levels perhaps by increasing the ATPase activity of Pgp 
(Ambudkar et al. 1992; Broxterman et al. 1988), so perhaps this hypothesis is not 
feasible. Another theory stems from the fact that Pgp expression is associated with 
intracellular alkalisation (Thiebaut et al. 1990), but apoptosis induced by 
chemotherapeutics, UV-irradiation, serum starvation and CD95-ligation is preceded by 
cellular acidification (Gottleib et al. 1996; Li et al. 1995). DNA laddering can be 
prevented by increasing intracellular pH (Sarin et al. 1997). Furthermore cells can be 
made resistant to CD95-mediated or serum staivation-induced apoptosis by increasing 
intracellular pH (Robinson et al. 1997; Gottleib et al. 1996). Therefore it is possible that 
Pgp alters intracellular pH, and inhibits caspase activity, causing the cell to become 
resistant to caspase-dependent apoptosis. In support of this theory, verapamil has been 
shown to cause acidification in Pgp-expressing cells, thus lowering pH sufficiently to 
allow caspase activation and apoptosis to occur (Robinson et al. 1997).
4.10.2 Toxicity of doxorubicin in DLKP cell lines
The anthracycline doxorubicin was used throughout this thesis to treat the four DLKP 
cells lines in question, and its level of toxicity varies between cell lines. DLKP-SQ are 
most sensitive being a clonal population isolated from the parental DLKP (McBride et al. 
1998). DLKP-A250 10p#7 are approximately 3-fold resistant compared to DLKP-SQ. 
When DLKP-A250 10p#7 were isolated they were determined to be 8-10 fold resistant 
compared to DLKP-SQ, but a different experimental setting was used; 96-well plate 
format and toxicity determined after 7 day drug-exposure. In these studies toxicity 
profiles were carried using a 2 hour doxorubicin pulse in 25 cm2 flasks and toxicity
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determined after 72 hours, so the difference in fold resistance must be due to the 
differences in experimental conditions. DLKP-A2B were approximately 45-fold resistant 
and DLKP-A5F were 150-fold resistant to DLKP-SQ, compared to 30-fold and 100-fold 
resistant to DLKP in 96-well plates (Heenan et al. 1998). Toxicity was determined after 
72 hours because the effect of doxorubicin on the DLKP cell lines was monitored over 72 
hours. Drug treatment induces cellular alterations in two parallel pathways, in the cell 
cycle and also in apoptosis induction. Therefore the effects of doxorubicin on the DLKP 
cell lines was investigated in respect to apoptosis induction over the same period of time.
4.10.3 Doxorubicin accumulation in DLKP cell lines
Drug resistance can alter drug uptake and cellular accumulation, and reduced cellular 
accumulation is often an indicator of drug resistance. Doxorubicin accumulation was 
investigated in DLKP-SQ, DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F to 
determine if the drug accumulation correlated with the resistant state of the cells. Sensitive 
cells can accumulate doxorubicin in their nuclei, as is seen in DLKP-SQ, and the 
doxorubicin can exert its cytotoxic effects resulting in chromatin condensation and nuclear 
fragmentation, a hallmark of apoptotic cells. The resistant variants accumulate less 
doxorubicin, and it is restricted to the cytoplasm of these cells. However the drug 
concentration used in the resistant cells was much higher than for DLKP-SQ, and is 
capable of inducing apoptosis. This was clearly seen in the resistant cells that were unable 
to withstand such a high drug insult and apoptosis occurred. This data indicates that an 
important mechanism of resistance in the DLKP-A250 10p#7, DLKP-A2B and DLKP- 
A5F is mediated through decreased intracellular drug accumulation, but this does not 
exclude the possibility of alternative resistance mechanisms being active also.
4.10.4 Toxicity of 5-FU and serum starvation to DLKP cells
The toxicity of 5-FU on DLKP-SQ, DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F 
was also investigated. 5-FU is not transported by Pgp, and therefore resistance to 5-FU is
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not associated with the Pgp status of the cell, but is due to alternative mechanisms of 
resistance. The resistant cell lines are equally sensitive as DLKP-SQ to 5-FU treatment, 
indicating the existence of an identical apoptotic pathway in these cell lines that is 
triggered by 5FU. However the effects of serum starvation reflect a different apoptotic 
induction pathway. DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F are more resistant 
to apoptosis induced by serum starvation than DLKP-SQ and results were shown in 
figure 3.10.5. Even though the extent of resistance is quite low, it is nevertheless 
significant and demonstrates that the resistant variants may have apoptotic resistance 
mechanisms other than Pgp-mediated resistance. In support of this finding, Robinson et 
al. (1997) reported that expression of the MDR1 gene in Chinese hamster ovary 
fibroblasts was associated with resistance to apoptosis induced by serum starvation. Pgp 
must therefore be involved in additional mechanisms that promote the survival of cells.
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4.11 Kinetics of Apoptosis in DLKP cell lines
Doxorubicin treatment results in a G2/M arrest and apoptosis in the DLKP-SQ cell line. 
The resistant variants have an altered cell cycle response to doxorubicin, as was discussed 
in preceding sections, but the resistant variants still retain the ability to undergo apoptosis. 
Apoptosis was characterised by the apoptotic morphology seen using time-lapse 
videomicroscopy. The typical events were rounding up of the cell, chromatin 
condensation, membrane blebbing and break up into apoptotic bodies. Many 
chemotherapeutic drugs such as melphalan, cisplatin and 5-fluorouracil induce apoptosis 
in cultured cell lines (Huschtscha et al. 1996). Doxorubicin has previously been reported 
to induce apoptosis in tumour cells by Sklandowski and Konopa (1993). All four DLKP 
cell lines undergo apoptosis after Doxorubicin treatment but with varying rates of 
apoptosis. As previously mentioned equitoxic doxorubicin concentrations are being used 
to induce apoptosis in the cells. This treatment was chosen so that an equivalent situation 
is present in each of the cell lines, that allows direct comparison to each other. The rate 
and extent of apoptosis depends on the drug concentration used and exposure time, this 
can be seen in figure 3.11.1 with DLKP-SQ cells.
Barlogie et al. (1976) previously demonstrated that doxorubicin has concentration- 
dependent effects on cells. A high doxorubicin concentration of 5pg/ml continuous 
exposure results in rapid induction of apoptosis with 50% of the cells dead within 5 hours, 
compared to a lower concentration of 0.6^g/ml, for a 2 hour exposure which resulted in a 
much slower rate of apoptosis with 1 % dead at 5 hours and 60% by 72 hours. DLKP- 
A250 10p#7 cells, when treated with 1 (ig/ml doxorubicin for 2 hours have a slow initial 
rate of apoptosis similar to DLKP-SQ (when treated with 0.6pg/ml Doxorubicin), a small 
percentage of cells die by 5 hours, but by 72 hours 48% apoptosis has occurred. In 
contrast DLKP-A2B have a rapid induction of apoptosis with up to 25% cells dead by 5 
hours, the rate slows at 12 hours when 60% cells have died. DLKP-A5F cells also have a 
high initial rate of apoptosis for the first 10 hours after which time it levels off. An 
important finding here was the occurrence of mitosis after doxorubicin treatment in the 
three resistant variants, DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F, and absence of 
mitosis in the sensitive DLKP-SQ. It was this unusual observation that prompted the
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subsequent detailed investigation into the doxorubicin-induced G2/M arrest in DLKP cell 
lines. Mitotic events occurred concurrently with apoptosis in all of the resistant variants, 
and a high percentage of the resulting daughter cells underwent apoptosis, a phenomenon 
previously reported as post-mitotic apoptosis by Vidair et al. (1996). It seems as if cells 
are pushed into mitosis with incompletely repaired DNA after doxorubicin treatment, and 
then cannot survive with defective DNA so undergo apoptosis, perhaps contributing to 
the genetic instability of the cells..
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4.12 Morphological Features of Apoptosis in DLKP-SQ cells
It was seen in section 3.11 that DLKP-cells readily undergo apoptosis after Doxorubicin 
treatment. The induction of apoptosis was further investigated in section 3.12 in which 
morphological and biochemical features were examined.
4.12.1 DNA fragmentation in DLKP-SQ
During the effector phase of apoptosis, genomic DNA is cleaved between nucleosomes, 
thus forming 180bp fragments, the size of DNA between one nucleomsome and the next. 
Caspase activity has been linked to this fragmentation. DNA fragmentation factor (DFF) 
or ICAD usually exists in an inactive form but during apoptosis caspases can cleave 
DFF/ICAD, and once cleaved its protease action on DNA is unleashed resulting in DNA 
cleavage (Liu et al. 1997). DNA fragmentation into nucleosomal fragments is one of the 
most recognisable biochemical features of apoptosis (Wyllie, 1980). Detection of 
intemucleosomal DNA fragmentation is widely used as one of the hallmarks of apoptosis. 
However in some cases DNA fragmentation may not occur during apoptosis, but this is 
dependent on the situation; the cell lines used and the apoptosis-inducing drug 
(Huschtscha et al. 1996).
Daunorubicin induced apoptosis along with DNA fragmentation in DLKP-SQ cells when 
used at concentrations from lpg/ml to lOpg/ml, control cells did not give a DNA ladder. 
Daunorubicin has previously been shown to induce intemucleosomal DNA fragmentation 
in acute myeloid cell lines such as HL-60 (Quillet-Mary et al. 1996). However 
doxorubicin-induced DNA fragmentation was not investigated in DLKP cell lines. DNA 
fragmentation was also analysed in the DLKP cells after doxorubicin treatment using 
TUNEL staining to detect the fragmented DNA. DNA fragmentation occurs in DLKP- 
SQ, DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F after doxorubicin treatment. The 
extent of DNA fragmentation varies with the rate of apoptosis, it can be seen that DLKP- 
A2B have quite a lot of DNA fragmentation at 24 hours compared to DLKP-SQ, 
reflecting the differences in apoptotic rates seen in timelapse videomicroscopy.
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4.12.2 Phosphatidylserine exposure in DLKP-SQ cells during Doxorubicin- 
induced apoptosis
Phosphatidylserine is a membrane phospholipid that normally localises on the internal 
surface of cellular plasma membranes, and is transported to the outer membrane of 
apoptotic cells (Fadok et al. 1992).
Phosphatidylserine expression during apoptosis was demonstrated in section 3.12 using 
annexin V staining. This is further evidence for an intact apoptotic mechanism in DLKP- 
SQ cells. Only a small percentage of cells stained with annexin V as illustrated in figure 
3.12.3.2, but this was expected because phosphatidylserine externalisation is a transient 
event in the apoptotic induction pathway. The same field of cells under white light 
identified which cells in the population have externalised phosphatidylserine. It can be 
seen from figure 3.12.3.2 that the cells positive for annexin V have not lost their 
membrane integrity, compared to some apoptotic cells in the field which have no annexin 
V staining. This has been previously been reported by Koopman et al. (1994), Gudas et 
al. (1986), and more recently by Martin et al. (1996) who looked at Jurkat cell apoptosis 
and found that loss of membrane integrity only occurred 8-12 hours after 
phosphatidylserine detection on the outer membrane of the plasma membrane. Recently 
Naito et al. (1997) demonstrated that phosphatidylserine externalisation is a downstream 
event of caspase activation during apoptosis in U937 cells, and its externalisation 
coincides with caspase activation. Pervaiz et al. (1998) provided further evidence for this 
in a study demonstrating that caspase-3 inhibition results in inhibition of 
phosphatidylserine externalisation. Thus phosphatidylserine externalisation is closely 
linked to caspase activation, and the fact that it occurs in DLKP-SQ cells undergoing 
apoptosis is evidence of active caspases in these cells.
256
4.13 Role of caspases in Doxorubicin-induced apoptosis in DLKP
It is now apparent that caspases play an important role in apoptosis. The initial discovery 
by Yuan et al. (1993) that ICE had high homology to the CED-3 proteins in C. elegans 
led to the identification of fourteen proteins constituting the caspase family. Caspases are 
synthesised as proenzymes and are activated by proteolytic cleavage, which generates two 
fragments of « 20 kDa and « 1 0  kDa. At present (as discussed in section 1) evidence 
exists for several specific pathways in which caspases exert their proteolytic activity 
resulting in the destruction of the cell. These proposed pathways comprise a cascade of 
caspases and caspase substrates, which can be caspases or other cellular proteins. There is 
a possibility that all caspases may be expressed in apoptotic cells but as to whether all of 
these participate in apoptotic events or not is currently under investigation.
Numerous reports demonstrate specific caspase activation during apoptosis and caspases 
activated vary according to cell line and apoptotic stimulus. Greidinger et al. (1996) 
reported three distinct ICE-like activities in Jurkat cells induced to undergo apoptosis by 
Fas ligation, and the differences were based on the substrate cleavage and distinct 
inhibition profiles. Martins et al. (1997) investigated activation of caspases during 
etoposide-induced apoptosis in HL-60 cells and discovered multiple active caspases with 
structural homology to caspasel (ICE) and these caspases had distinct enzyme activities. 
They also reported caspase-3 activation during etoposide-induced apoptosis whilst pro­
enzyme levels of caspase-1 and caspase-2 did not decrease, implying that caspase-3 is 
selectively activated in HL-60 cells in etoposide-induced apoptosis even though other 
caspases are present in their pro-enzyme form. Polverino and Patterson (1997) examined 
caspase activation in HL-60 cells and found that caspase-3 is selectively activated during 
apoptosis in HL-60. More recently Grossmann et al. (1998) demonstrated presence of 
pro-caspase-1, -10,-6 and -3 in normal epithelial cells, and selective sequential activation 
of caspase-6 and caspase-3 during apoptosis. Based on these reports it was important to 
determine which caspases are present in DLKP cell lines, and to characterise their 
activation in doxorubicin- induced apoptosis.
A further incentive to investigate caspase activation in DLKP cell lines comes from recent
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reports linking caspase deficiency with drug resistance. Los et al. (1997) investigated 
defects in caspase-3 activation in Fas-resistant and doxorubicin-resistant CEM cell lines. 
They found defective caspase-3 activation in both cell lines after Fas ligation implying that 
defective activation of caspases could be a mechanism to overcome drug resistance. 
Nagane et al. (1998) recently reported that suppression of cisplatin-induced apoptosis 
was mediated by overexpression of Bcl-XL and inhibition of caspase-3 activity in cisplatin- 
resistant cell lines. Kojima et al. (1998) also investigated cisplatin resistance and 
subsequent caspase activation during cisplatin-induced apoptosis in a human SCC-25 
squamous carcinoma cell line. They found that resistance to apoptosis could be mediated 
by deficient caspase-3 activation. The resistant variant of SCC-25 overexpressed Bc1-Xl 
and there was no detectable cytochrome c release. U937 cells which were resistant to 
doxorubicin were also resistant to cisplatin-induced apoptosis and were shown to have 
Bc1-Xl overexpression, high Pgp levels and deficient caspase-3 activation (Kojima et al. 
1998).
Analysis of caspase expression was carried out using western blotting on cellular extracts 
taken before and after doxorubicin treatment. It is important to remember that active 
caspases have a short half-life in the cell, and therefore it can be difficult sometimes to 
pick up active fragments of caspases. Sometimes researchers use cell extracts and induce 
caspase activation in vitro, and monitor caspase activation by 35S-methionine 
incorporation followed by electrophoresis and autoradiography which effectively detects 
the fragmented protein, and perhaps this technique would clarify the results obtained 
using western blotting.
Caspase-2
Caspase-2 was originally identified as Nedd2, a homologue of a mouse gene that when 
overexpressed, induces apoptosis in mammalian cells (Kumar et a l 1994). Caspase-2, 
because of its long prodomain and its similarity to caspase-9, may play a role in apoptotic 
induction. Susin et al. (1999) recently reported caspase-2 release from the mitochondria, 
along with caspase-9 release during the apoptotic process. They found an increase in 
processed caspase-2 in the cytosol of apoptotic cells, therefore caspase-2 may actively 
participate in the apoptotic process.
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Caspase-2 involvement in Doxorubicin-induced apoptosis in DLKP-SQ was investigated 
in section 3.13.1 using a mouse monoclonal antibody (Transduction Laboratories). There 
was no reduction in the proform of caspase-2 over 50 hours as cells were undergoing 
apoptosis. Similar results using the same antibody were found by Polverino and Patterson 
(1997) in that they could not detect a decrease in procaspase-2 during induction of 
apoptosis in HL-60 cells. However when they used a different antibody from Santa Cruz 
Inc., they did observe a decrease in procaspase-2 with a corresponding increase in a 
12kDa fragment, but the results were ambiguous due to the non-specific cross-reactivity 
of the Santa Cruz antibody. Results seem surprising in that no detectable levels of 
procaspase-2 were found in DLKP-A2B and barely detectable levels in DLKP-A5F 
compared to DLKP-SQ, but in subsequent Western blots, low levels of procaspase-2 
were detected in the resistant variants. In the less resistant DLKP-A250 10p#7 low levels 
of procaspase-2 were detected compared to DLKP-SQ, but nevertheless higher than in 
DLKP-A2B and DLKP-A5F.
Caspase-3
Resistant variants have lower caspase-3 protein expression levels than DLKP-SQ, and the 
reduction is most notable in the most resistant cells DLKP-A2B and DLKP-A5F. In 
section 3.13.2 caspase-3 proenzyme levels in DLKP-SQ were examined over time 
following Doxorubicin treatment. It can be seen that there is no caspase-3 processing in 
either DLKP-SQ or DLKP-A250 10p#7. When procaspase-3 levels are compared in the 
four cell lines before and after drug treatment, procaspase-3 levels do not change, 
following a similar trend to procaspase-2 levels. These results are completely unexpected 
given that the majority of reports published implicate caspase-3 activity in apoptosis. 
DNA damaging agents such as Ara-C, cisplatinum, etoposide, camptothecin (Datta et 
al., 1996), CPT-II (Suzuki et al., 1996) and MC540 (Pervaiz et al., 1998) have been 
shown to activate caspase-3 activity. One explanation for this is that if procaspase-3 is 
expressed in abundance and caspase-3 processing and activation occurs at a minimal level, 
then the high levels of pro-caspase-3 could mask any slight decrease in pro-caspase-3 
which therefore may not be detected on Western blots. The antibody used to detect 
caspase-3 does not pick up the processed form of the enzyme, so a reduction in
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proenzyme levels is the only available measure of enzyme processing. Simizu et 
al.( 1998) recently demonstrated the requirement of caspase-3 for apoptosis 
(mediated by hydrogen peroxide production) induced by camptothecin, vinblastine, 
inostamycin and adriamycin. Keane et al. (1997) have also shown that caspase-3 
activity is essential for apoptosis to occur after staurosporine treatment in 
astrocytoma and neuronal cells. Therefore the situation in DLKP cells is very 
unusual; i.e. the cells can apparently undergo apoptosis without activation of 
caspase-3. Nagane et al. (1998) demonstrated suppression of caspase-3 activity in 
drug resistant human glioblastoma cells. Cisplatin resistant squamous carcinoma cells 
fail to activate caspase-3 when compared to parental cells (Kojima et al., 1998). 
Therefore the resistance of DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F could 
be due in part to the very low levels of expression and failure to activate caspase-3 in 
the cells.
Caspase-7
Caspase-7 shares over 50% sequence similarity with caspase-3 and shares substrate 
specificity (Lippke et al. 1996). Overexpression of caspase-7 can induce apoptosis in 
various cell lines (Duan et al. 1996; Lippke et al. 1996), Fas and TNF can trigger its 
activation resulting in the induction of apoptosis (Duan et al. 1996). Caspase-7 is an 
effector caspase and can be processed by caspase-3 (Fernandes-Alnemri et al. 1995) and 
also by caspase-8 (Muzio et al. 1998). In some cases its involvement in apoptosis is 
implicated rather than caspase-3. During lovastatin-induced apoptosis in the prostate 
cancer cell line LNCaP procaspase-7 mRNA is upregulated, and the proenzyme is 
activated by proteolytic processing, resulting in PARP cleavage and apoptosis while 
procaspase-3 is not activated (Marcelli et al. 1998). Therefore procaspase-7 is capable 
of implementing further downstream events to induce apoptosis, without a 
contribution from caspase-3.
Procaspase-7 protein levels were looked at in the four DLKP cell lines, before and 
after doxorubicin treatment to investigate its possible role in doxorubicin-induced 
apoptosis. Using western blotting it was concluded that there are approximately equal 
levels of procaspase-7 in all four cell lines indicating that sensitive and resistant
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DLKP cells express procaspase-7 to the same extent. The antibody used was raised 
to the p 17 fragment in procaspase-7, and therefore should detect the proenzyme, and 
the active pl7 fragment. Doxorubicin treatment does not induce activation of 
procaspase-7 and there is no reduction in procaspase after doxorubicin treatment in 
any of the cell lines. Furthermore there was no detection of pi7 fragments in the 
drug-treated samples, confirming that procaspase-7 is not activated in doxorubicin- 
induced apoptosis in any of the DLKP cell lines.
Caspase-6
Procaspase-6 is a 40kDa protein which shares some substrate specificity with 
caspase-3. It is a downstream caspase which can be activated by caspase-3 (Orth et 
al., 1996) and caspase-6 is responsible for lamin cleavage during apoptosis (Orth el 
al. 1996) The antibody used should pick up both procaspase and the active 24kDa 
active fragment. There are relatively equal amounts of procaspase-6 in the four 
DLKP cell lines, and after doxorubicin treatment there is no decrease in the 
procaspase-6, and active p24 fragments could not be detected using western blotting. 
These results suggest that caspase-6 is not activated in doxorubicin-induced 
apoptosis in DLKP cell lines, and may not play a role in the apoptotic pathway in 
DLKP cells.
Caspase-8
Caspase-8 plays an important role in the CD95-mediated apoptotic pathway, being 
the first caspase to be activated. It has a unique DED domain, absent in other 
caspases (also present in caspase-10) which allows it to bind directly to FADD, the 
double adaptor protein, linking it to the CD95 receptor.
Treatment of neuroblastoma cells with doxorubicin results in cleavage of caspase-8 
to active 18kDa fragments, 41kDa and 43kDa intermediate inactive fragments, and 
also cleavage of procaspase-3 to its active form (Fulda el al. 1998b). Neuroblastoma 
cells treated with doxorubicin induce apoptosis by activating the CD95 pathway, and 
following doxorubicin treatment the cells upregulate CD95 and CD95L which
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mediate the death signal to the downstream apoptosis machinery (Muller et al. 1997; 
Fulda et al. 1997, 1998b).
The main effector of caspase-8 activation is the CD95 system, although caspase-8 
can also be activated by cytochrome c release (described in section 1.5.7). In some 
cellular systems, such as betulinic acid treatment of neuroblastoma cells, caspase-8 
can be activated independently of CD95 and CD95L induction. This then triggers 
activation of the effector phase involving caspase-3 cleavage which ultimately leads 
to PARP cleavage (Muller et a l , 1997). Caspase-8 can also be activated directly be 
cytochrome c, resulting in cleavage of its proform to active fragments in Jurkat cells 
(Ferrari et al., 1998). Doxorubicin can efficiently induce caspase-8 activation in 
CD95-sensitive and CD95-resistant cells, so caspase-8 activation is not restricted to 
apoptosis mediated by death receptors, but can also be induced by proapoptotic 
stimuli in a CD95-independent pathway (Ferrari et al. 1998). Activation of caspase-8 
in the CD95-mediated pathway is ATP-independent, but in the absence of a 
functional CD95 (in CD95-resistant cells) system, caspase-8 requires ATP to become 
proteolytically cleaved, probably involving activation by apaf-1 which requires ATP 
for its activity.
Therefore caspase-8 activation is a key event in signal transduction from the initiator 
phase to the effector phase, and given the wealth of evidence existing for 
doxorubicin-induced activation of the CD95 pathway (Fulda et al. 1997, 1998a, 
1998b; Friesen et al. 1997), the levels and timely activation of procaspase-8 represent 
critical factors in maintaining an intact CD95 signalling pathway. Another important 
point to consider is that resistant cells have the potential to develop a defective 
apoptotic signalling pathway, so perhaps the DLKP resistant variants could have 
alterations in caspase-8-mediated signalling. Perera and Waldman (1998) evaluated 
the modulation of expression profiles of genes associated with apoptotic pathways 
induced by activation in human monocytes. Interestingly, they found that activated 
monocytes that were resistant to apoptosis also had downregulated caspase-8 
mRNA thus inhibiting the CD95 signalling pathway. This resistance however 
depended on the stimulus used, when monocytes were activated, they became were
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resistant to etoposide and CD95-induced apoptosis and yet remained sensitive to 
UV- and staurosporine-induced apoptosis. This report highlights the specificity of 
resistance to different forms of apoptosis induction such as signalling by death 
receptors, DNA damage, cytochrome c and apafl involvement.
Using Western blotting to examine procaspase-8 levels, it can be seen from figure
3.13.5.1 that there is a definite decrease in procaspase-8 expression in the resistant 
variants. This result may have important implications on the ability of these cells to 
resist apoptotic induction. Reduction in procaspase-8 protein levels may limit the 
ability of these calls to undergo apoptosis via the CD95-mediated apoptotic pathway, 
because procaspase-8 is the principle apical caspase activated by CD-95. Looking at 
doxorubicin treated cells, there was no decrease in procaspase-8 levels, and also 
absence of caspase-8 activation, judged by the absence of caspase fragments. This 
result questions the involvement of caspase-8 activation in the doxorubicin-induced 
apoptosis in DLKP cell lines. The fact that procaspase-8 activation did not occur 
suggests that the CD95 pathway may be defective in some way.
O
Caspase-4
Caspase-4 has 55% sequence similarity to caspase-1 and shares similar substrate 
preference (Cohen, 1997). It has been shown on a number of occasions to be 
activated and involved in apoptosis. It is thought that caspase-4 may have a role in 
activation of caspase-3 and could be the link between caspase-8 and caspase-3 in 
some cellular models, such as Fas-mediated apoptosis in NIH3T3 cells (Kamada et 
al. 1997). However procaspase-3 can be directly activated in vivo by caspase-8 
(Stennicke et al. 1998) and recently Slee et al. (1999) demonstrated that caspase-4 
can be activated by caspase-9, thus questioning a general role for caspase-4 in 
apoptosis induction. Results demonstrated that procaspase-4 protein levels do not 
vary among the sensitive and resistant DLKP variants, and is not activated in any of 
the DLKP cells lines during doxorubicin-induced apoptosis.
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Caspase-9
Caspase-9 is a critical factor at the apex of the apoptotic pathway involving 
cytochrome c release and apaf-1. The search for the human homologue of CED-4 led 
to the discovery of apoptotic protease activating factors (apafs). Apaf-1 is the human 
homologue of CED-4, apaf-2 is cytochrome c and apaf-3 was discovered to be 
procaspase-9 (Liu et al. 1997). During an apoptotic signal transduction, cytochrome 
c is released from the mitochondria, and in the presence of dATP it binds to apaf-1. 
Binding of cytochrome c to apaf-1 is thought to promote clustering of apaf-1, to 
which procaspase-9 can bind. The close proximity of procaspase-9 molecules 
facilitates activation through autocatalysis. Caspase-9, when active, has been shown 
to activate all the other known caspases (Slee et al. 1999), and so has a key role to 
play in transducing the death signal to the downstream machinery to bring about 
destruction of the cell.
Caspase-9'/_ (double knockout) mice die at the embryo stage, and caspase-9 
deficiency also results in brain malformation, due to reduced apoptosis in the absence 
of caspase-9 (Kuida et al. 1998; Hakem et al. 1998). These results reinforce the 
important role of caspase-9 during development. Caspase-9 is required for activation 
of caspase-3 in vivo, indicating that caspase-9 is upstream of caspase-3. It is also 
required for an effective apoptotic response (including caspase-3 activation and DNA 
fragmentation) in thymocytes exposed to etoposide, y-irradiation and 
dexamethasome. However apoptosis induced by CD95 or UV-irradiation can still 
occur in thymocytes isolated from caspase-9' ' mice (Hakem et al. 1998; Kuida et al. 
1998) suggesting that redundant apoptotic pathways are utilised depending on the 
stimulus presented to the cell.
A recent report by Kuida et al. (1998) demonstrated that mice defective in caspase-9 had 
defective caspase-3 activation; therefore it appears vital to examine caspase-9 levels in the 
cell lines, because caspase-9 may be a critical factor in the activation of caspase-3 through 
the cytochrome c mediated pathway. Furthermore Hu et al. (1998) reported that Bcl-XL 
protein can inhibit the association of apaf-1 with caspase-9 and thus prevent caspase-9 
processing. This is a significant finding particularly relevant to the DLKP cells resistant
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cell lines, because the resistant cell lines overexpress Bcl-XL, and this could be a potential 
key to the absence of caspase-3 activity seen in the resistant cell lines.
Any reduction in, or faulty caspase-9 could lead to a defective induction of apoptosis. 
DLKP resistant variants do not have reduced procaspase-9 compared to sensitive 
DLKP-SQ indicating that the resistant state of the cells is not due to downregulated 
caspase-9. But the effect of doxorubicin treatment on the cells has not been looked 
at. Fearnhead et al. (1998) demonstrated that cells with a mutant caspase-9 which 
was unable to undergo autocatalytic processing were resistant to drug-induced 
apoptosis, and this was mainly due to the prevention of caspase-9 activation . Even 
though DLKP-SQ, DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F express 
caspase-9 to an equal extent, it remains to be seen if the resistant variants have 
alterations in the activation of procaspase-9.
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4.14 STAT1 protein expression in DLKP variants
Signal transducers and activators of signal transduction (STAT) are involved in many 
cellular signalling pathways, particularly those involving signal transduction pathways 
of interferons, cytokines and growth factors (Darnell, 1997). STATs have membrane- 
associated domains as well as DNA binding domains. Cells lacking STAT1 protein 
are resistant to TNFa-induced apoptosis (Kumar et al. 1997). The study by Kumar et 
al. (1997) revealed that these cells lacked caspases-1, -2 and -3 mRNA and protein 
expression. Absence of caspase expression was directly linked to the STAT-1 levels 
in the cells. Re-introduction of STAT-1 to the cells restored caspase-3 mRNA and 
protein expression to normal levels. STAT-1 therefore may play a role in mediating 
expression of caspases, and also sensitivity to apoptosis induction.
DLKP resistant variants have reduced levels of procaspase-3 protein expression 
(figure 3.13.2.2). Considering the findings by Kumar et al. (1997) it was important to 
establish if there was a link between this reduced procaspase-3 expression and STAT- 
1 levels in the DLKP cells, so that the possibility of STAT1 involvement in drug 
resistance could be clarified. STAT-1 protein expression in DLKP cells was 
determined using Western blotting with an antibody specific for the alternative splice 
forms of STAT-1 (a and (3). Results in 3.14.1 demonstrated that STAT-1 expression 
is equal in the four cell lines. From these results it can be concluded that STAT-1 
expression in DLKP cell lines is not linked to reduced procaspase-3 levels in the 
resistant DLKP variants.
There is no difference in STAT-1 protein expression in doxorubicin-treated cells 
compared to the untreated controls. However, King and Goodburn, (1998) 
demonstrated STAT-1 cleavage from 91kDa to an 81kDa product in HeLa cells 
undergoing apoptosis induced by dsRNA, cycloheximide and etoposide, and this 
cleavage was mediated by a caspase. The caspase responsible for this specific 
cleavage of STAT-1 may be caspase-3, because recombinant caspase-3 was capable 
of cleaving STAT-1 into the 81kDa form, and a this cleavage could be inhibited by 
the caspase inhibitor zVAD. The absence of STAT1 cleavage in DLKP cell lines
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reinforces the theory that caspase-3 does not play a major role in doxorubicin- 
induced apoptosis in DLKP cell lines.
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4.15 PARP Cleavage in DLKP cell lines
Poly (ADP)ribose polymerase is an abundant nuclear enzyme involved in the formation of 
ADP ribose polymers during DNA damage, which have a role in DNA repair (Satoh et al.
1992). PARP has been shown to be specifically cleaved from 116 kDa to 85 kDa and 25 
kDa signature fragments during apoptosis induced by a variety of chemotherapeutic 
agents (Kauftnann et al. 1993). The cleavage site in PARP occurs at DEVD -I GVDE 
(Nicholson et al. 1995) and this (DEVDix) is the preferred cleavage site for a number of 
caspases including caspase-3, -7 and -2 (Nicholson and Thomberry, 1997). Therefore it is 
plausible that PARP may be cleaved by any of these caspases.
Tewari et al. (1995) and Nicholson et al. (1995) reported that PARP is cleaved in vitro 
by caspase-3/cpp32. Caspase-6 (Mch2) can cleave PARP into the 85 kDa and 25 kDa 
signature fragments (Orth et al. 1996) as well as caspase-7 which can also cleave PARP 
in to the signature apoptotic fragments (Fernandes-Alnemri et al. 1995). Other caspases 
such as caspase-1, -2 and-4 are also capable of cleaving PARP in vivo, but cleavage only 
occurs when these caspases are expressed at high intracellular concentrations (Gu el al. 
1995). Shah et al. (1995) developed a simple detection technique for PARP cleavage 
using Western blotting, and PARP is now a readily accepted indicator of apoptosis and 
caspase activity.
PARP was therefore examined in the four DLKP cells lines undergoing apoptosis (see 
section 3.15). PARP cleavage does not occur after Doxorubicin treatment in any of the 
four cell lines. There is however a slight decrease in intact PARP in DLKP-A2B cells by 
50 hours but no corresponding increase in the 85 kDa fragment. Though unusual, these 
results do however agree with the unchanging procaspase-3 levels after Doxorubicin 
treatment. The experiment was repeated numerous times with three different antibodies 
and similar results were obtained.
HL-60 cells undergoing doxorubicin-induced apoptosis were analysed for PARP cleavage 
as a comparison to the situation in the DLKP cells. It is very clear from the Western blots 
that PARP is cleaved from 116kDa to 85kDa in the apoptotic HL60 cells, yet PARP
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remains completely intact in the apoptotic DLKP-SQ cells. This is definitive evidence that 
the absence of PARP cleavage in the DLKP cell lines, whilst undergoing doxorubicin- 
induced apoptosis is not a result of the detection system employed, but rather an intrinsic 
feature of the cells.
It has been established that apoptosis can take place in the absence of PARP cleavage 
(Adjei et al. 1996), and also in the absence of PARP protein itself (Leist et al. 1997), 
thus questioning the necessity of PARP cleavage in the apoptotic process. Leist et al.
(1997) demonstrated that apoptosis can occur in PARP-deficient mice, and that PARP- 
deficient mice were equally susceptible to apoptosis induced by a variety of apoptotic 
stimuli. These results suggest that PARP cleavage may have a non-essential role in 
apoptosis. Adjei and co-workers (1996) investigated the role of PARP cleavage in 
CPT-induced apoptosis in Hep 3B cells, and found that PARP was not cleaved 
during apoptosis in these cells. Absence of PARP cleavage was associated with very 
low expression of procaspase-3 protein and reduced caspase-3 enzyme activity 
during apoptosis. This finding might explain the situation in the DLKP cells which 
have very low caspase-3 expression accompanied by very low caspase-3 activity 
during Doxorubicin-induced apoptosis. However, the fact that other caspases are 
capable of cleaving PARP does not fully explain the results in DLKP, given that 
caspase-7 is equally expressed in the cells. However the level of caspase-7 in the cells 
following doxorubicin treatment is unclear. PARP cleavage can still occur in vivo in 
the absence of caspase-3 expression (Janicke et al. 1998) indicating that caspase-3 is 
not required for PARP cleavage to occur.
PARP can still be cleaved even in the absence of caspase-3, -2, -6 and -7. Knockout mice 
which have a deficiency for these caspases still retain the ability to cleave PARP, thus 
casting doubt on the significance of its cleavage in apoptosis (Kuida et al. 1996; Tim 
Zheng, pers. Comm ).
Additionally, Friesen el al. (1997) reported that PARP was not cleaved after 
Doxorubicin treatment in leukemia cells which were resistant to apoptosis due to a 
defective CD95 signalling pathway. Absence of PARP cleavage may also delay the
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onset of apoptosis (Olivier et al. 199®). Therefore DLKP cells which are resistant to 
Doxorubicin may possess a supplementary resistance mechanism in the form of 
defective caspase activation and absence of PARP cleavage.
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4.16 Fodrin Cleavage in DLKP cells during doxorubicin-induced apoptosis
The membrane-associated cytoskeletal protein fodrin is cleaved from 240kDa to 150kDa 
and 120kDa fragments during apoptosis (Martin et al. 1995). Fodrin cleavage is mediated 
by caspase activity. Vanags el al. (1996) demonstrated that this cleavage was mediated by 
cpp32/ICE-like proteases, and the caspase inhibitor VAD.cmk could inhibit fodrin 
cleavage in Jurkat cells, but only partially inhibit cleavage in TNF-treated U937 cells, 
indicating that the inhibition was cell and stimulus-specific. Janicke el a l, (1998) 
demonstrated that fodrin cleavage is mediated by caspase-3 and not by caspases-1 and -2, 
using the caspase-3-deficient MCF-7 cell line. They also confirmed that caspase-3 is 
required for fodrin cleavage to 120 kDa, whereas the 150 kDa fragment can be formed in 
the absence of caspase-3. It is thought that 150 kDa cleavage is mediated by calpain 
activity (Nath et al. 1996). Consistent with these findings Zheng et a l (1998) 
demonstrated that fodrin is only cleaved in caspase-3+/+ hepatocytes but not in caspase-3'/_ 
cells confirming the requirement of caspase-3 in fodrin cleavage. However Cryns et al. 
(1996) reported that fodrin is cleaved by a protease distinct from the one responsible for 
cleaving PARP. Apoptosis and fodrin cleavage in Fas-treated Jurkat cells could be 
prevented in the presence of YVAD.cmk, a tetrapeptide inhibitor specific for ICE-like 
caspases. DEVD.cho, a tetrapeptide inhibitor specific for cpp-32-like (caspase-3-like) 
caspases could not inhibit fodrin cleavage, yet effectively inhibited apoptosis in the cells. 
This finding suggested that fodrin cleavage can even be uncoupled from the apoptotic 
pathway. Conversely, PARP cleavage was completely inhibited by YVAD.cmk and 
DEVD.cmk. The dramatically different sensitivities of fodrin and PARP suggest that these 
cleavage events are mediated by different caspases, and the fodrin-cleaving protease is not 
a cpp-32-like protease (i.e. caspase-3, -7, -6), because it is not inhibited by DEVD-cho.
It is clear from the results in figure 3.16.1 that fodrin is effectively cleaved during 
doxorubicin-induced apoptosis in all four cell lines From the reports by Janicke et a l
(1998) and Zheng et al. (1998) it could be concluded that caspase-3 is activated in DLKP 
cells lines during apoptosis, as judged by the appearance of the 120 kDa cleavage product 
in the apoptotic cells. These results are in contrast to the caspase-3 processing Westerns, 
in which caspase-3 is not seemingly activated during apoptosis. Very low levels of
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caspase-3 were detected in the resistant lines even though fodrin was shown to be cleaved 
in these cell lines. Figure 3.16.1 provides conclusive evidence for the existence of caspase- 
3-like activity in all four cell lines, but perhaps this activity is at a level which is 
undetectable as a change in proenzyme levels by Western blotting. If current reports are 
accurate then caspase-3 activity is required for fodrin cleavage. In DLKP cell lines the 
detection of fodrin cleavage in the absence of PARP cleavage represents an unusual 
situation. Fodrin is clearly cleaved indicating that there must be caspase-3 activity, but 
then why does caspase-3 not cleave PARP into the apoptotic signature fragments? One 
plausible explanation is that these two substrates are differentially localised in the cell, 
fodrin is a membrane-associated cytoskeletal protein, whereas PARP is a nuclear protein, 
so perhaps fodrin is more accessible for caspase-3 cleavage than PARP.
However if the report by Cryns et al. (1996) is considered, the situation in DLKP cell 
lines might be viewed differently. There may be a distinct protease active in apoptotic 
DLKP cells, capable of cleaving fodrin, and no PARP cleavage occurs due to the lack of 
caspase-3 activation. This hypothesis would explain the cleavage of fodrin together with 
absence of PARP cleavage. Looking at the timing of apoptosis onset in DLKP cells, it is 
quite a lengthy process, so in the intervening time before nuclear condensation, cytosolic 
caspase-3 may have adequate time to cleave fodrin, whereas the nuclear condensation 
events are rapid, and PARP might remain intact. However, the nucleus also contains 
active caspases during apoptosis (Martins et al. 1997) that are activated at a similar rate 
to cytosolic caspases, so the action of these caspases on PARP cannot be excluded. In 
addition, HL-60 cells undergo apoptosis with rapid nuclear condensation (not shown) and 
exhibit PARP cleavage, thus questioning the theory of slow apoptotic rate as a reason for 
absence of PARP cleavage.
Another possibility for absence of PARP cleavage may be the existence of a noncleavable 
mutant of PARP in the DLKP cells. It was also seen in Western blotting that the 
procaspase-3 does not decrease during apoptosis in DLKP, so perhaps the active caspase- 
3 is not present in sufficient amounts to carry out PARP cleavage, but is adequate to carry 
out fodrin cleavage.
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4.17 Role of Caspase Inhibitors in Doxorubicin-induced Apoptosis
Previous sections have elucidated the role of caspases in doxorubicin-induced apoptosis in 
DLKP cell lines, by looking directly at caspase processing and caspase-substrate cleavage. 
An alternative method of investigation involves the use of peptide inhibitors modelled on 
the cleavage site of caspase substrates. The tripeptide inhibitor zVAD.fmk is thought to 
be a general caspase inhibitor and is reversible and cell permeable. DEVD.fmk is an 
inhibitor based on the PARP cleavage sequence, DEVD -I , and can inhibit caspases 
which normally cleave PARP, namely the cpp32 family comprising caspase-3, caspase-2 
and caspase-7 among others. The YVAD inhibitor is modelled on the cleaved sequence in 
pro-interleukin IB, YVAD -I and inhibits caspases such as caspase-4 and caspase-1. 
Numerous reports demonstrate caspase inhibition by zVAD.fmk, and a subsequent 
inhibition of apoptosis as judged by absence of the morphological and biochemical 
features of apoptosis. Slee etal. (1996) demonstrated that zVAD.fmk inhibited apoptosis 
in THP1 cells and Jurkat cells by inhibition of caspase-3 processing. zVAD was used in 
combination with doxorubicin to assess its affects on apoptotic induction in DLKP-SQ 
cells. The chosen end point was viability of cells after doxorubicin treatment, and results 
were not as expected. zVAD treatment provided no survival enhancement in any of the 
combinations used (detailed in section 3.17). The percentage kill after 72 hours in the 
presence of zVAD.fmk equalled the percentage cell kill due to doxorubicin alone. The 
various combinations of preincubation, co-incubation and re-addition after 24 hours failed 
to protect the cells from apoptosis induced by doxorubicin. This phenomenon was 
previously reported by Lotem and Sachs (1996), who found that myeloid leukaemic cells 
when treated with zVAD.fmk were afforded no protection from apoptosis induced by 
doxorubicin.
Taxol-induced apoptosis was also investigated; the concentration used (50-80ng/ml) 
resulted in rapid apoptotic induction over 6 hours compared to the slower timescale of 24 
hours with doxorubicin. Again no cytoprotective effect was observed by the use of 
zVAD.
Considering these results, it was decided to carry out an investigation looking at the
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ability of the other, more specific caspase inhibitors, DEVD.fink and YVAD.fmk to 
protect the DLKP cells from doxorubicin-induced apoptosis. The three different inhibitors 
were used in combination with two different doxorubicin concentrations which gave a 
high and medium level of cell kill. Results were consistent with the previous findings; 
again, no increased viability was seen in the presence of the caspase inhibitors. Looking at 
photographs of DLKP-SQ treated with either doxorubicin alone or in combination with 
one of the three inhibitors, it can be seen that there is approximately equal cell kill in 
inhibitor/doxorubicin-treated cells and doxorubicin+treated cells alone over 72 hours. To 
further investigate any difference in the rate of apoptosis, or a possible delay in induction 
of apoptosis in the presence of inhibitors timelapse videomicroscopy was carried out to 
compare kinetics of cell death in doxorubicin-only and doxorubicin-zVAD treated cells. 
Analysis revealed a similar rate of cell death in both situations, and the mechanism of cell 
death was confirmed to be apoptotic, based on the appearance of the characteristic 
morphological alterations in the cells, so zVAD does not affect the timing of apoptosis 
onset in DLKP-SQ.
These results suggest the possibility of a caspase-independent pathway in doxorubicin- 
induced apoptosis. Adjei el al. (1996) found that apoptosis induced by the topoisomerase 
I inhibitor, camptothecin occurs independently of caspase-1 and caspase-3 activity in 
Hep3B hepatocarcinoma cells. Yet Datta et al. (1996) reported that chemotherapy drugs 
such as cisplatinum, etoposide and camptothecin induce activation of caspase-3. It is 
obvious that the caspase-dependence or independence depends very much on the cell lines 
being used and the agent used to induce apoptosis. Results suggest a possibility where 
doxorubicin may induce apoptosis via a pathway independent of caspase-3 activation, but 
as yet this pathway remains elusive in DLKP-SQ cells.
Cytotoxicity levels in the caspase inhibitor experiments were measured after 72 hours. 
One could argue that this timepoint is too late in the process, and at this stage any effects 
the inhibitors may have on apoptosis would be bypassed. However time-lapse 
videomicroscopy over this time revealed that the cells died at a similar rate to cells which 
were just treated with doxorubicin, and exactly the same percentage viability resulted after 
72 hours, indicating that zVAD has no effect on the cells, so the time of viability analysis
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is of little consequence to the overall findings.
4.18 Fluorogenic Caspase-3 Assays
Using the fluorogenic caspase-3 assays provides a direct method for measuring caspase 
enzyme activity. Using the caspase-3 specific fluorogenic peptide DEVD. AMC, caspase-3 
activity was monitored in each of the cell lines following the method described by Martins 
et al. (1997) before and after doxorubicin treatment. Actual fluorescence readings from 
each independent assay (four cell lines) varied from day to day but the resulting trend 
remained the same for each of the cell lines, so statistical analysis was not feasible. 
Representative results can be seen in figure 3.18.1. It can be seen that there is a high basal 
activity in DLKP-SQ untreated cells compared to cells undergoing apoptosis and from 
this result caspase-3 seems to be only marginally activated during apoptosis in DLKP-SQ.
In contrast to this, caspase-3 activity in DLKP-A250/10p#7 cells increases to quite high 
levels in apoptotic cells, with highest activity seen at 60 hours. DLKP-A5F also exhibits 
an increase in caspase-3 activity but not to the extent seen in A250 10p#7 cells. DLKP- 
A2B also exhibited an increase in caspase-3 activity parallel to that of DLKP-A5F but the 
data is not included on this graph.
The effect preincubated zVAD.fink had on caspase-3 activity was also investigated. In 
DLKP-SQ there was a reduction in caspase-3 activity, indicating that the inhibitor is 
entering the cell. The caspase-3 activity was almost completely inhibited in DLKP-A250 
10p#7 at 60 hours in the presence of zVAD.fink, and this effect is also seen in DLKP- 
A5F.
When all results are combined, it can be concluded that there is a detectable basal caspase- 
3 activity in DLKP-SQ cells and this does not significantly increase during Doxorubicin- 
induced apoptosis. DLKP-A250 10p#7 on the other hand experience an increased 
activation of caspase-3 activity, and furthermore this activity is inhibited by zVAD.fink. A 
similar but not as pronounced effect is seen in DLKP-A2B and DLKP-A5F.
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4.19 CD95 receptor Levels
The possibility of a caspase-3 independent apoptotic pathway led to investigation of the 
CD95 system in DLKP cells. CD95/CD95-L interaction plays an important role in the 
apoptotic signalling pathway, and are involved in apoptosis induced by chemotherapy 
drugs, amongst other stimuli. Doxorubicin and other cytotoxic drugs are thought to 
induce apoptosis through induction of CD95 and CD95L with subsequent activation 
of caspase-8.
Upon an apoptotic signal, the CD95 receptors trimerise, allowing CD95-L to bind 
and a death signal to be transduced. Therefore the amount of CD95 present is an 
important factor for efficient signalling to occur. It has previously been reported that 
cells resistant to apoptosis have altered regulation of CD95. Friesen et al. (1997) 
demonstrated that doxorubicin-resistant cells have downregulated CD95 receptor 
compared to sensitive cells, and resistant cell lines neither upregulate CD95L, or 
activate caspase-3, resulting in inhibition of PARP cleavage. Together these defects 
contribute to a defective signalling pathway. Doxorubicin treatment can cause 
upregulation of CD95 expression in some cell lines, such as neuroblastoma cells 
(Fulda el al. 1998) and it is thought that this upregulation can enhance the death 
signal by interacting with CD95L.
CD95 receptor levels were examined using Western blotting in the four DLKP cell 
lines before and after doxorubicin treatment. CD95 is expressed to the same extent in 
sensitive and resistant cell lines, with no downregulation of CD 9 5 in the resistant 
variants. After doxorubicin treatment, there is no upregulation of CD95 in any of the 
cell lines. It had been thought, that if after doxorubicin treatment DLKP-SQ cells 
upregulated CD95 perhaps the resistant variants would not upregulate CD95 to the 
same extent, and this failure to upregulate CD95 following doxorubicin treatment 
could be an additional resistance mechanism in the resistant variants. However results 
show that there is no upregulation of CD95 after doxorubicin treatment in any of the 
cell lines.
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4.20 Inhibitors of CD95/CD95L
Results using caspase inhibitors indicate that there could be another mechanism by which 
the apoptotic pathway could operate, perhaps bypassing the need for caspase activation. 
The CD95 pathway does require caspase activity to initiate the apoptotic response, but 
only at a downstream level, after the receptors have transduced the apoptotic stimulus 
from the external environment to inside the cell.
The interaction between CD95- and drug-induced apoptosis has received a lot of 
attention over the past few years, with many conflicting reports of independence and 
interdependence between the signalling pathways activated by the two sets of stimuli. 
Fulda et al. (1997) found that treatment of neuroblastoma cells with such drugs as 
doxorubicin, cisplatinum and VP-16 induced apoptosis, which was accompanied by an 
induction of CD95 receptor and CD95L. CD95-resistant neuroblastoma cells were also 
resistant to chemotherapeutic drug-induced apoptosis. Los et al. (1997) also 
demonstrated that cells resistant to doxorubicin-induced apoptosis were also resistant to 
CD95-induced apoptosis. Cross-resistance between drug-induced apoptosis and the 
CD95 pathways gives important insights into the mechanism of drug sensitivity and 
resistance in tumour cells. In the development of resistance, a common element of the 
apoptotic pathway must be damaged in some way, resulting in resistance to diverse 
stimuli which can activate different branches of the pathway involving either CD95 or 
drugs.
However evidence for drug-induced apoptosis independent of the CD95/CD95L system 
also exists. Many studies showing that CD95/CD95L inhibitors fail to inhibit drug- 
induced apoptosis suggest that there is a pathway independent of the CD95 system 
(Eischen et al. 1997; Villunger el al. 1997; Micheau et al. 1999). These independently- 
activated pathways converge on a common downstream pathway involving caspase-3 
activation. Eischen et al. (1997) concluded that CD-95 resistant Jurkat cells are not 
resistant to drug-induced apoptosis and also that the CD95-blocking antibody ZB4, 
cannot prevent drug-induced apoptosis in CD95-sensitive Jurkat cells. This is clear 
evidence that there are distinct pathways activated by CD95 and cytotoxic drugs.
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In section 3.17 cell permeable inhibitors of caspases were tested for their ability to 
block doxorubicin-induced apoptosis in the DLKP cell lines, without success. It can 
also be seen in section 3.20 that ZB4 offered no protection to the cells from 
doxorubicin-induced apoptosis, approximately the same number of cells died when 
treated with ZB4 and doxorubicin, as those treated with doxorubicin alone. However 
ZB4 could reduce CD95-induced apoptosis in DLKP-SQ indicating that it is capable 
of inhibiting CD95-mediated apoptosis. The effect of NOK-2 on doxorubicin-induced 
apoptosis was also investigated and it was concluded that NOK-2 has no protective 
effect against doxorubicin-induced apoptosis in DLKP cell lines.
As previously mentioned, cytotoxic drugs such as cisplatin, doxorubicin and 
fludarabine can induce apoptosis in the presence of ZB4 and NOK-2 in CEM lines 
(Villunger el al., 1997) thus questioning the involvement of the CD95/CD95L 
signalling in drug-induced apoptosis. Doxorubicin has previously been shown to 
induce apoptosis in Jurkat cell lines, and to do so even in the presence of the CD95 
blocker ZB4, and etoposide treatment of the cells displayed similar characteristics 
(Eischen el ah, 1997) These results raise the possibility that chemotherapeutic drugs 
can induce apoptosis independently of the CD95 pathway. Furthermore, Micheau et 
ah (1999) recently reported on the inability of ZB4 to prevent drug-induced 
apoptosis in a variety of human cell lines. They suggest that cytotoxic drugs can 
induce apoptosis through a pathway involving caspase-8 and FADD, independent of 
CD95L action, and found that downregulation of FADD expression was associated 
with resistance to drug-induced apoptosis.
Considering that the DLKP cells can still die by apoptosis in the presence of either 
caspase inhibitors or CD95 blockers, a combination of inhibitors was employed, 
consisting of the CD95 blocker ZB4 and the general caspase inhibitor zVAD.fmk, in 
an attempt to discover if both inhibitors together could prevent DLKP-SQ from 
apoptosis. Cells were preincubated with both inhibitors for 1 hour before doxorubicin 
addition, and again at the time of drug addition. However even the combination could 
not prevent apoptosis from occurring. Analysis of the kinetics of apoptosis of cells 
exposed to the combination treatment using timelapse videomicroscopy, reveals a
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similar rate to kinetics of apoptosis induced by doxorubicin alone, suggesting that the 
inhibitors have no effect on the rate of apoptotic induction in doxorubicin-treated 
cells. Apoptosis in inhibitor-treated cells occurs at a slightly faster initial rate, if 
anything, but the two rates closely parallel each other over the 72 hours monitored.
These results suggest that DLKP cells can induce apoptosis in a seemingly novel 
manner, independent of the caspase- or CD95-dependent signalling pathways. A 
possibly significant characteristic of the resistant DLKP cells is the overexpression of 
Pgp and Bc1-Xl . Ha et al. (1998) recently provided evidence of a caspase-3-independent 
apoptotic pathway in Bcl-2 overexpressing cells. Using polyamine analogues which 
resulted in G2/M arrest and apoptosis, they observed activation of caspase-3, DNA 
fragmentation, PARP cleavage and cytochrome c release. Yet when bcl-2 was 
overexpressed all the apoptotic features were inhibited but the cells still underwent 
apoptosis suggesting the existence of a caspase-independent pathway. The overall 
conclusions and future experimental work are detailed in section 4.21.
279
5.0 Conclusions and Future work
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5.0 Conclusions and Future work
In this thesis the effects of doxorubicin on the cell cycle and on apoptotic pathways were 
investigated in variants of a human lung carcinoma cell line DLKP. Particular emphasis was 
placed on identification of any alterations that may exist in resistant variants compared to 
sensitive DLKP-SQ. DLKP-A250 10p#7, DLKP-A2B and DLKP-A5F exhibit varying 
levels of resistance to doxorubicin and other anticancer drugs. In contrast to much of the 
literature which uses identical drug concentrations to investigate apoptosis in wild-type 
versus resistant cells, equitoxic doxorubicin concentrations were used to treat the cell lines, 
and the cell cycle response and induction of apoptosis were monitored. Cell cycle 
conclusions are outlined first, followed by conclusions drawn from the apoptosis-related 
results.
There were no alterations in cyclins (-B, -D, -E, -A) or cdks (-1, -2, -4, -6) expression in 
resistant variants compared to sensitive DLKP-SQ cells, indicating that the resistant cells do 
not experience alterations in expression of cell cycle regulators as a mechanism or 
consequence of their resistant state. Doxorubicin treatment of DLKP-SQ cells induced a 
G2/M arrest by 24 hours; interestingly, it was at this time that apoptosis occurred, 
suggesting that the cells halt at the G2/M checkpoint, and then undergo apoptosis. In 
contrast the resistant variants did not completely arrest in G2/M; some cells only transiently 
arrest in G2/M or can bypass the G2/M arrest and accumulate in G1. This suggests that 
resistant cells may have a defective G2/M checkpoint that allows the cells to overcome the 
G2/M arrest, even if they have experienced DNA damage. Further investigation was carried 
out to identify the cellular alterations in the resistant variants that allow a G2/M override. 
The activity and regulation of cyclin B-cdkl kinase was looked at in detail in sensitive and 
resistant cells before and after doxorubicin treatment. There is no difference in cyclin B or 
cdkl expression following doxorubicin treatment and sensitive and resistant cells equally 
retain the ability to form a kinase complex. However levels of inhibitory tyrosine 15 
phosphorylation seem to be higher in DLKP-SQ after doxorubicin treatment, which would 
account for the G2/M arrest, and the cells also experience a slight decrease in cdkl kinase 
activity. The resistant cells have an elevated cdkl kinase activity after doxorubicin 
treatment; perhaps this is a cellular response to enable them to pass into mitosis. This G2/M 
bypass would result in cells with increased genomic instability, if they divide with damaged
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or incompletely replicated DNA. Caffeine treatment in combination with doxorubicin 
treatment, allows the DLKP-SQ cells to bypass the G2/M arrest in a similar fashion to the 
resistant variants. This suggests that the resistant variants may possess cellular alterations 
similar to those induced by caffeine in the DLKP-SQ cells, which allows the cells to 
override the G2/M checkpoint. One possibility is that caffeine may alter chkl kinase 
activation in the G2/M checkpoint, which leads to inappropriate activation of cdc25C and 
by pass the G2/M checkpoint.
The regulators of Tyrl5 phosphorylation on cdkl, cdc25C phosphatase and weel, were 
also investigated. Cdc25C protein levels and phosphatase activity did not change following 
drug treatment in resistant or sensitive cells, suggesting that it may not be the critical factor 
responsible for the G2/M override seen in the resistant variants. The activity status of 
cdc25C was investigated using Western blotting to measure the phosphorylation status by 
altered mobility in SDS-PAGE and gave largely inconclusive results, perhaps due to the 
experimental system in use.
Weel is a negative regulator of cdkl kinase, and is responsible for the inhibitory 
phosphorylation on Tyrl5. Weel expression levels did not vary after drug treatment, but 
phosphorylation levels did change slightly in DLKP-SQ compared to the resistant variants. 
When phosphorylated, weel is inactive, and this results in a decreased phosphorylation on 
Tyrl5 of cdkl. DLKP-SQ appear to experience a decrease in weel phosphorylation, 
following doxorubicin treatment, indicating that weel is fully active, perhaps maintaining 
the Tyrl5 phosphorylations on cdkl, and the G2/M arrest. Therefore weel in the resistant 
cells may not be fully active, allowing cells to bypass the G2/M arrest.
Further investigation of the altered cell cycle response to doxorubicin in resistant variants 
may lead to discovery of a unique cell cycle effect in resistant cells. Initial studies would 
involve a study of cdc25C phosphatase activity. This would involve an in vitro phosphatase 
assay, using purified cyclin B-cdkl complex, and measuring the ability of cdc25C to 
dephosphorylate cdkl on tyrl5. The resistant variants may have a higher phosphatase 
activity following doxorubicin treatment, resulting in removal of the inhibitory 
phosphorylation on Tyrl5 of cdkl, and entry to mitosis.
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The involvement of weel kinase in the G2/M override could also be further investigated. 
From mobility in SDS-PAGE gels, weel seems to be more active in DLKP-SQ following 
drug treatment, thereby preventing the DLKP-SQ cells from entering mitosis. If the activity 
of weel is reduced in the resistant variants after drug treatment, it would allow them to 
bypass the G2/M arrest. Kinase activity of weel could be studied using an in vitro kinase 
assay, looking at the ability of immunoprecipitated weel to phosphorylate cyclin B-cdkl 
complex in vitro. Both regulators of cdkl need to be examined in detail, because they are 
closely involved together in the activation and inhibition of cdkl kinase. The regulator of 
weel, niml could also play a role in inactivation of the weel kinase in the resistant variants, 
and its kinase activity could also be investigated using in vitro kinase assays.
The precision and accuracy of the DNA damage-induced checkpoint is extremely important 
in maintaining genomic stability of cells, as discussed earlier. The integrity of the DNA 
damage-induced checkpoint must be investigated because it may be a key factor in the 
G2/M override in the resistant variants. Chkl kinase is activated in response to DNA 
damage; chkl kinase activity in DLKP cells would define the response to the drug 
treatment. Perhaps the chkl kinase response is attenuated in the resistant variants, allowing 
them to continue in the cell cycle without halting in response to the checkpoint.
The fact that the G2/M override is only seen in the resistant variants suggests that this 
response may be linked to the resistant state of the cells. All the resistant variants express 
Pgp, as shown by Western blotting. An interesting experiment to investigate this possible 
link would involve deletion or inactivation of Pgp through transfection of an MDR 
ribozyme in a resistant variant, and monitoring the cell cycle response of these Pgp-deficient 
cells to doxorubicin. This would confirm whether the altered cell cycle response is restricted 
to Pgp-expressing cells. It could also uncover a novel role for Pgp in the cell cycle, perhaps 
implicating Pgp in promoting cell cycle progression, either through its effects on abrogating 
the DNA damage-induced G2 checkpoint, or through inappropriate mitosis.
Many recent studies have confirmed the importance to cyclin B localisation in the G2 arrest 
response to DNA damage. Cyclin B localisation will be investigated in the sensitive 
compared to the resistant cells. Perhaps cyclin B in resistant variants is not exported from
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the nucleus as efficiently as in the sensitive variants; residual cyclin B in the nucleus could 
therefore promote premature entry to mitosis. Localisation of cyclin B can be studied using 
immunocytochemistry, with specific fluorescent-labelled antibodies.
p21 expression could not be detected after drug treatment in the DLKP cells, even though 
the cells are visibly undergoing apoptosis (results not shown) and presumably have 
experienced DNA damage. This points to the p53 status in these cell lines. The cells do not 
arrest in G1 at the concentrations of Doxorubicin used, only a G2/M arrest is seen. It is 
known that cells which are defective in p53 do not have an ability to arrest in Gl, and 
subsequently arrest in G2/M. It would be interesting to determine the p53 status of DLKP 
cells in order to further characterise their response to drug treatment.
The DLKP cells used throughout the course this thesis were asynchronous. This is a very 
important experimental parameter, that has many consequences on the results following 
drug treatment. Asynchronous cells were chosen because the effects to be monitored after 
doxorubicin treatment were solely drug effects, and it was thought that cell synchronisation 
could hamper these results. Cell synchronisation is usually carried out using various 
chemicals such as nocodazole and hydroxyurea, or by serum starvation or thymidine 
starvation. However, all these treatments induce cellular alterations, which could interfere 
with the doxorubicin-induced effects, and the overall effect seen might not be a true 
reflection of the situation in the cell. In light of the results obtained, especially those in the 
cdc25 and weel sections, the asynchronous cells could possibly mask any differences that 
might be present. The control cells are asynchronous, with approximately 5% in mitosis; 
this is a similar situation to G2-arrested cells in that there are very few cells in mitosis, so it 
is difficult to differentiate between the drug-induced G2-arrested cells and the resistant 
variants that continue to cycle in a similar fashion to the control cells. Cell synchronisation 
must therefore be carried out; this should give more clear-cut results, and cells that arrest 
in G2 will be easily distinguished form those that continue to cycle. In future experiments 
cell synchronisation could be carried out using centrifugal elutriation (non-chemical 
treatment), if possible. FACS (fluorescent activated cell sorting) could also be used to 
separate the cells according to their DNA content. The cells would be drug treated as 
before. Then the cell cycle responses would be monitored, and findings should explain 
altered cell cycle response in the resistant DLKP cells more clearly.
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A summary of the events in the apoptotic pathway that occur, as reported in the literature, 
following doxorubicin treatment can be seen in figure 4.4. Also included (in italics) are the 
findings in the DLKP cell lines. From the results, the situation concerning doxorubicin- 
induced apoptosis in DLKP appears quite unusual. Apoptosis occurs and cells exhibit 
classical morphological features of apoptosis such as DNA fragmentation, nuclear 
condensation and phosphatidylserine extemalisation, confirming that the end result of the 
signalling pathways activated by doxorubicin is apoptotic cell death. In addition preliminary 
results suggest that cytochrome c is released from mitochondria after doxorubicin treatment 
(not included in results section, needs to be further investigated).
A significant level of caspase activation was not seen, however, and this observation is 
puzzling because caspases constitute the critical components of the apoptotic pathway in all 
cells. However this may be due to the antibodies used in Western blotting; they may be 
unable to pick up the active fragments due to the very short half-life of active caspases in 
the cell. Caspase-3 expression is significantly reduced in resistant variants, suggesting that 
caspase expression may be linked to drug resistance. Perhaps a decrease in caspase 
expression may be an attempt by a resistant cell to alter or dismantle its apoptotic signalling 
pathway to increase its chances of survival. The parental cell line and resistant variants 
express procaspase-3 mRNA to an equal extent, suggesting that there must be some post- 
transcriptional control which prevents translation of the procaspase-3 mRNA. Future 
experiments on the effects of doxorubicin treatment on procaspase-3 mRNA expression 
will reveal any altered regulation of the procaspase-3. Translation regulation of procaspase- 
3 gene expression might, play a role in controlling the protein expression of procaspase-3. 
One interesting aspect would be to investigate the regulation of translation of procaspase-3, 
perhaps there may be some alterations in the components governing procaspase-3 
translation, such as the translation initiation factor, eIF-4E. If procaspase-3 mRNA is 
upregulated following doxorubicin treatment, resulting in increased protein synthesis, this 
would explain the failure to detect any decrease in procaspase-3 expression during 
apoptosis.
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Figure 4.4 Summary of apoptotic pathway in DLKP
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Another unusual finding is the inability of cell permeable caspase inhibitors and CD95 
inhibitors to prevent cell death in the DLKP cell lines. It is possible that an alternative 
pathway exists in the DLKP cell lines which is independent of CD95 and caspase activation, 
but still results in apoptotic cell death, but this does not concur with the currently accepted 
view of apoptosis. Another observation not in line with the literature on apoptosis is that 
fodrin is cleaved in the absence of PARP cleavage, suggesting that PARP cleavage is not a 
marker for apoptosis in the DLKP cell lines. Overall the findings suggest that DLKP cells, 
when treated with doxorubicin die by apoptosis, and some but not all of the characteristic 
apoptotic alterations occur in these cells. Further investigation of these cell variants may 
lead to the discovery of novel apoptotic pathways.
Apoptosis in DLKP cell lines appears to occur in the presence of both caspase and 
CD95 inhibitors, and control experiments confirmed that the inhibitors were 
permeating the cells. One theory arising from the inability of synthetic inhibitors to 
prevent doxorubicin-induced apoptosis in DLKP cells is that the inhibitors suppress 
activity of a subset of caspases, but perhaps some caspases exist whose activity is not 
prevented by the synthetic inhibitors zVAD.fmk, DEVD.fmk and YVAD.fmk. This 
raises the possibility of redundancy amongst the 14 known caspases, an assumption 
that is quite plausible. It would be interesting to see if the downstream substrates of 
caspases are still cleaved, in the presence of inhibitors. This experiment would confirm 
if the inhibitors just prevent activation of a subset of caspases, allowing other caspases 
to continue in the apoptotic signalling pathway.
The involvement of Pgp in resistance of the cells to apoptosis will also be investigated. 
The resistant variants have much reduced procaspase-3 protein expression, and also 
express high levels of Pgp. This observation raises the possibility that Pgp expression 
may result in reduction of procaspase-3 expression. To test this hypothesis, levels of 
procaspase-3 protein expression and activation will be examined in a resistant cell line, 
which has been transfected with an MDR-ribozyme, and thereby knocking out Pgp 
expression. The Pgp status in the DLKP cells could also be linked to the inability of 
synthetic inhibitors to prevent doxorubicin-induced apoptosis. DLKP-SQ express very 
low levels of Pgp, and higher levels of Pgp are expressed in DLKP-A250 10p#7,
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DLKP-A2B and DLKP-A5F. Perhaps the Pgp can actively export the synthetic 
inhibitor out of the nucleus, and prevent the inhibitory actions on the apoptotic 
signalling pathway from taking place. One method to further investigate this possibility 
would involve co-incubation of the Pgp inhibitor verapamil with the caspase inhibitor 
before doxorubicin treatment. If this treatment prevented apoptosis, then it could be 
concluded that Pgp expression effectively reduces the ability of synthetic caspase 
inhibitors to prevent apoptosis induction.
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